Virologic - 500 Beiträge pro Seite

[robby13]

Heute nun sind die Zahlen bei Virologic fällig. Aktuell notiert da Papier bei 1,45€ , bzw. 1,62$.
Ev. erleben wir ja eine positive Überraschung !

VLGC - VIROLOGIC INC (NASDAQ)
Date Open High Low Last Change Volume % Change
11/03/03 1.71 1.74 1.61 1.62 -0.06 931800 -3.57 %



Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Weak Strengthening

Short Term Indicators
7 Day Average Directional Indicator Buy Maximum Strengthening
10 - 8 Day Moving Average Hilo Channel Buy Weak Strengthening
20 Day Moving Average vs Price Buy Average Strengthening
20 - 50 Day MACD Oscillator Buy Weak Average
20 Day Bollinger Bands Buy Minimum Strengthening

Short Term Indicators Average: 100% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Buy Maximum Strengthening
50 Day Moving Average vs Price Buy Average Strengthening
20 - 100 Day MACD Oscillator Buy Weak Strongest
50 Day Parabolic Time/Price Buy Weak Strengthening

Medium Term Indicators Average: 100% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Average Strongest
100 Day Moving Average vs Price Buy Average Strengthening
50 - 100 Day MACD Oscillator Buy Average Strongest

Long Term Indicators Average: 100% - Buy

Overall Average: 100% - Buy

robby

[heikekarina]

wir bleiben zuversichtlich

[claudi34]

noch 4 stunden, dann beginnt die konferenz...
die zahlen-präsentation wird auch auf der hphttp://www.virologic.com live übertragen...
freu mich schon auf das fest...

[Dolocher]

Was haben die Zahlen denn nun gebracht?
Konnte mir das leider nicht live ansehen...

[CutPall]

Company Reports Third Quarter Revenue of $9.1 million, an Increase of Over 50 Percent over Third Quarter of 2002


SOUTH SAN FRANCISCO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC - News) today reported financial results for the third quarter and nine months ended September 30, 2003.
The Company reported revenue of $9.1 million for the third quarter of 2003, an increase of 54 percent over revenue of $5.9 million for the third quarter of 2002. The growth was attributed to continuing steady performance of the Company`s patient testing products, which rose to $6.2 million in the third quarter of 2003 from $4.6 million in the third quarter of 2002, an increase of 35 percent. The growth was further enhanced this quarter by increases in pharmaceutical drug development and NIH grant revenues.

Gross margin was 50 percent in the third quarter of 2003 compared to 39 percent reported during the same quarter last year. Operating costs and expenses for the third quarter of 2003 were $9.6 million, compared to $11.5 million for the same period in 2002. The decrease in operating costs and expenses was the result of a company-wide focus to increase efficiencies and achieve improved economies of scale, partially offset by higher costs associated with increasing testing volume. Gross margin improvement was also driven by an increased contribution from pharmaceutical revenue during the third quarter.

Net loss for the third quarter of 2003 was $0.4 million, or $0.01 per common share, compared to a net loss of $5.6 million, or $0.23 per common share, for the same period in 2002.

In the third quarter of 2003, the Company recorded stock dividends to preferred stockholders of $0.4 million, resulting in net loss applicable to common stockholders of $0.02 per common share. In the third quarter of 2002, the Company recorded stock dividends to preferred stockholders of $0.2 million, resulting in net loss applicable to common stockholders of $0.24 per common share.

Nine Month Results

The Company reported revenue of $24.0 million for the first nine months of 2003, an increase of 31 percent over revenue of $18.3 million for the same period of 2002. Operating costs and expenses for the first nine months of 2003 were $29.3 million, compared to $35.8 million for the same period of 2002. This decrease was the result of ongoing operational improvements and economies of scale, and was partially offset by higher costs associated with increasing testing volume.

Net loss for the first nine months of 2003 was $5.1 million, or $0.17 per common share, compared to a net loss of $17.2 million, or $0.74 per common share, for the same period in 2002.

In the first nine months of 2003, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.2 million resulting from a warrant exchange approved by the Company`s stockholders on February 4, 2003 relating to the sale of Series C convertible preferred stock, and recorded stock dividends to preferred stockholders of $1.4 million, resulting in net loss applicable to common stockholders of $0.28 per common share. In the first nine months of 2002, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.9 million from the sale of Series B convertible preferred stock, and recorded stock dividends to preferred stockholders of $0.7 million, resulting in net loss applicable to common stockholders of $0.89 per common share.

The Company had $9.1 million of cash, restricted cash and short-term investments at September 30, 2003.

"We believe we are on track to achieve near the middle of our projected $32 to $36 million revenue range for 2003," said Bill Young, Chairman and CEO of ViroLogic. "We continue to focus our efforts on revenue generating activities in our patient testing and pharmaceutical drug development businesses. At the same time, our pragmatic expense management has led to a significantly reduced net loss and, combined with growing revenues, increased gross margin. This should enable us to generate cash from operating activities at a quarterly revenue run rate of approximately $10 to $11 million. While we will be providing full year 2004 guidance on our fourth quarter and year end conference call in February 2004, preliminarily we expect annual revenue growth that is consistent with levels we have achieved over the last two years. On the expense side, we plan to leverage the efficiencies of our existing infrastructure and scale operations to further grow our business, and build sustainable long-term profitability."

USA nachbörslich 1.75$

[dolly999]

und wie waren die Erwartungen?

Was wurd auf der Konferenz so gesagt?

[robby13]

VLGC nachbörslich um satte 14,72% auf 1,87$ im positivem Terrain ! Die Rakete kann ( mit etwas Geduld ) starten !
robby

[Dolocher]

Hier ganz ausführlich:

Investor Relations - Press Releases



ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ) News Release - 11/4/2003


--------------------------------------------------------------------------------
ViroLogic Announces Third Quarter 2003 Financial Results

Company Reports Third Quarter Revenue of $9.1 million, an Increase of Over 50

Percent over Third Quarter of 2002
SOUTH SAN FRANCISCO, Calif., Nov. 4 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the third quarter and nine months ended September 30, 2003.

The Company reported revenue of $9.1 million for the third quarter of 2003, an increase of 54 percent over revenue of $5.9 million for the third quarter of 2002. The growth was attributed to continuing steady performance of the Company`s patient testing products, which rose to $6.2 million in the third quarter of 2003 from $4.6 million in the third quarter of 2002, an increase of 35 percent. The growth was further enhanced this quarter by increases in pharmaceutical drug development and NIH grant revenues.

Gross margin was 50 percent in the third quarter of 2003 compared to 39 percent reported during the same quarter last year. Operating costs and expenses for the third quarter of 2003 were $9.6 million, compared to $11.5 million for the same period in 2002. The decrease in operating costs and expenses was the result of a company-wide focus to increase efficiencies and achieve improved economies of scale, partially offset by higher costs associated with increasing testing volume. Gross margin improvement was also driven by an increased contribution from pharmaceutical revenue during the third quarter.

Net loss for the third quarter of 2003 was $0.4 million, or $0.01 per common share, compared to a net loss of $5.6 million, or $0.23 per common share, for the same period in 2002.

In the third quarter of 2003, the Company recorded stock dividends to preferred stockholders of $0.4 million, resulting in net loss applicable to common stockholders of $0.02 per common share. In the third quarter of 2002, the Company recorded stock dividends to preferred stockholders of $0.2 million, resulting in net loss applicable to common stockholders of $0.24 per common share.

Nine Month Results

The Company reported revenue of $24.0 million for the first nine months of 2003, an increase of 31 percent over revenue of $18.3 million for the same period of 2002. Operating costs and expenses for the first nine months of 2003 were $29.3 million, compared to $35.8 million for the same period of 2002. This decrease was the result of ongoing operational improvements and economies of scale, and was partially offset by higher costs associated with increasing testing volume.

Net loss for the first nine months of 2003 was $5.1 million, or $0.17 per common share, compared to a net loss of $17.2 million, or $0.74 per common share, for the same period in 2002.

In the first nine months of 2003, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.2 million resulting from a warrant exchange approved by the Company`s stockholders on February 4, 2003 relating to the sale of Series C convertible preferred stock, and recorded stock dividends to preferred stockholders of $1.4 million, resulting in net loss applicable to common stockholders of $0.28 per common share. In the first nine months of 2002, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.9 million from the sale of Series B convertible preferred stock, and recorded stock dividends to preferred stockholders of $0.7 million, resulting in net loss applicable to common stockholders of $0.89 per common share.

The Company had $9.1 million of cash, restricted cash and short-term investments at September 30, 2003.

"We believe we are on track to achieve near the middle of our projected $32 to $36 million revenue range for 2003," said Bill Young, Chairman and CEO of ViroLogic. "We continue to focus our efforts on revenue generating activities in our patient testing and pharmaceutical drug development businesses. At the same time, our pragmatic expense management has led to a significantly reduced net loss and, combined with growing revenues, increased gross margin. This should enable us to generate cash from operating activities at a quarterly revenue run rate of approximately $10 to $11 million. While we will be providing full year 2004 guidance on our fourth quarter and year end conference call in February 2004, preliminarily we expect annual revenue growth that is consistent with levels we have achieved over the last two years. On the expense side, we plan to leverage the efficiencies of our existing infrastructure and scale operations to further grow our business, and build sustainable long-term profitability."

Recent Achievements
-- ViroLogic was ranked number 19 on the 2003 Deloitte Technology Fast
500, a list of the 500 fastest growing technology companies in North
America, based on revenue growth for the years 1998 - 2002.
-- ViroLogic was awarded a grant from the National Institute of Allergy
and Infectious Diseases (NIAID), a division of the U.S. National
Institutes of Health, to develop a Hepatitis C virus (HCV) drug
susceptibility assay. This grant award follows three previously
announced NIH grants to ViroLogic and brings the total grant awards
announced this quarter to more than $4 million to be funded over three
years.
-- ViroLogic announced the publication of updated guidelines from the
International AIDS Society USA (IAS-USA) and the U.S. Department of
Health and Human Services (DHHS) further supporting the value and
importance of resistance testing as a means to improve virologic
outcome among HIV infected individuals.
-- ViroLogic researchers and collaborators presented four studies using
the Company`s technology at the 43rd ICAAC in September, including a
presentation by Dr. Eric S. Daar, M.D., Director, Division of HIV
Medicine, Harbor-UCLA Research and Education Institute and Associate
Professor of Medicine, David Geffen School of Medicine at UCLA, Los
Angeles, which outlined the statistical analysis of data demonstrating
the utility of HIV Co-Receptor Tropism and Replication Capacity, a
gauge of "viral fitness," as predictors of clinical progression to
AIDS.
-- ViroLogic promoted Ken Hitchner to the position of Vice President,
Pharmaceutical Collaborations.

Conference Call Details
ViroLogic will hold a conference call today at 5:00 p.m. ET to discuss third quarter 2003 earnings results. The call will be hosted by Mr. Bill Young, Chairman & CEO of ViroLogic, Inc. To participate in the teleconference, please call 800-299-8538 fifteen minutes before the conference begins and ask to be connected to the ViroLogic teleconference. International callers please dial 617-786-2902. The call will also be webcast live at http://www.virologic.com/webcast.html. Please see web site for details.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.virologic.com.

Certain statements in this press release are forward-looking, including statements relating to anticipated growth in sales of testing products and ongoing benefits from cost reduction measures, expectations regarding 2003 and 2004 guidance, the development of new technology, the receipt of non-dilutive grants, projected operating results, continued acceptance of the Company`s products for patient testing and increasing demand from vaccine and drug development partners. These risks and uncertainties include, but are not limited to, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.


VIROLOGIC, INC.
SELECTED FINANCIAL DATA
(In thousands, except per share amounts)

Three months ended Nine months ended
September 30, September 30,
2003 2002 2003 2002
(Unaudited) (Unaudited)
Statement of Operations Data:
Revenue (a) $9,125 $5,927 $24,046 $18,292
------- ------- -------- --------
Operating costs and expenses:
Cost of product revenue 4,403 3,463 12,490 10,649
Research and development 1,090 2,469 3,525 8,286
General and administrative 2,113 2,279 6,954 7,661
Sales and marketing 1,990 3,333 6,301 9,181
------- ------- -------- ---------
Total operating costs and
expenses 9,596 11,544 29,270 35,777
------- ------- -------- --------
Operating loss (471) (5,617) (5,224) (17,485)
Interest income 22 54 85 252
Interest expense (32) (75) (120) (246)
Other income 52 52 156 295
------- -------- -------- --------
Net loss (429) (5,586) (5,103) (17,184)
Deemed dividend to preferred
stockholders -- -- (2,155) (2,860)
Preferred stock dividend (413) (249) (1,386) (715)
------- ------- -------- --------
Net loss applicable to common
stockholders $(842) $(5,835) $(8,644) $(20,759)
==== ==== ===== =====
Basic and diluted amounts per
common share:
Net loss $(0.01) $(0.23) $(0.17) $(0.74)
Dividends to preferred
stockholders (0.01) (0.01) (0.11) (0.15)
------- ------- -------- -------
Net loss applicable to common
stockholders $(0.02) $(0.24) $(0.28) $(0.89)
==== ==== ===== ====
Weighted average shares used in
computing basic and diluted net
loss per common share 34,365 24,695 30,809 23,449


September 30, December 31,
2003 2002 (b)
(Unaudited)
Balance Sheet Data
Cash, cash equivalents and short-term
investments $8,285 $11,145
Accounts receivable, net 5,109 4,924
Working capital 11,017 (239)
Restricted cash 776 707
Total assets 26,805 30,486
Long term obligations, less current portion 169 419
Redeemable convertible preferred stock 3,880 4,249
Total stockholders` equity $17,111 $7,014

(a) Revenue for the three and nine months period ended September 30, 2003
includes contract revenue of $366,000 and $950,000 compared to
$255,000 and $697,000 for the corresponding periods in 2002. Contract
revenue consists of NIH grant, commercial development and other
revenue. The costs associated with contract revenue for the three and
nine months ended September 30, 2003 totaled $432,000 and $767,000
compared to $255,000 and $697,000 for the corresponding periods in
2002, and are included in research and development expenses.
(b) The balance sheet data is derived from audited financial statements
for the year ended December 31, 2002, included in the Company`s Annual
Report on Form 10-K filed with the Securities and Exchange Commission.

SOURCE ViroLogic, Inc.

CONTACT:
Karen Wilson, CFO, of ViroLogic, Inc.,
[phone] or
[e-mail]

[Dolocher]

ist ja weiter oben schon mal gepostet...na,doppelt hält besser...

[robby13]

wer lesen kann ist klar im Vorteil !

[heikekarina]

[MaxLubin]

so und jetzt geht los!

...wer da für 1.49 verkauft hat

[heikekarina]

vor allen Dingen hätte er/die 1,54€ bekommen können

[heikekarina]

da sind die 1,54€ ja schon wieder. Ob sich da jemand ärgert?

[Viva-los-Tioz]

[Viva-los-Tioz]

USA 1,80$

[heikekarina]

ich sagte doch immer. long bleiben und in Ruhe abwarten. Totgesagte leben länger. Chart hat ein klares Kaufsignal regeneriert.

[robby13]

[Viva-los-Tioz]

1,85 $

[robby13]

Haben wir vielleicht eine zweite GERON in den Fingern ?
Die Zahlen waren jedenfalls Topp, es wird weiter gen Norden gehn!
Robby

[Viva-los-Tioz]

USA 1,87 $

Wünsche uns einen fetten grünen Virologic Tag

Gruß
Viva

[robin05]

hallo robby,

virologic halte ich schon ziemlich lange,
wuerde lieber wissen, ob dein toptip Edel Music noch
irgendwann abgeht ?

1000 Dank

robin

[heikekarina]

täusche ich mich, oder wird der Kurs gedeckelt.
Im ´3 Jahreschart klar zu erkennen das wir gestern die Tiefststände aus dem Jahr 2001 in der Aufwärtsbewegung getestet haben. Um die 1,80$ ahben wir einen Widerstand wie schon vor wenigen Monaten. Heute waren wir bereits über die 1,90$, und jedesmal wird ein Ansteigen durch kleine Verkäufe verhindert.

[udoernst]

na heike,
jetzt hat ein neuer anlauf auf die $ 2.- begonnen...

[heikekarina]

@udoernst

sehe ich auch so. Der erste Anstieg war aber auch wirklich übertrieben.

[heikekarina]

merkt hier eigentlich keiner was?

[heikekarina]

und immer noch unter Parität.

[udoernst]

na, dann freuen wir uns beide eben alleine, was heike?!

[wissi71]

Ich freu mich auch.... gern dauerhaft.

[thommyboy]

nix da, ich bin auch noch da und freue mich wenn man sich den umsatzverlauf der letzten 6 monate anschaut ist klar, daß da was am laufen ist...

[heikekarina]

ich hoffe nur das alle am Ball bleiben.

Gestern konnte meiner Meinung nach ein mehr als offensichtliches Deckeln des Kurses bemerkt werden. Das alte Spiel. Ich schmeisse ienpaar wenige, die anderen alles. Kurz vor Börsenschluss ein Trade mit 250K. Danach haben einige die kurz vor dem Nervenzusammenbruch gewesen sind ebenfalls die Gelegenheit genutzt zu verkaufen. Ich bleibe nach wie vor bei meiner persöhnlichen Einschätzung das wir bald die 2€ Marke passieren werden.

[robby13]

@robin05

gebe von Edel Music kein Stück aus der Hand ! Natürlich ist die Kursentwicklung von Edel in den letzten Wochen eher enttäuschend. Habe weiterhin noch etwas Geduld !
Das Unternehmen ist gesund , von der Börse noch nicht wiederentdeckt !
robby

[MaxLubin]

11:51:43 2.000 800 Nasdaq-NM at Ask
11:51:43 2.000 200 Nasdaq-NM at Ask
11:51:14 1.980 2500 Nasdaq-NM at Bid
11:51:14 1.980 1000 Nasdaq-NM at Bid
11:51:14 1.980 1200 Nasdaq-NM at Bid
11:51:14 1.980 1000 Nasdaq-NM at Bid
11:51:14 1.980 22600 Nasdaq-NM at Bid
11:50:54 2.000 1000 Nasdaq-NM at Ask
11:50:52 1.990 500 Nasdaq-NM
11:50:52 1.990 500 Nasdaq-NM

[udoernst]

in stuttgart jetzt auch schon ein bid von € 1,70.-

[Dolocher]

Investor Relations - Press Releases



ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ) News Release - 11/17/2003


--------------------------------------------------------------------------------
ViroLogic Announces New Jersey Medicaid Initiates Policy Covering HIV Drug Resistance Tests

48 States and the District of Columbia Medicaid Programs Now Reimburse
for Resistance Testing
SOUTH SAN FRANCISCO, Calif., Nov. 17 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the New Jersey Medicaid Program has initiated a benefit coverage policy for phenotypic and genotypic HIV drug resistance testing, effective November 1, 2003. New Jersey joins 47 other states and the District of Columbia to implement Medicaid policies enabling reimbursement of the Company`s HIV drug resistance assays.

New Jersey has the fifth highest incidence of cumulative reported AIDS cases. This includes the highest percentage of women reported with AIDS and the third highest number of reported pediatric AIDS cases. Medicaid is the single largest payer for these patient populations.

"Drug resistance threatens the recent gains made in treating HIV infection. HIV resistance testing offers clinicians the ability to adjust patient treatment accordingly. This new policy provides further validation of the utility of our resistance tests to manage HIV infection and will expand accessibility for many more patients who are likely to benefit from this important technology," said Tien Bui, ViroLogic`s Vice President of Sales and Marketing.

In addition to statewide Medicaid coverage, Medicare and many private payers, including but not limited to Aetna US Healthcare, BlueCross BlueShield, Humana and United HealthCare provide reimbursement and benefit coverage for ViroLogic`s HIV drug resistance assays. Several key states and the District of Columbia also provide funding for Ryan White Title programs.

Questions about HIV drug resistance testing and reimbursement can be directed to ViroLogic`s reimbursement hotline at 1-87-PHENOAID (1-877-436-6243), or to www.phenosense.com.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.virologic.com.

Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from physicians or from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

SOURCE ViroLogic, Inc.
-0- 11/17/2003
/CONTACT: Karen Wilson, CFO of ViroLogic, [phone], or
[e-mail]/
/Web site: http://www.virologic.com /
(VLGC)

CO: ViroLogic, Inc.
ST: California, New Jersey, District of Columbia
IN: BIO MTC HEA
SU: PDT LEG



RN-GF
-- SFM055 --
9922 11/17/2003 07:30 EST http://www.prnewswire.com

[udoernst]

das release zeigt wieder einmal mehr, dass vlgc auf dem richtigen weg ist....

[MaxLubin]

ViroLogic Announces New Jersey Medicaid Initiates Policy Covering HIVDrug Resistance Tests

SOUTH SAN FRANCISCO, Calif., Nov 17, 2003 /PRNewswire-FirstCall via Comtex/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the New Jersey Medicaid Program has initiated a benefit coverage policy for phenotypic and genotypic HIV drug resistance testing, effective November 1, 2003. New Jersey joins 47 other states and the District of Columbia to implement Medicaid policies enabling reimbursement of the Company`s HIV drug resistance assays.

New Jersey has the fifth highest incidence of cumulative reported AIDS cases. This includes the highest percentage of women reported with AIDS and the third highest number of reported pediatric AIDS cases. Medicaid is the single largest payer for these patient populations.

"Drug resistance threatens the recent gains made in treating HIV infection. HIV resistance testing offers clinicians the ability to adjust patient treatment accordingly. This new policy provides further validation of the utility of our resistance tests to manage HIV infection and will expand accessibility for many more patients who are likely to benefit from this important technology," said Tien Bui, ViroLogic`s Vice President of Sales and Marketing.

In addition to statewide Medicaid coverage, Medicare and many private payers, including but not limited to Aetna US Healthcare, BlueCross BlueShield, Humana and United HealthCare provide reimbursement and benefit coverage for ViroLogic`s HIV drug resistance assays. Several key states and the District of Columbia also provide funding for Ryan White Title programs.

[heikekarina]

vorbörslich bereits wieder über 1,90$

[robby13]

heute könnten wir durchaus über 2$ schließen.
Bei steigender Nasdaq reagiert vlgc kaum positiv , da vermutlich in Software und IT umgeschichtet wird. Sollten wir ev. einige neg. Tage bekommen , dürfte vlgc dovon eher profitieren !
robby

[robby13]

Time Price Volume Exchange Info


09:44:59 1.920 3300 Nasdaq-NM at Ask
09:44:50 1.910 500 Nasdaq-NM at Ask
09:44:50 1.880 500 Nasdaq-NM
09:44:40 1.910 200 Nasdaq-NM at Ask
09:44:17 1.870 3200 Nasdaq-NM at Bid
09:44:14 1.880 100 Nasdaq-NM
09:44:14 1.880 200 Pacific
09:44:14 1.880 100 Pacific
09:44:12 1.890 1200 Cincinnati
09:44:12 1.892 100 Cincinnati

[heikekarina]

ich kann langsam aber sicher nicht mehr verstehen das Virologic immer wieder geschmissen wird.

[Dolocher]

Zumindest die Deutschen Anleger scheinen mir etwas überängstlich zu sein,so das ein paar % Gewinn immer gleich realisiert werden.Ich bleibe long,denn die nächsten Quartalszahlen weisen mit ziemlicher Sicherheit bereits einen (wenn auch kleinen) Gewinn aus.
Für meine(VLGC) Zunkunft sehe ich grün...

[Tawos]

Heute wird vielleicht die 2 $ Marke geknackt, wenn nicht weiss ich auch nicht mehr :-( Allen Investierten viel Glück...

[heikekarina]

das die 2$ Marke heute geknackt wird, wünschen wir uns seid längerem hier. Auch die Amis scheinen mehr als interessiert zu sein, diese Marke fallen zu sehen. Die Pakete die über den Tisch gehen weisen zumindest darauf hin. Ein wenig Geduld werden wir noch haben müssen.

[CutPall]

Na ja, wirklich geschmissen wird Virologic ja nicht. Nach dem Anstieg der letzten Wochen ist die derzeitige Konsolidierung nichts Aussergewöhnliches, ausserdem ist der Gesamtmarkt ja auch nicht gerade euphorisch. Um 2$ scheinen ja einige Verkäufer unterwegs zu sein, aber die werden wir sicher auch bald knacken .
Bemerkenswert finde ich das Virologic in Frankfurt gut 3% billiger zu haben ist als in den Staaten. Hat einer von euch Erfahrungen mit Arbitragen ? Scheint ja leicht verdientes Geld zu sein, wenn man mit genug einsteigt, um die Gebühren auszugleichen.

[heikekarina]

@CutPall

es redet ja cu keiner davon das Anleger schmeissen die nur 1000 Stück im Depot haben. Diejenigen die grössere Pakete besitzen schmeissen auch nicht mehr. Das kannst Du hier und drüben beobachten. Du wirst leicht feststellen können, das es sich anscheinend um unerfahrene Anleger handelt.
Von einer Konsolodierung kannst Du auch nicht mehr sprechen, da Virologic sich bereits in einer Aufwärtsbewegung befindet und die 2$ Marke zweimal durchbrochen hat, die wiederum die Tiefstkurse aus dem Jahr 2001 dastellen. Hatte ich aber bereits zweimal geschrieben. Es kann Möglich sein das das Marktumfeld, das z.Z herrscht einen Anstieg verzögert, da mit Sicherheit ein wenig Nervosität in den Markt kommt.

[CutPall]

Kann das sein, dass die Anzahl der Aktien gestiegen ist . Die Marktkapitaliserung war doch noch vor ein paar Tagen bei gleichen Kursen um die 65 Mio $, jetzt ist sie laut Yahoo bei 82 Mio ??? Oder bilde ich mir das jetzt nur ein ?

[heikekarina]

da liegt wohl ein Fehler vor

[CutPall]

bei wem ??

[MaxLubin]

#49 bei yahoo! schau dir mal des an ..

http://host.wallstreetcity.com/wsc2/Free_RT_Quotes.html?temp…

Markt Kap. M59

[Dolocher]

Die 2$ fallen ganz sicher,ist nur eine Frage der Zeit,wir hatten diese Probleme schon bei anderen wichtigen Widerständen z.B. bei 1,60...
Bei Virologic dauert das eben immer etwas länger,allerdings halte ich das für eine recht gesunde und stabile Entwicklung und spricht dafür,das "Zocker" in diesem Wert nur eine untergeordnete Rolle spielen.
Ich habe die Hoffnung,das wir die 2$ noch vor Jahresende sehen werden...

[heikekarina]

das ist eine gesunde Einstellung

[CutPall]

@ MaxLubin

Mit deinem Link komme ich nur zu einer Anmeldeseite. Laut quicken.com ist die MK ebenfalls 80 Mio mit 44,364000 Aktien:
http://www.quicken.com/investments/snapshot/?p=VLGC&tag=1

Hier waren die Zahlen auch vor ein paar Tagen definitiv anders, nähmlich auch ca 60 Mio MK. Offensichtlich sind tatsächlich die Anzahl der Aktien in den letzten Tagen gestiegen, Yahoo und Quicken haben aktualisiert, die anderen Quellen wohl noch nicht. Würde auch den Druck auf den Kurs der Aktie in den letzten Tagen erklären. Mal schauen, ob man auf der HP von Virologic etwas mehr erfährt.

Grüsse

CutPall

[claudi34]

wenn ich die meldung zu den quartalszahlen richtig gelesen habe, werden an premium-shareholders statt einer dividende neue aktien ausgegeben. das könnte die erklärung sein.
werd mal ein mail an die IR verfassen.
lg aus münchen

[MaxLubin]

CONF: VLGC To Present At NYSSA Health Care Conference @ 13:30 ET[delayed]

Ridgeland, MS, NOV 19, 2003 (EventX/Knobias.com via COMTEX) -- Company representatives of ViroLogic Incorporated (NasdaqNM: VLGC) will be presenting at the NYSSA 7th Annual Health Care Industry Conference today. The Company`s presentation is scheduled to begin at 13:30 ET.

Expected Speaker(s):

William D. Young, Chairman and CEO

Misc Releated Info:

** Original Confirmation

** Conference Information:

NYSSA 7th Annual Health Care Industry Conference

This conference will provide investors with an opportunity to learn more about investing in various sectors of the health care industry, including biotechnology, medical devices, lab tools & services, and health care services. CEOs and CFOs from cutting edge companies will discuss their strategies for sustaining growth and increasing shareholder value.

Conference Dates: 11/18/2003-11/19/2003

The Harvard Club 27 West 44th Street

New York, NY

www.nyssa.org/events/111803-health-care-industry-conference.html

GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by at least 10 minutes. To get all Knobias alerts in real-time daily, visit www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.


CONTACT: Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx

[CutPall]

Hier ein paar Auszüge aus den letzten 10-Q Quartalsdaten Report (Quelle:http://www.quicken.com/investments/sec/frame/?p=VLGC)

...
As of November 10, 2003 there were 44,364,172 shares of the registrant’s common stock outstanding.
...


Common stock, $0.001 par value, 100,000,000 shares authorized; 39,145,417 and 28,263,255 shares issued and outstanding at September 30, 2003 and December 31, 2002, respectively



...

Das heisst die MK liegt bei einem Kurs von 1.86$ bei über 82 Mio`s.
Zwischen 30. September und 10. November müssen nochmals ca. 5 Mio Aktien in Umlauf gebracht worden sein, offensicht war dies die "non cash devidend".
Insgesamt haben sie die Zahl, der in Umlauf befindlichen Aktien innerhalb von einem Jahr um satte 50% erhöht !

Durch die "preferred stocks" haben wir in Zukunft noch weitere Verwässerungen zu erwarten.

Schade eigentlich, ursprünglich sah das ganze viel erfolgversprechender aus.

Gruss

CutPall

[Dolocher]

Vielleicht schaffen wir heute trotzdem die 2$,leider hat VLGC die Angewohnheit gegen Handelsende kräftig nachzugeben

[Tawos]

Super start heute , gerade fällt die 2$ Marke hoffentlich auch nachhaltig.

[claudi34]

so ich hab mich mal schlau gemacht.....
die berechnungen über die tatsächliche mk sind auf den ersten blick etwas schwierig.
in summe gibt es 100 mio shares zu 0,001 (die übliche nominale). davon sind rund 60 mio im umlauf(common shares) und die anderen 40 mio sind jene stücke, die etappenweise common shares im verhältnis 10:1 erhalten. also maximal 4 mio aus dem umlauf (der firmenanteil)
wie hoch der aktuelle streubesitz ist, kann ich nicht eruieren. lt. yahoo sind etwa 27% der shares im besitz institutioneller anleger.
insgesamt sind die indikatoren für den wert bullish.
vor allem in bezug auf flächendeckende hepatitis-tests in den usa (epidemie-angst), sars, west-nil, ebola. dazu kommt, dass die who 50 mio.usd pro jahr zusätzlich in die hiv-bekämpfung investieren will. in all diesen bereichen kann viro mit seinen testsystemen punkten.
lg aus münchen

[udoernst]

was passiert denn da jetzt auf einmal??
weiß jemand warum wir so einen anstieg haben?
adhoc? news?? freu!!

[wissi71]

Würde mich auch interessieren! Wobei es natürlich gut aussieht....

[turbos1]

Ich beoachte Virologic schon seit langem. Lohnt es sich noch bei dem jetzigen Kurs von 2,06 $ einzusteigen ? oder sollte man auf eine vorübergehende Schwäche warten ?

[robby13]

High: 2.100
Low: 1.850
Open: 1.850
Change: +0.19
Volume: 1,349,800


Bid: 2.050
beachte BID / ASK !
Ask: 2.060

Bid/Ask Size: 13,000 / 1,200


52 Wk High: 2.250
52 Wk Low: 0.750
%Change: 10.6%


Market Cap: 91M
Price/Sales: 1.9
EPS: $-0.77
P/E Ratio: N/A 11:55:09 2.050 3800 Pacific at Ask
11:55:09 2.050 1200 Pacific at Ask
11:55:09 2.050 700 Nasdaq-NM at Ask
11:55:07 2.050 200 Pacific at Ask
11:55:07 2.050 1600 Pacific at Ask
11:55:06 2.050 1200 Pacific at Ask
11:55:06 2.050 300 Nasdaq-NM at Ask
11:55:06 2.050 700 Nasdaq-NM at Ask
11:55:03 2.050 1800 Pacific at Ask
11:55:03 2.050 1200 Pacific at Ask


Click here for all of today`s intraday
robby





Market

[wissi71]

Hängt von deiner beabsichtigten Anlage dauer ab. Mittel- und langfristig gesehen machst du keinen Fehler. Kursrückschläge kann es immer mal geben. Ich denke, dass die nächsten Tage interessant sind. Etabliert sich Virologic über 2 $ - so glaube ich - geht es so schnell nicht mehr drunter.

[wissi71]

Robby, was meinst du?? Schaffen wir heute die 2 $ auch zum Börsenschluss??

[robby13]

#64
teile Deine Meinung durchaus ! Sollten die 2,00$ heute signifikant halten , gehts rasch Richtung 2,50$ !

[robby13]

Ich bin ja nu hier der Börsen-OPA, sei es drum .Für VLGC wird in 12/04 min. 10$ bezahlt , konservativ !
Schaut Euch mal die Pipeline an, dazu die Meinung ernstzunehmender Experten.
VLGC bleibt natürlich ein spekulatives Invest , andererseits mit krasser 500% - Chance , mittelfristig.
robby

[claudi34]

health care konferenzen bringen fast immer einen schwung in biostocks. bei virologic kommt dazu, dass die meisten ihrer testsysteme in den bereich "medical equipment" fallen und nicht die langen zulassungsprozeduren der fda durchlaufen müssen.
ein weiterer punkt ist (leider) die terrorangst. (ich bin eigentlich keine freudin von krisen-money.. aber).
virologic kann natürlich auch mit testreihen punkten, die sogenannte killerviren aufspüren. (va. west-nil, ebola, epstein-barr)
zusätzlich dürfte das who-projekt zur aids-bekämpfung eine rolle spielen. bekanntlich sollen zusätzlich 50 mio.USD pro jahr für die hiv-prophy zur verfügung stehen.

meine meinung: viro ist sicherlich kein zockerwert, sondern könnte ein invest sein, das im nächsten jahr nette kohle bringt. mein kursziel sind 4 euro auf eine sicht von 6 mon
aber bei bios habe ich schon die tollsten überraschungen erlebt. tenbagger und flops.
muss jeder selbst entscheiden, ob er das risiko eingeht.
lg
aus münchen

[robby13]

VLGC schließt heute bei 2,10 $ !

Date Open High Low Last Change Volume % Change
11/20/03 1.85 2.10 1.85 2.04 +0.18 1699403 +9.68%



Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Weak Average

Short Term Indicators
7 Day Average Directional Indicator Buy Weak Weakest
10 - 8 Day Moving Average Hilo Channel Hold Falling
20 Day Moving Average vs Price Buy Weak Weakening
20 - 50 Day MACD Oscillator Buy Strong Strongest
20 Day Bollinger Bands Hold Falling

Short Term Indicators Average: 60% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Hold Bearish
50 Day Moving Average vs Price Buy Strong Weakening
20 - 100 Day MACD Oscillator Buy Maximum Strongest
50 Day Parabolic Time/Price Sell Strong Weakening

Medium Term Indicators Average: 25% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Weak Weakest
100 Day Moving Average vs Price Buy Strong Average
50 - 100 Day MACD Oscillator Buy Maximum Strongest

Long Term Indicators Average: 100% - Buy

Overall Average: 64% - Buy

[heikekarina]

Euphorie schon und gut. Bis 2,50$ kann es sehr schnell, aber auch sehr langsam gehen, zumal hier noch ein paar Wiederstände erwarten.

[robby13]

heikarina
jaaaaaaaa, 1000% in 3 Tagen erwartet ja keiner....

[claudi34]

wie schon gesagt.. ein verdoppler bis Q1/2004 vom jetzigen niveau und ich bin zufrieden.
lg

ps: was ist mit medimmune??? die gewinnwarnung kenne ich, aber langfristig müsste flumist doch ein geschäft sein?

[wissi71]

... die 2 $ sind doch eine harte Nuss...

[Dolocher]

sieht nicht so aus,als könnte die 2$ halten,aber lange kann es nicht mehr dauern bis sie fällt und dann kann es recht schnell ein ganzes Stück nach oben gehen und die Geduldigen waren auch in den letzten Monaten die Gewinner

[turbos1]

wissi71
Danke, für die Beantwortung meiner Frage.
Ich glaube auch, dass virologic langfristig ein durchaus interessantes Investment ist. Werde heute vorsichtig einsteigen.
Mal sehen, wie sich der Kurs entwickeln wird ?

[MaxLubin]

Last: 1.990
Close: 1.990
High: 0.000
Low: 0.000
Open:
Change: +0.10
Volume: 286,200

Bid: 1.990
Ask: 2.000
Bid/Ask Size: 100 / 100


52 Wk High: 2.250
52 Wk Low: 0.750
%Change: 5.2%

da tut sich was ...

[wissi71]

Schaun mer mal, ob heute die 2 $ fallen...

[heikekarina]

ich denke nicht Simone

[claudi34]

bei 1,99 steht ein kleinerer eisberg (42k).. dann wäre das orderbuch fast sauber bis 2,09...
lg aus münchen.

stay cool, stay long...
da wird was draus

[heikekarina]

claudi34

Problem ist nur das es zwischen durch immer ein paar Nervöse in USA geben wird, die vorher schmeissen.

Ansonsten ganz klar deiner Meinung

Stay long

[heikekarina]

claudi34

gemerkt? unter 2$ wird immer noch verkauft. Leider auch grössere Pakete. Was uns jedoch nicht schrecjen sollte. Alles eine Frage der Zeit

[wissi71]

Ich hatte heut ein gutes Gefühl... Seht ihr auch ne 2 vorn beim Schlusskurs?

[wissi71]

Ich fass es nicht! So was von knapp daneben...

[MaxLubin]

Study Shows Assessing Early Virologic Response (EVR) To PEG-INTRON(R)Weight-Based Therapy For Hepatitis C Can Reduce Treatment Duration andCosts

KENILWORTH, N.J., Nov 24, 2003 /PRNewswire-FirstCall via Comtex/ -- Assessment of early virologic response (EVR) in patients with chronic hepatitis C following 12 weeks of individualized, weight-based dosing of PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection in combination with REBETOL(R) (ribavirin, USP) Capsules can identify patients unlikely to achieve a sustained response to a full course of therapy and, as a result, could reduce treatment duration and drug costs, according to a new study published in the current issue of The American Journal of Gastroenterology(1). The study is the first large detailed economic analysis of the use of EVR in making hepatitis C treatment decisions.

EVR is defined as at least a 99 percent (>2 log10) reduction in hepatitis C virus load (number of hepatitis C virus particles in the blood) at week 12 of therapy. A 12-week EVR provides patients and physicians with an early indicator for the likelihood of eradicating the hepatitis C virus from the blood at the end of treatment and, for those patients who attain EVR, it can help encourage patients to complete therapy.

"Our research showed that treatment management algorithms that monitor early viral response to PEG-INTRON and REBETOL combination therapy can substantially reduce mean treatment duration and drug costs," said lead author John B. Wong, M.D., professor of medicine, chief, Division of Clinical Decision Making, Department of Medicine, Tupper Research Institute, Tufts-New England Medical Center, Tufts University School of Medicine, Boston. "These findings can be very helpful for clinicians in making treatment decisions, especially given that not all patients will respond to treatment and adhering to therapy can be difficult for some patients. Clinical decisions regarding continuation of therapy for those with a negative EVR, should consider numerous factors, including the stage of liver disease, patient preferences and other potential treatment benefits," Wong said.

Combination therapy with peginterferon and ribavirin is the recognized standard of care worldwide in the treatment of chronic hepatitis C. Still, some patients do not achieve a sustained virologic response (SVR) even with a full course of this combination therapy. SVR, the accepted criterion for efficacy, is defined as the sustained undetectability of the hepatitis C virus six months following the end of treatment.

In the PEG-INTRON and REBETOL pivotal clinical study(2), 74 percent of patients demonstrated an EVR following 12 weeks of individualized, weight-based dosing of PEG-INTRON (1.5 ug/kg/week) and REBETOL (800 mg/day) combination therapy and, of those patients, 72 percent (positive predictive value) went on to achieve an SVR after a full, 48-week course of treatment. Importantly, of those patients who failed to attain an EVR at 12 weeks, none achieved an SVR (100 percent negative predictive value)(3).

Study and Results

The study extends the previous EVR findings(3) by examining the impact of assessing EVR on the cost of antiviral therapy for previously untreated patients with chronic hepatitis C. The study authors applied viral response and drug dosage data from the PEG-INTRON and REBETOL pivotal clinical study to a previously published and validated Markov model to project lifelong clinical and economic outcomes. Natural history and economic estimates were based on published literature, expert panel estimates and actual variable and reimbursement cost data.

The researchers calculated costs and savings based on halting treatment in patients who did not achieve an EVR at 12 or 24 weeks, taking into consideration costs associated with therapy and clinical tests, future hepatitis-related complications and estimates of patient lifespan and quality of life.

The analysis showed that the assessment of 12-week EVR for PEG-INTRON and REBETOL reduced costs by approximately 45 percent. Most of this cost savings was in patients infected with hepatitis C genotype 1, the most common virus type worldwide and most difficult to treat successfully. The cost savings of 12-week EVR testing in patients with hepatitis C genotype 2 or 3 was minimal because nearly all of these patients demonstrated a 12-week early virologic response.

Schering-Plough Commitment to Hepatitis C

As the leading innovator of interferon-based treatments for hepatitis C, Schering-Plough on Sept. 23, 2003, announced plans to initiate the IDEAL trial, a major clinical study involving 2,880 patients that for the first time will directly compare the two approved forms of pegylated interferon therapy for chronic hepatitis C: PEG-INTRON versus PEGASYS (peginterferon alfa-2a/Hoffmann-La Roche, Inc.), both used in combination with ribavirin. Schering-Plough Research Institute, in collaboration with leading medical centers, will conduct the comparative study in response to requests by the hepatitis C medical and patient communities, and to clear up misperceptions in the marketplace about these two treatments.

The company on Oct. 13, 2003, announced U.S. marketing approval of PEG-INTRON REDIPEN(TM), the first and only pen delivery system approved for administering pegylated interferon therapy. The pre-filled, disposable REDIPEN is designed to be simpler to use than a traditional vial and syringe, thus enhancing patient confidence with dosing of their PEG-INTRON regimen and making treatment administration easier for some patients.

PEG-INTRON and REBETOL Combination Therapy

PEG-INTRON and REBETOL combination therapy is the most prescribed treatment for hepatitis C worldwide and is indicated for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and are at least 18 years of age. More than 300,000 hepatitis C patients worldwide, including 175,000 U.S. patients, have received this combination therapy since its introduction in 2001.

PEG-INTRON, the only interferon product for hepatitis C approved for dosing according to body weight, uses proprietary PEG technology developed by Enzon, Inc. (Nasdaq: ENZN) of Bridgewater, N.J. PEG-INTRON, recombinant interferon alfa-2b linked to a 12,000 dalton polyethylene glycol (PEG) molecule, is a once-weekly therapy that has been shown to exert both antiviral and immunomodulatory effects. Schering-Plough holds an exclusive worldwide license to PEG-INTRON. REBETOL is an oral formulation of the antiviral agent ribavirin, a synthetic nucleoside analog.



WARNING

-- REBETOL monotherapy is not effective for the treatment of chronic
hepatitis C virus infection and should not be used alone for this
indication. (See WARNINGS.)

-- The primary toxicity of ribavirin is hemolytic anemia. The anemia
associated with REBETOL therapy may result in worsening of cardiac
disease that has led to fatal and nonfatal myocardial infarctions.
Patients with a history of significant or unstable cardiac disease
should not be treated with REBETOL. (See WARNINGS, ADVERSE REACTIONS,
and DOSAGE AND ADMINISTRATION.)

-- Significant teratogenic and/or embryocidal effects have been
demonstrated in all animal species exposed to ribavirin. In addition,
ribavirin has a multiple-dose half-life of 12 days, and so it may
persist in nonplasma compartments for as long as 6 months. Therefore,
REBETOL therapy is contraindicated in women who are pregnant and in the
male partners of women who are pregnant. Extreme care must be taken to
avoid pregnancy during therapy and for 6 months after completion of
treatment in both female patients and in female partners of male
patients who are taking REBETOL therapy. At least two reliable forms
of effective contraception must be utilized during treatment and during
the 6-month post-treatment follow-up period. (See CONTRAINDICATIONS,
WARNINGS, PRECAUTIONS-Information for Patients and Pregnancy Category
X.)

-- Alpha interferons, including PEG-INTRON and INTRON A, may cause or
aggravate fatal or life-threatening neuropsychiatric, autoimmune,
ischemic and infectious disorders. Patients should be monitored
closely with periodic clinical and laboratory evaluations. Patients
with persistently severe or worsening signs or symptoms of these
conditions should be withdrawn from therapy. In many but not all cases
these disorders resolve after stopping therapy with PEG-INTRON or
INTRON A. (See WARNINGS, ADVERSE REACTIONS.)

PEG-INTRON

There are no new adverse events specific to PEG-INTRON as compared to INTRON A, however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. The most common adverse events associated with PEG-INTRON were "flu-like" symptoms, occurring in approximately 50% of patients, which may decrease in severity as treatment continues. Application site disorders were common (47%), but all were mild (44%) or moderate (4%) and no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving PEG-INTRON. Alopecia (thinning of the hair) is also often associated with alpha interferons including PEG-INTRON.

Psychiatric adverse events, which include insomnia, were common (57%) with PEG-INTRON, but similar to INTRON A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEG-INTRON. PEG-INTRON is contraindicated in patients with autoimmune hepatitis and decompensated liver disease.

The following serious or clinically significant adverse events have been reported at a frequency <1% with PEG-INTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages and cotton wool spots.

Renal failure patients should be closely monitored for signs and symptoms of interferon toxicity and PEG-INTRON should be used with caution in patients with creatinine clearance <50 mL/min. Patients on PEG-INTRON therapy should have hematology and blood chemistry testing before the start of treatment and then periodically thereafter.

INTRON A

All patients receiving INTRON A therapy experienced mild-to-moderate side effects. Some patients experienced more severe side effects, including neutropenia, fatigue, myalgia, headache, fever, chills and increased SGOT. Other frequently occurring side effects were nausea, vomiting, depression, alopecia, diarrhea and thrombocytopenia. DEPRESSION AND SUICIDAL BEHAVIOR, INCLUDING SUICIDAL IDEATION, SUICIDAL ATTEMPTS, AND COMPLETED SUICIDES, HAVE BEEN REPORTED IN ASSOCIATION WITH TREATMENT WITH ALFA INTERFERONS, INCLUDING INTRON A THERAPY.

DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking" statements concerning, among other things, the future prospects of the company and its products, which the reader of this release should understand are subject to substantial risks and uncertainties. The company`s business prospects and the prospects of its products may be adversely affected by general market and economic factors, competitive product development, product availability, current and future branded, generic and OTC competition, market acceptance of new products, federal and state regulations and legislation, the regulatory review process in the United States and foreign countries for new products and indications, existing manufacturing issues and new manufacturing issues that may arise, timing of trade buying, patent positions, litigation and investigations, and instability or destruction in a geographic area important to the company due to reasons such as war or SARS. For further details and a discussion of these and other risks and uncertainties, see the company`s Securities and Exchange Commission filings, including the company`s 8-K filed Oct. 22, 2003.

Schering-Plough Corporation is a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical products worldwide.

For more information about Schering-Plough, visit the company`s website at www.schering-plough.com. For information about hepatitis and for full prescribing information for PEG-INTRON and REBETOL, visit www.hepatitisinnovations.com.

PEGASYS and COPEGUS are trademarks of Hoffmann-La Roche Inc. See PEGASYS and COPEGUS product inserts for information on these products.




References
(1) Wong JB, Davis GL, McHutchison JG, Manns MP, Harvey J, Albrecht J, for
the International Hepatitis Interventional Therapy (IHIT) Group.
Economic and clinical effects of evaluating rapid viral response to
peginterferon alfa-2b plus ribavirin for the initial treatment of
chronic hepatitis C. Am J Gastroenterol 2003;98(11):2,354-2,362.

(2) Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar
R, Goodman ZD, Koury K, Ling M-H, Albrecht JK, and the International
Hepatitis Interventional Therapy (IHIT) Group. Peginterferon alfa-2b
plus ribavirin compared with interferon alfa-2b plus ribavirin for
initial treatment of chronic hepatitis C: a randomised trial. Lancet
2001; 358:958-965.

(3) Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J.
Early virologic response to treatment with peginterferon alfa-2b plus
ribavirin in patients with chronic hepatitis C. Hepatology, Vol. 38,
No. 3, 2003, pp. 645-652.

SOURCE Schering-Plough Corporation


CONTACT: Media - Robert J. Consalvo, [phone], or Investors -
Lisa W. DeBerardine, [phone], both for Schering-Plough Corporation
/Company News On-Call: www.prnewswire.com/comp/777050.htm

[heikekarina]

@MaxLubin

und was soll uns das jetzt sagen?

positiv? negativ? neutral?

[heikekarina]

Der erste Block liest sich nicht schlecht

Übersetzung ist zwar nicht die beste, aber auf Deutsch


Die Studie Erscheinen, die frühe Virologic Antwort (EVR) festsetzen zu Stöpsel-INTRON(R)Weight-Gegründeter Therapie für Hepatitis C können Behandlung-Dauer andCosts verringern KENILWORTH, New Jersey, Nov. 24, 2003/PRNewswire-FirstCall über Comtex/-- Einschätzung der frühen virologic Antwort (EVR) bei Patienten mit der chronischen Hepatitis C, die 12 Wochen des individualisierten, Gewicht-gegründeten Dosierens Stöpsel-intron(r) (peginterferon alfa-2b) folgt des Puders für Einspritzung im Verbindung mit REBETOL(R) (Ribavirin, USP) Kapseln kann die Patienten kennzeichnen, die unwahrscheinlich sind, eine unterstützte Antwort zu einem vollen Kurs der Therapie zu erzielen und könnte Behandlungdauer- und -drogekosten, entsprechend einer neuen Studie infolgedessen verringern, die in der gegenwärtigen Ausgabe des amerikanischen Journals von Gastroenterology(1) veröffentlicht wird. Die Studie ist die erste große ausführliche ökonomische Analyse des Gebrauches EVR, wenn sie Behandlungentscheidungen der Hepatitis C trifft. EVR wird als mindestens Verringerung 99 Prozent (> 2 log10) der Viruslast der Hepatitis C (Zahl der Viruspartikel der Hepatitis C im Blut) an Woche 12 der Therapie definiert. Ein 12-week EVR liefert Patienten und Ärzte mit einer frühen Anzeige für die Wahrscheinlichkeit des Ausrottens des Virus der Hepatitis C vom Blut am Ende der Behandlung und, für jene Patienten, die EVR erreichen, es können helfen, Patienten anzuregen, Therapie durchzuführen. "unsere Forschung zeigte, daß Behandlungmanagementalgorithmen, die frühe Virenantwort zum Stöpsel-intron und zur REBETOL Kombination Therapie überwachen, Mittelbehandlungdauer- und -drogekosten im wesentlichen verringern können," sagte Leitung Autor John B. Wong, M.D., Professor von Medizin, Leiter, Abteilung der klinischen Beschlußfassung, Abteilung von Medizin, Tupper Forschungsinstitut, Büschel-Neue England medizinische Mitte, Büschel-Universitätsschule von Medizin, Boston ", das diese Entdeckungen für Kliniker sehr nützlich sein können, wenn man Behandlungentscheidungen trifft, besonders angenommen, nicht alle Patienten auf Behandlung reagieren und das Befolgen Therapie für einige Patienten schwierig sein kann. Die klinischen Entscheidungen betreffend sind Fortsetzung der Therapie für die mit einem negativen EVR, sollten zahlreiche Faktoren, einschließlich des Stadiums der Leberkrankheit, geduldige Präferenzen und anderen möglichen Behandlungnutzen betrachten, "gesagtes Wong. Kombination Therapie mit peginterferon und Ribavirin ist der anerkannte Standard von Obacht weltweit in der Behandlung der chronischen Hepatitis C. Still, einige Patienten erzielen nicht eine unterstützte virologic Antwort (SVR) sogar mit einem vollen Kurs dieser Kombination Therapie. SVR, das geltende Kriterium für Wirksamkeit, wird als das unterstützte undetectability des Virus der Hepatitis C sechs Monate dem Ende der Behandlung folgend definiert. Im Stöpsel-intron und im REBETOL klinisches als Drehpunktstudy(2), demonstrierten 74 Prozent Patienten ein EVR, das 12 Wochen des individualisierten, Gewicht-gegründeten Dosierens des Stöpsels-intron (1,5 ug/kg/week) folgt und REBETOL (800 mg/day) Kombination Therapie und, jener Patienten, 72 Prozent (positiver vorbestimmter Wert) fuhren fort, ein SVR nach einem vollem, 48-week zu erzielen Behandlungsmethode. Wichtig von jenen Patienten, die ein EVR bei 12 Wochen erreichen nicht konnten, erzielten keine ein SVR (100 Prozent negatives vorbestimmtes value)(3).

[heikekarina]

keine Ahnung, was das heißen soll


Studie und Resultate Die Studie verlängert das vorhergehende EVR findings(3), indem sie die Auswirkung des Festsetzens von von EVR auf die Kosten der Antivirentherapie für vorher unbehandelte Patienten mit chronischer Hepatitis C. The überprüft, Studie, die Autoren Virenantwort anwendeten und Drogedosierungdaten vom Stöpsel-intron und REBETOL klinische als Drehpunktstudie zu einem vorher erschienenen und validierten Markov modellieren, um lebenslängliche klinische und ökonomische Resultate zu projizieren. Naturgeschichte und ökonomische Schätzungen basierten auf erschienenen Schätzungen der Literatur-, Expertengruppe und tatsächlicher Variable und Vergütungkostendaten. Die Forscher errechneten die Kosten und Sparungen, die auf anhaltener Behandlung bei den Patienten basierten, die ein EVR nicht bei 12 oder 24 Wochen erzielten und zogen in Erwägung die Kosten, die mit Therapie und klinischen Tests, zukünftigen Hepatitis-in Verbindung stehenden Komplikationen und Schätzungen der geduldigen Lebensdauer und der Lebensqualität dazugehörig sind. Die Analyse zeigte, daß die Einschätzung von 12-week EVR für Stöpsel-intron und REBETOL Kosten um ungefähr 45 Prozent verringerte. Die meisten Sparungen dieser Kosten war bei den Patienten, die mit Genotypus 1 angesteckt wurden, die allgemeinste Virusart der Hepatitis C weltweit und am schwierigsten, erfolgreich zu behandeln. Die Kostensparungen von 12-week EVR, das bei Patienten mit Genotypus 2 oder 3 der Hepatitis C prüft, waren minimal, weil fast ~~~~ diese Patienten eine frühe virologic Antwort 12-week demonstrierten. Schering-Pflug Verpflichtung gegenüber Hepatitis C Als der führende Pionier der Interferon-gegründeten Behandlungen für Hepatitis C, pegylated Schering-Pflug an Sept. 23, 2003, die verkündeten Pläne, zum des IDEALEN Versuches einzuleiten, eine klinische hauptsächlichstudie, die 2.880 Patienten mit einbezieht, dessen zum ersten Mal direkt zwei genehmigten Formen vergleicht, Interferontherapie für chronische Hepatitis C: Stöpsel-intron gegen PEGASYS (peginterferon alfa-à/Hoffmann-La Roche, Inc.), beide verwendet im Verbindung mit Ribavirin. Schering-Pflug Forschungsinstitut, gemeinsam mit dem Führen der medizinischen Mitten, leitet die vergleichbare Studie in Erwiderung auf Anträge durch die Hepatitis C medizinische und geduldige Gemeinschaften und räumt misperceptions im Markt über diese zwei Behandlungen auf. Die Firma an Okt. 13, 2003, verkündete VEREINIGTE STAATEN Marketing-Zustimmung des Stöpsels-intron REDIPEN(TM), die erste und nur das Federanlieferung System, das für das Ausüben genehmigt wurde, pegylated Interferontherapie. Das pre-filled, Wegwerf-REDIPEN wird entworfen, um, zu verwenden als eine traditionelle Phiole und eine Spritze einfacher zu sein und so erhöht geduldiges Vertrauen mit dem Dosieren ihrer Stöpsel-intron Regierung und dem Bilden der Behandlungleitung einfacher für einige Patienten. Stöpsel-intron und REBETOL Kombination Therapie Stöpsel-intron und REBETOL Kombination Therapie ist die vorgeschriebene Behandlung für Hepatitis C weltweit und wird für die Behandlung chronischer Hepatitis C bei Patienten mit ausgeglichener Leberkrankheit angezeigt, die nicht vorher mit Interferonalpha behandelt worden sind und ist mindestens 18 Jahre des Alters. Mehr als 300.000 Patienten der Hepatitis C weltweit, einschließlich 175.000 VEREINIGTE STAATEN Patienten, haben diese Kombination Therapie seit seiner Einleitung 2001 empfangen. Stöpsel-intron, das einzige Interferonprodukt für Hepatitis C genehmigte für das Dosieren entsprechend Körpergewicht, verwendet die eigene STÖPSEL-Technologie, die durch Enzon, Inc. entwickelt wurde (Nasdaq: ENZN) von Bridgewater, New Jersey Stöpsel-intron, das recombinant Interferon alfa-2b, das mit einem verbunden wird Molekül des 12.000 Dalton Polyäthylenglykols (STÖPSEL), ist eine einmal wochentliche Therapie, die gezeigt worden ist, um die Antiviren- und immunomodulatory Effekte anzuwenden. Schering-Pflug hält einen exklusiven weltweiten Lizenz Stöpsel-intron. REBETOL ist eine Mundformulierung des Antivirenmittelribavirins, eine synthetische Nukleosidentsprechung

[MaxLubin]

#85 .. das wollte ich auch wissen

[udoernst]

wer zu faul ist, die amek. version zu lesen, schaue einfach auf die kurse

mal schauen, ob die $ 2.- heute überwunden werden...

[heikekarina]

@udoernst

BM

[heikekarina]

Virologic will ja über die 2$!!! Nur die Amis müssten das gute Stück auch mal laufen lassen. Denen geht es aber nicht anders wie uns hier. Die meisten nehmen vor lauter Gier lieber mit, als diesen Wert auch mal ein paar Monate zu halten.

[claudi34]

die news hat mit der virologic-aktie nichts zu tun, sondern bezieht sich auf neue medikamente von schering.
"virologic response" heißt im konkreten fall, dass die hepatitis-erreger in einem frühen stadium auf die therapie mit den genannten präparaten ansprechen.

virologic stellt bekanntlich keine medikamente her, sondern produkte und tests zum raschen nachweis von viralen infektionen und zum erkennen des erregertyps.
lg aus münchen

ps: wer zeit hat, wird bei dem "baby" im kommenden jahre kurse von über 4 bucks sehen

[heikekarina]

hmm, sieht heute nicht dolle aus

[wissi71]

Hab mir auch etwas mehr versprochen. Aber bis zum Feierabend ist ja noch etwas Zeit....

[Dolocher]

Die 2$-Marke hält! ...aber nicht mehr lange!

[MaxLubin]

...klar, weil noch diese Woche fällt 2.25$

[heikekarina]

Guten Morgen

[MaxLubin]

Morgen

[CutPall]

Vorbörslich sieht es wieder ganz nett aus:

Bid: 2.05 x 5000
Ask: 2.00 x 100

[heikekarina]

100

[CutPall]

Wenn das Verhältnis zwischen Käufer und Verkäufer weiterhin so bleibt, könnte es ein schöner Tag werden

[heikekarina]

wir werden es sehen. Genug Anläufe hat es in den letzten Tagen bereits gegeben. Wir üben uns weiter in Geduld!!!

[udoernst]

#101 könnte recht behalten...

dann hätten wir die bären platt gemacht....

kennt jemand das short-interest von vlgc?
nicht dass den shorties der kurs noch um die ohren fliegt??

[CutPall]

War ja nur ein Scherz.
Die letzte Handelsstunde in den Staaten dürfte mal wieder zeigen, ob wir uns noch geduldigen müssen oder nicht. Dieser Verkaufsdruck ist schon lästig, bin wirklich neugierig wer das ist. An Privatanleger glaub ich nicht, eher die Empfänger von Gratisaktien.

[heikekarina]

lange dürften die Shorties tatsächlich nicht mehr durchhalten. Obwohl es den Anschein hat das es noch vereinzelte Versuche gibt

[heikekarina]

2,08$, selbst bei Gratisaktien würde ich nicht verkaufen

Habe vor 3 Jahren mal Aktien im Wert von 7.500€ durch ein Spinoff gartis bekommen. Damaliger Kurs 1,60. Heute 4,50.
Frage mich immer wieder, warum ich die nicht verkaufe.

[heikekarina]

2,09$ und das Bid zieht fleissig mit. Da bin ich wirklich gespannt ob das so weiter geht

[CutPall]

Hmm, der Angriffspunkt der Shorties, die Verwässerung durch die "non cash dividend" ist schon bekannt und inzwischen abgeschlossen. Auch sonst ist offensichtlich an negativen Nachrichten nichts zu erwarten, im Gegenteil, der Break-Even steht vor der Tür. Einen Grund für eine wirkliche Spekulation gegen Virologic sehe ich zur zeit nicht. Wie gesagt, höchstens noch Gewinnmitnahmen aus ausgegebenen Gratisaktien, waren ja ne ganze Menge.

[CutPall]

Ich denke, ein Grossinvestor, der Gratisaktien statt einer Bar-Ausschüttung erhält, könnte sich da anders als ein Privater verhalten und trotz guter Chancen verkaufen, da er vielleicht die Einnahmen in seiner Kalkulation schon fest verplant hat und er das Geld in Cashform erwartet.

[heikekarina]

für das der Markt in USA erst seid einer Stunde eröffnet ist, sind die Stückzahlen weit über dem, was wir in den letzten Tagen erlebt haben. Bisher haben wir schon fast 50% der sonst üblichen Tagesumsätze gesehen

[CutPall]

Sieht wirklich wieder gut aus! Bis jetzt war es ja leider so, dass wenn wir stark begonnen hatten und die 2$ geknackten, die letzte Handelstunde uns wieder mit massiven Verkäufen platt gemacht hat. Ich werde mir den Kurs wohl erst um 22 Uhr wieder anschauen.

[heikekarina]

noch ca. 100K und das übliche Tagesvolumen ist erreicht. Bis 2,00$ ist nach unten alles abgesichert. Ich denke das wir uns zumindset für Heute keine zu grossen Gedanken machen müssen. Obwohl ich es lieber sehen würde, wenn VLGC in kleineren Sprüngen nach oben gehen würde

[heikekarina]

auf der Askseite bereits 2,70 zu sehen. Die werden zwar nicht gleich an diesem Handelstag fallen, aber sie werden

[CutPall]

Ich denke, der Bereich um 2$ ist nur dynamisch und mit starken Umsätzen zu knacken, so umkämpft wie er in der letzten Zeit war. Nach dem (hoffentlichen) Passieren des Jahreshochs um 2.25$ kann es von mir aus auch wieder langsamer vorangehen.

[bernie55]

"112"..........
würde auch viel lieber kleine anstiege mit kleinen zwischenpausen sehen.........uns allen "good luck"

[heikekarina]

@bernie55

dito

[wissi71]

Kleine und sehr sichere Sprünge wären mir auch lieber, aber es macht auch viel Spass, sich den heutigen Kursverlauf anzusehen...
Übrigens mal ein Dankeschön an alle! Hier läuft eine niveauvolle Unterhaltung, die ich immer wieder gern mal nachlese. Bitte weiter so!

[Viva-los-Tioz]

Das sieht doch alles sehr gut aus

Auf weitere grüne Tage


Gruß
Viva

[heikekarina]

Guten Morgen

Was ist bei W:0 los? Haben die mal wieder Schwierigkeiten ihre Seiten auf Vordermann zu bringen?

[heikekarina]

nur so am Rande

Symbol: VLGC
Last Trade: 2.26 Nov 25
After Hours Change: 0.031 (1.39%)
Today`s Change: 0.28 (14.14%)
Bid: 2.24
Ask: 2.40

[robby13]

Time Price Volume Exchange Info


18:28:43 2.260 2300 Pacific
18:28:03 2.260 200 Cincinnati at Bid
18:21:44 2.290 2500 Cincinnati
18:18:10 2.290 2100 Cincinnati
18:01:18 2.350 1000 Pacific
18:00:43 2.320 1000 Pacific
18:00:27 2.290 300 Cincinnati
17:40:03 2.290 1500 Cincinnati
17:40:02 2.270 500 Pacific
17:30:34 2.290 1200 Cincinnati

[robby13]

VLGC - VIROLOGIC INC (NASDAQ)
Date Open High Low Last Change Volume % Change
11/25/03 2.00 2.32 2.00 2.23 +0.25 3231123 +12.63%



Composite Indicator -- Signal -- -- Strength -- -- Direction --
Trend Spotter (TM) Buy Maximum Strongest

Short Term Indicators
7 Day Average Directional Indicator Buy Strong Strongest
10 - 8 Day Moving Average Hilo Channel Buy Maximum Strongest
20 Day Moving Average vs Price Buy Maximum Strongest
20 - 50 Day MACD Oscillator Buy Maximum Strongest
20 Day Bollinger Bands Buy Average Strongest

Short Term Indicators Average: 100% - Buy

Medium Term Indicators
40 Day Commodity Channel Index Buy Average Strongest
50 Day Moving Average vs Price Buy Maximum Strongest
20 - 100 Day MACD Oscillator Buy Maximum Strongest
50 Day Parabolic Time/Price Buy Maximum Strongest

Medium Term Indicators Average: 100% - Buy

Long Term Indicators
60 Day Commodity Channel Index Buy Maximum Strongest
100 Day Moving Average vs Price Buy Maximum Strongest
50 - 100 Day MACD Oscillator Buy Maximum Strongest

Long Term Indicators Average: 100% - Buy

Overall Average: 100% - Buy

[claudi34]

aktuell (10.55):
außerbörslich usa:

bid: 2,24
ask: 2,40

lg aus münchen

[udoernst]

hier der gestrige Kommentar von "american bulls":

"Today a Long White Candlestick formed. Buyers were aggressive and buying pressure was strong. Be careful, this may lead to excessive bullishness!"

nun, für alle investierten wäre das ja nicht so schlimm, nicht wahr?

[heikekarina]

Symbol: VLGC
Last Trade: 2.25 11:48AM ET
After Hours Change: N/A
Today`s Change: 0.27 (13.64%)
Bid: 2.22
Ask: 2.25


@udoernst

denke nicht das hier jemand etwas gegen diese Ausssage hat

[heikekarina]

(RTM/ECN): 2.26 0.031 (1.39%)

[heikekarina]

hier mal die derzeitigen BID und ASK Orders ausserbörslich
So könnte es ruhig weiter gehen


Bid Orders
Price Order Size Institution
1.91 2000 Archipelago

Ask Orders
Price Order Size Institution
2.29 1000 Archipelago
2.38 500 Archipelago
2.40 3745 Archipelago
2.43 500 Archipelago
2.45 2000 Archipelago
2.47 2000 Archipelago
3.13 1500 Archipelago


Bid Orders
Price Order Size Institution
2.25 300 Island
2.20 500 Island
2.10 4800 Island
2.04 300 Island
2.00 2000 Island
2.00 1000 Island
2.00 500 Island
1.85 2000 Island
1.80 26900 Island
1.71 1000 Island
1.65 300 Island

Ask Orders
Price Order Size Institution
2.43 2000 Island
2.45 1750 Island
2.48 1000 Island
2.70 5031 Island
2.70 6000 Island
2.72 4000 Island
2.86 2000 Island
2.97 9000 Island
2.98 4500 Island
2.99 4000 Island
47.00 125 Island

[claudi34]

kurzfristig wäre eine konsolidierung notwendig, um luft für einen nachhaltigen aufschwung zu haben.
sind noch etliche zocker (siehe us-boards) in dem papier drinnen.
ein fivebagger (gesehen von der basis 1,43USD) ist das ding allemal.
wenn es eine bullen-rallye gibt, werden wir halt einen sehr schnellen fiver haben, sonst auf sicht von 6 mon.
lg
aus münchen
claudi

[claudi34]

orderbuch hat im moment luft bis 2,7 .
selbst dort liegt mit 11.031 nur ein kitzekleiner eisberg.
lg aus münchen

[heikekarina]

Orderbuch war bereits gestern bis 2,70 ordentlich gefüllt

[heikekarina]

Symbol: VLGC
Last Trade: 2.35 10:02AM ET
After Hours Change: N/A
Today`s Change: 0.121 (5.43%)
Bid: 2.34
Ask: 2.38

[udoernst]

was geht denn da ab? ne short-squeeze??

[heikekarina]

ich würde mal sagen, das das der Ausbruch sein dürfte

[claudi34]

short-interest für november lagen bei 1,3 mio shares...
jetzt wird gecovert

[heikekarina]

ruft mal diese Seite auf, da könnt ihr erfahren wie die Analysten eingetsellt sind. Sieht sehr positiv aus


http://www.stockta.com/cgi-bin/analysis.pl?symb=VLGC&num1=3&…[IMG][/url]

[heikekarina]

[LoggerC]

Was geht denn hier ab?

[heikekarina]

das geht hier ab. Kurs in FSE unter Parität

Last Trade: 2.41 11:08AM ET

[heikekarina]

2.44 11:15AM ET

[bernie55]

2.48
11:35:25

[heikekarina]

2.49 12:41

[wissi71]

Hallo an alle! Sieht heut wieder gut aus. Ich denke, dass sicher nach dem Anstieg erst mal ne Verschnaufpause angesagt ist. Wär ja auch gesund. Und dann wieder weiter...

[Tawos]

.

Hab hier noch ein Sahnestück prcs WKN: 934859 für Euch , persönlich leider in 2001 für $16 rein aber bin guter dinge das ich die bald wieder sehe.

tawos

[MaxLubin]

... 8X8, INC. 907912
wenn dann richtig

[MaxLubin]

14:32:51 2.490 64300 Nasdaq-NM at Ask
14:32:10 2.460 10000 Nasdaq-NM at Bid
14:32:05 2.480 1300 Nasdaq-NM
14:32:04 2.470 1000 Nasdaq-NM
14:32:02 2.470 5000 Nasdaq-NM at Ask
14:32:00 2.470 5000 Nasdaq-NM at Ask

[bernie55]

2.54 um 14.47

[MaxLubin]

16:03:38 2.660 195300 Nasdaq-NM
16:02:24 2.680 500 Nasdaq-NM
16:00:27 2.680 20000 Nasdaq-NM
16:00:26 2.680 20000 Nasdaq-NM
16:00:01 2.671 100 Nasdaq-NM at Ask
16:00:01 2.700 200 Nasdaq-NM at Ask
15:59:53 2.690 400 Cincinnati
15:59:52 2.690 400 Nasdaq-NM
15:59:50 2.690 400 Cincinnati at Ask
15:59:50 2.690 600 Nasdaq-NM at Ask

[bernie55]

2.69 um 15:48:49

[CutPall]

Da waren sie die amerikanischen Zocker, VLGC ist in der Beliebtheitsskala der US-Foren gewaltig gestiegen. Aus den erhofften ruhigen weiteren Kursverlauf wird wohl nichts mehr. Die nächste Zeit wird sicher so volativ wie spannend bleiben. Mal sehen wie weit die Gier geht

[robby13]

Nuja , Gier hin oder her. Wichtiger erscheinen mir eher die Fundamentaldaten ( Produktpipeline usw. ) der Firma und jene scheinen nicht uninteressant zu sein.
(www.virologic.com )
Einerseits sind kleinere Biotechwerte immer risikoreich , bieten verschiedentlich aber auch hohes Kurspotential.
Virologic bleibt weiterhin hochintessant. Technische Korrekturen werde ich gelassen aussitzen.
robby

[CutPall]

Greed is good ! Zumindest im Fall von Virologic
Den Kursverlauf sehe ich natürlich auch fundamental begründet und nicht nur durch Zocker angetrieben und wenn noch ein bischen Massengier dazukommt, kann man sich das ganze ziemlich relaxed anschauen.

[robby13]

Selbst recht seriöse Börsenbriefe ( Taipan ) setzen Kursziele von 5$ für vlgc an. Schaun mer mal was uns die nächsten Tage so ins Haus steht. Vielleicht gibts ja auch seitens vlgc positive News ?
robby

[linklink]

Orderbuch

Bid Orders
Price Order Size Institution
2.70 26 Island
2.60 38000 Island
2.55 1500 Archipelago
2.55 3000 Island
2.53 2000 Island
2.45 300 Archipelago
2.44 450 Island
2.41 1000 Island
2.20 2000 Island
2.15 100 Island
2.06 1000 Island

Ask Orders
Price Order Size Institution
2.73 4800 Island
2.74 500 Island
2.87 4000 Archipelago
2.89 4500 Archipelago
2.89 1000 Island
2.90 100 Island
2.93 1000 Archipelago
2.99 200 Island
3.16 1500 Archipelago
4.52 200 Island
47.00 125 Island

[claudi34]

das orderbuch wird immer besser und in den ami-boards fällt immer öfter das wort takeover .
könnte was dran sein. angeblich hat ja pfizer das unternehmen im vorjahr aus der krise gerettet.
lg aus münchen

[jannyk1]

hi-
wo kann ich am besten virologic kurse möglichst realtime
in usa verfolgen?
Tip?
Danke

[claudi34]

orderbuch: www.island.com dann im feld rechts oben vlgc eintippen.
lg.

[Dolocher]

Mal was zum Thema Übernahme,
J+J soll ja angeblich bereits 10% an VLGC besitzen,genaues weiss ich dazu allerdings nicht.Wäre das aus Eurer Sicht ein möglicher Kandidat und weiss jemand etwas zu der Beteiligung von J+J?

[jannyk1]

danke

[Bullebio]

ich habe schon mal den verdacht geäußert, dass vlgc übernommen werden könnte. J&J wäre auch ein geeigneter kanditat dafür. zumindest die kursentwicklung deutet eventuell darauf hin. wir werden sehen.

allen ein schönes WE, und träumt schon mal von den 3$.
diese werden nächste woche realität.

tschau

[Bioexp]

Hi Leute!
Montag wird korriegiert,ziemlich sicher.
Gewinne realisieren,später wieder nachlegen.

[turbos1]

Ich glaube noch nicht an eine nachhaltige Korrektur.

[robby13]

Hi VLGC - Freunde ! Hier war die Korrektur ! Schaun wir mal wie es weiter geht , die Umsätze zum Handelsende waren erstaunlich !Vielleicht eine Chance für " Nichtinvestierte " morgen um 2,4€ in FSE einzusteigen !?

Last 10 trades


Time Price Volume Exchange Info


16:53:26 2.889 11600 Nasdaq-NM
16:38:07 2.870 59500 Nasdaq-NM
16:31:57 2.870 59500 Nasdaq-NM
16:13:01 2.887 28400 Nasdaq-NM
16:03:45 2.912 150000 Nasdaq-NM
16:00:18 2.910 500 Nasdaq-NM at Ask
16:00:18 2.910 14000 Pacific at Ask
16:00:18 2.910 500 Pacific at Ask
15:59:42 2.870 6700 Nasdaq-NM at Bid
15:59:42 2.875 300000 Nasdaq-NM
robby

[heikekarina]

Guten Morgen,

das war gestern mächtig volatil

In den Yahoo-Boards wurde davon geschrieben Virologic bis auf die 2,70$ runter zu prügeln. Ich denke aber nicht das das der alleinge Grund war, sondern auch der gestrige Gesamtmarkt seinen Teil dazu beigetragen hat. Interessant war aber das die Amis klar ab ca. 21:00 Uhr von Daytradern sprachen, die jetzt wohl raus sind, und das jetzt wieder in Richtung 3$ angesetzt werden kann.
Virologic will nach oben und wird nach oben gehen. Alle Indikatoren sind bullish bis very bullish. Also liebe Virologicfreunde, Nerven behalten und auch bei volalilen Handel die Nerven behalten.

[turbos1]

Ich bin auch weiterhin zuversichtlich, dass es weiter nach oben geht. Man muss einfach starke Nerven haben. Wenn es heut ein wenig noch nach unten gehen sollte, würde ich die vorübergehende Schwäche nutzen , um ein wenig nachzukaufen.

[bernie55]

Ich denke auch, dass wir uns nicht verrückt machen sollen......
In den letzten Monaten ging es auch rauf und runter, nur mit dem Unterschied, dass der Wert vor dem Komma eine 0 bzw. eine 1 hatte, zum jetzigen Zeitpunkt aber eine 2 bzw. eine 3 vor dem Komma hat........
also blickt nach vorne - Longies - die 3....4....5....warten auf uns
grüße bernie

[heikekarina]

Nerven behalten. Nächste Woche geht es weiter. 2-3Tage Konsolodierung sollten schon erlaubt sein

[claudi34]

eine verschnaufpause mit moderaten abschlägen und ruhigem handel... aus meiner sicht.
ohne konsolidierung wäre der aufschwung wohl nicht nachhaltig.

[robby13]

die 2,80$ - Schlußkurs gehen bei den Abschlägen an der Nasdaq völlig in Ordnung !
robby

[heikekarina]

wie angekündigt hier der Report zu Virologic aus USA von einem freundlichen User. Wer diesen im Original haben möchte, sendet mir bitte sein E-Mail per BM


Health Enabling Technologies & Services
MERRIMAN CURHAN
FORD & CO.
601 Montgomery Street
Suite 1800
San Francisco, CA 94111
[phone] Main
[phone] Fax
[phone] Trading
www.merrimanco.com
December 3, 2003
Please see the Important
Disclosures Section at
the end of this report.
ViroLogic, Inc. (VLGC) Buy
Initiating Coverage with a Buy Rating; Pioneering
Individualized Medicine
• Leadership in a growing market. ViroLogic is currently the only company
offering a comprehensive suite of HIV drug resistance testing
products. We estimate the near-term market for HIV drug resistance
tests is at least $100 million in the U.S. and growing at approximately
15% per year. We estimate ViroLogic’s current approximately 20%
market share can grow to nearly 30% by 2005, and. We believe the
addressable market could eventually exceed $1 billion.
• Strong case for resistance testing. Drug treatment costs can exceed
$25,000 annually as a patient progresses through therapy and the virus
in their body becomes increasingly resistant to anti-viral drugs. Assuming
an average monthly drug treatment cost of $1,400 avoiding the
choice of even one ineffective drug for a period of just two months
would more than cover the cost of a resistance test.
• New products. We expect the launch of GeneSeq HCV and
PhenoSense HCV tests for use in drug development in 2003 and 2004
respectively to generate additional sales and earnings growth. In addition,
we believe the company can leverage its technology to develop
assays for other disease areas such as oncology.
• Unrecognized value. We are initiating coverage with a Buy rating and
a 12-month price target of $3.75, or 4.0x our FTM sales estimate of
$42.5 million. We believe that sales multiple of 4.0x is justified based
on ViroLogic’s growth potential versus that of comparable companies.
MERRIMAN
CURHAN
FORD & CO.
Sean McKenna
[phone]
[e-mail]
($ in mm, except
per share data) FY02A FY03E FY04E
SALES Old New Old New Old New
Q1 $5.7 $5.7 $7.0 $7.0 $9.8 $9.8
Q2 6.7 6.7 8.0 8.0 11.4 11.4
Q3 5.9 5.9 9.1 9.1A 11.8 11.8
Q4 7.0 7.0 9.6 9.6 12.4 12.4
FY (Dec) $25.3 $25.3 $33.7 $33.7 $45.3 $45.3
P/S 4.8x 3.6x 2.7x
EPS
Q1 ($0.43) ($0.43) ($0.18) ($0.18) ($0.00) ($0.00)
Q2 (0.24) (0.24) (0.09) (0.09) $0.01 $0.01
Q3 (0.24) (0.24) (0.02) (0.02)A $0.01 $0.01
Q4 (0.48) (0.48) (0.00) (0.00) $0.02 $0.02
FY (Dec) ($1.38) ($1.38) ($0.30) ($0.30) $0.04 $0.04
P/E NM NM NM
ViroLogic, a leader in drug resistance
testing, develops and markets
products that guide and improve
treatments of serious viral
diseases such as AIDS and hepatitis.
The company’s products are
designed to help physicians optimize
treatment regimens that
lead to better patient outcomes
and reduced costs. ViroLogic’s
technology is also being used by
numerous pharmaceutical companies
to develop new and improved
anti-viral therapeutics and
vaccines targeted at emerging
drug-resistant viruses.
Market Cap (mm): $120.7
Float (mm): 38.9
10 Day Avg. Vol. (mm): 1.9
Institutional Ownership: 27%
Shares Out (mm): 44.4
MCF Estimates
Market Data
Stock Performance
Company Description
Valuation
Key Metrics
Price: $2.72
Rating: Buy
Price Target: $3.75
Cash & ST Investments $8.3
Debt (mm): $0.5
Price / FTM Sales: 4.0x
Summary
We are initiating coverage of ViroLogic with a Buy rating and a 12-
month price target of $3.75, or 4.0x our FTM sales estimate of $42.5
million. The company develops and markets products to guide and
improve treatments of serious viral diseases such as AIDS and hepatitis.
In our opinion, ViroLogic is positioned as a market leader because
it offers the most advanced HIV/AIDS resistance tests available. In
addition, we believe that increased awareness of the economic value of
HIV drug resistance testing and individualized medicine should allow
ViroLogic to realize greater market penetration.
Investment Conclusion
SOURCE: StockCharts.com
December 3, 2003 2
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Key Investment Points
Strong case for resistance testing. Drug resistance to HIV/AIDS treatment has become a serious crisis.
Drug treatment costs can exceed $25,000 annually as a patient progresses through therapy and the
virus in their body becomes increasingly resistant to anti-viral drugs. In designing an optimal treatment,
physicians often employ an expensive trial-and-error process requiring different drug treatment combinations.
Assuming an average monthly drug treatment cost of $1,400, avoidance of choosing even one ineffective
drug for a period of only two months would more than cover the cost of a resistance test. In addition,
patients may be able to achieve clinical and immunologic stability on a simpler, less expensive regimen.
Leadership in a growing market. In our opinion, ViroLogic is positioned as a market leader because it
offers the most advanced HIV/AIDS resistance tests available. ViroLogic is currently the only company
offering a comprehensive suite of HIV drug resistance testing products, including the only commercially
available measurement of viral fitness. We estimate the near-term market for HIV drug resistance tests is
at least $100 million in the United States and that nearly 140,000 patient tests are being reported annually.
In addition, we estimate that the market for HIV patient drug resistance testing is growing at approximately
15% per year. We estimate that ViroLogic’s current market share of approximately 20% can
grow to nearly 30% by 2005. In our opinion, the addressable market could eventually exceed $1 billion.
Favorable reimbursement picture. Recently issued guidelines issued by the U.S. Department of Health
and Human Services in July 2003 recommend that drug resistance tests be routinely used in designing
drug treatments for HIV patients. Medicare and nearly all private payors, including Aetna U.S. Healthcare,
the Blue Cross Blue Shield Organizations, Humana, and UnitedHealthCare pay for resistance testing. Over
80% of HIV/AIDS patients in the United States now have access to coverage for resistance testing. Currently,
48 state Medicaid programs, including California, Florida, and New York, the states with the largest
HIV/AIDS patient populations, had favorable coverage policies for drug resistance testing.
High value proposition for pharma. Pharmaceutical companies invest approximately $30 billion annually
in R&D, with this amount roughly doubling every five years. The high cost of taking new drugs to
market is partly the result of a labor intensive trial and error process. We believe that ViroLogic products
may be highly valued by HIV/AIDS drug developers who can use the company’s technology to separate
likely responders from non-responders in the clinical trials process and gather resistance data required for
FDA approval. The HIV treatment market remains relatively immature, with only 20 HIV-specific marketed
products supplying the global HIV-treated population. We estimate the anti-HIV drug market at approximately
$5 billion and the total anti-viral market at approximately $8 billion.
New products should fuel growth. We expect the introduction of new enhancements to the company’s
HIV drug resistance tests and continued uptake in demand for the company’s Entry Inhibitor assays
(tests) to make significant contributions to revenue and earnings in 2004. We expect the launch of Gene-
Seq HCV and PhenoSense HCV tests for use in drug development in 2003 and 2004 respectively to generate
additional sales and earnings growth. In addition, we believe the company can leverage its technology
to develop drug resistance tests for diseases in other therapeutic areas including hepatitis, immunology
and oncology as well as pursue international expansion.
Unrecognized value. We are initiating coverage with a Buy rating and a 12-month price target of $3.75,
or 4.0x our FTM sales estimate of $42.5 million. Specialty Laboratories, a competitor, trades at 2.5x forward
sales, excluding cash while ViroLogic trades at 2.6x forward sales, excluding cash. We believe a
sales multiple of 4.0x for ViroLogic is warranted, based on ViroLogic’s growth potential versus that of Specialty
Laboratories. Our 12-month price target of $3.75 is based on 4.0x our FTM sales estimate of $42.5
million.
December 3, 2003 3
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Nice entry point — potential for price appreciation
We are initiating coverage with a Buy rating and a 12-month price target of $3.75, or 4.0x our FTM sales estimate
of $42.5 million. ViroLogic, a leader in drug resistance testing develops and markets products to guide
and improve treatments of serious viral diseases such as AIDS and hepatitis. In our opinion, ViroLogic is positioned
as a market leader because it offers the most advanced HIV/AIDS resistance tests available. In addition,
we believe that increased awareness of the economic value of HIV drug resistance testing and individualized
medicine may allow ViroLogic to realize greater market penetration.
Table 1: ViroLogic Peer Group Comparison
Companies such as Quest Diagnostics and Laboratory Corporation of America (see Table 1) offer products
similar to ViroLogic’s (though we believe ViroLogic’s products are superior to those of Specialty Laboratories).
However, in our opinion, these companies do not make the best financial comparables because their projected
revenue growth at 7% to 8% is far lower than our 37% projected revenue growth for ViroLogic. Specialty
Laboratories, trading at 2.5x forward sales, excluding cash, is the closest of ViroLogic’s comparable
companies from a market capitalization perspective. ViroLogic trades at 2.6x forward sales, yet has far
higher growth potential. Given the growth differential between ViroLogic and Specialty Laboratories, we believe
a sales multiple of 4.0x is warranted for ViroLogic. Our 12-month price target of $3.75 is based on 4.0x
our FTM sales estimate of $42.5 million.
Solid business model with well-defined markets
ViroLogic develops and markets drug resistance tests that are used to determine whether or not a given viral
drug treatment is likely to be effective. The company’s business consists of two key markets: patient testing
and drug development, which comprise approximately 70% and 30% of product revenues, respectively. The
company’s patient testing products are designed to help physicians optimize viral drug treatment regimens
that lead to better patient outcomes and reduced costs. ViroLogic’s drug development products are being
used by numerous pharmaceutical companies to develop new and improved anti-viral therapeutics targeted
at new drug targets and emerging drug-resistant viruses, as well as vaccines.
The company markets two primary types of tests (assays) in each product segment: genotypic and phenotypic
(Table 2). These different but often complementary assays are used to assess viral drug resistance.
Resistance refers to the sensitivity of a virus to a specific drug treatment. Genotypic assays use a variety of
techniques, predominantly nucleic acid sequencing, to identify genetic mutations in the patient’s viral genome
that are associated with drug resistance. The results produce a qualitative “yes/no” prediction of drug
resistance. Phenotypic assays determine the concentration of a drug required to inhibit the growth of a virus
(replication).
Table 1 Mkt LTM FTM P / P /
Cap Cash / Sales Sales % LTM FTM LTM % FTM LTM FTM
Company Ticker Price (MM) Sh (MM) (MM) Chg Sales* Sales* EPS Chg EPS P/E* P/E*
ViroLogic Inc VLGC $2.72 120.7 $0.19 31.0 42.5 37.2% 3.6x 2.6x ($0.77) NM $0.02 NM NM
Specialty Labs Inc SP $15.80 346.1 $1.18 119.1 127.7 7.2% 2.7x 2.5x ($0.30) NM $0.05 NM NM
Lab Corporation of America LH $36.80 5,313.9 $0.24 2,858.0 3,095.0 8.3% 1.8x 1.7x $2.06 18% $2.44 17.7x 15.0x
Bio Reference Labs Inc BRLI $17.79 226.1 $0.28 104.2 119.2 14.3% 2.1x 1.9x $0.38 42% $0.54 46.1x 32.4x
Quest Diagnostics Inc DGX $74.12 7,795.9 $0.87 4,567.7 4,903.1 7.3% 1.7x 1.6x $3.90 16% $4.52 18.8x 16.2x
Mean**: 9.3% 2.1x 1.9x 27.5x 21.2x
Median**: 7.8% 2.0x 1.8x 18.8x 16.2x
* Excludes last reported cash
** Excludes ViroLogic
Source: First Call and Merriman Curhan Ford Estimates
December 3, 2003 4
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Assay Type Advantages Disadvantages
Genotype
Identifies drug resistance mutations
in viral genes using
nucleic acid amplification and
sequencing
Routine lab procedure
Readily available
Short time period
Detects certain mutations
Correct interpretation requires
comprehensive knowledge of
genetic determinants of resistance
Unpredictable phenotypic effects
Limited value for new drugs,
highly experienced patients
and drug development
Phenotype
Measures the concentration of
a drug that will inhibit viral
replication
Measures net effect of mutations
on drug susceptibility
Provides data on crossresistance
and hypersusceptibility
Useful for new drugs, highly
experienced patients and drug
development
Longer testing period
More expensive
Source: Medscape and Merriman Curhan Ford & Co
Table 2: Resistance Tests
ViroLogic’s products and pipeline (Table 3) feature several key assays that we believe should contribute to
company’s growth. The company’s PhenoSense GT assay is currently the only available commercial test
that offers a measurement of viral fitness as part of a comprehensive drug resistance analysis. The Replication
Capacity HIV test, which is currently included as part of the of PhenoSense GT assay, measures the
inherent ability of HIV-1 to replicate in the absence of drugs. In addition, we expect ViroLogic’s Entry Inhibitor
assays to make significant contributions to revenue and earnings in 2004. This product is used for
testing resistance to drugs that are designed to interfere with the entry of the HIV virus into a cell. We expect
the launch of the GeneSeq HCV assay in 2003 and PhenoSense HCV assay in 2004 to generate additional
sales and earnings growth. These assays are designed to help drug developers formulate new drugs
for hepatitis B and hepatitis C. We believe that a successful launch of GeneSeq HCV and PhenoSense HCV
should demonstrate ViroLogic’s ability to leverage its technology platform into new test markets.
December 3, 2003 5
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Application
Test Type Functions Patient
Testing
Drug
Development
PhenoSense HIV phenotypic
Directly measures resistance
of a patient’s HIV to
protease and reverse transcriptase
inhibitors · ·
GeneSeq HIV genotypic
Detects drug resistance
mutations in HIV-1 protease
and reverse transcriptase · ·
PhenoSense GT phenotypic,
genotypic
PhenoSense HIV and
GeneSeq HIV test combination
· ·
Replication
Capacity HIV
viral fitness
Measures inherent ability of
HIV-1 to replicate in the
absence of drugs · ·
PhenoScreen phenotypic
Provides high-throughput
screening for potential clinical
drug candidates
NA ·
PhenoSense
HIV Entry Phenotypic Directly measures resistance
of HIV-1 to entry inhibitors
Expected
2004 ·
GeneSeq
HIV Entry Genotypic Detects drug resistance
mutations in HIV-1 envelope (1) ·
PhenoSense HIV
Vaccine Entry phenotypic
Assay that measures HIV
antibodies for development
of HIV vaccines.
NA ·
PhenoSense HBV phenotypic
Evaluates susceptibility of
Hepatitis B virus to polymerase
inhibitors
(1) (1)
GeneSeq HBV genotypic Evaluates the genetic sequences
of Hepatitis B virus (1) ·
PhenoSense HCV phenotypic
Evaluates susceptibility of
Hepatitis C virus to polymerase
and protease inhibitors.
Expected
2006 Expected 2004
GeneSeq HCV genotypic
Evaluates the genetic sequences
of Hepatitis C polymerase
and protease.
Expected
2005
Expected
2003
(1) Timing under evaluation; product release dependant on securing NIH grants and/or external funding and on product
demand.
Sources: company reports and Merriman Curhan & Ford
Table 3: ViroLogic Products and Pipeline
December 3, 2003 6
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Leadership in a growing market
In our opinion, ViroLogic’s comprehensive product suite places in a unique position to capitalize on a
growing market opportunity. We estimate that the market for HIV drug resistance assays is at least $100
million in the United States, and that nearly 140,000 patient tests are being reported annually. In addition,
we estimate that the market for HIV drug resistance testing is growing at approximately 15% per
year. In our opinion, ViroLogic’s current market share of approximately 20% can grow to nearly 30% by
2005. Of the estimated 140,000 patient resistance tests conducted in the United States in 2003, Quest
Diagnostics and LabCorp combined are estimated to have performed approximately 50%. ViroLogic performs
approximately 20% of resistance tests, and Tibotec-Virco (division of Johnson & Johnson), Specialty
Laboratory, and other laboratories — including hospitals and academic labs — together perform the remaining
30%.
Growing list of HIV/AIDS drug treatments should boost sales
According to figures provided by the World Health Organization, an estimated 40 million people worldwide
are infected with the human immunodeficiency virus (HIV). The continued spreading of the virus, along
with the difficulty of treating it, has led to a proliferation of drugs on the market. In our opinion, the
growing list of FDA approved drugs available for treating HIV/AIDS patients (Table 4) is a key driver ViroLogic
product sales. As the list of FDA approved drugs increases, we anticipate an increased demand for
ViroLogic’s products.
Table 4: Anti-HIV Drugs Currently Approved in the United States
Table 4 Anti-HIV Drugs Currently Approved in the US
Nucleoside/Nucleotide Reverse
Transcriptase Inhibitors (NRTIs) Generic Name Manufacturer FDA Approved LTM Sales ($MM)
Epivir 3TC/lamivudine GlaxoSmithKline 1991 $211
Hivid DDC/zalcitabine Roche 1989 5
Retrovir AZT/zidovudine GlaxoSmithKline 1988 31
Videx ddl/didanosine Bristol-Meyers Squibb 1989 12
Videx EC ddl/didanosine Bristol-Meyers Squibb 2000 117
Viread tenfovir disoprxil fumarate Gilead 2001 169
Zerit D4T/stavudine Bristol-Meyers Squibb 1990 299
Ziagen abacavir GlaxoSmithKline 1991 166
Combivir AZT/3TC GlaxoSmithKline 1997 572
Trizivir (2) AZT/3TC/ABC GlaxoSmithKline 2000 330
Total $1,912
Non-Nucleoside Analog Reverse
Transcriptase Inhibitors
Rescriptor delavirdine Agouron/Pfizer 1996 $7
Sustiva efavirenz Bristol-Meyers Squibb 1996 313
Viramune nevirapine Boehringer Ingelheim 1994 149
Total $469
Protease Inhibitors
Agenerase amprenavir GlaxoSmithKline 1996 $53
Crixivan indinavir Merck 1995 123
Fortovase saquinavir Roche 1993 41
Invirase saquinavir Roche 1993 19
Kaletra lopinavir Abbott Laboratories 2000 319
Norvir ritonavir Abbott Laboratories 1996 67
Viracept nelfinavir Agouron/Pfizer 1997 340
Total $962
Entry Inhibitors
Fuzeon enfuvirtide Trimeris and Hoffman-La Roche March-03 NA
(1) For the 12 months ended December 31, 2002 per IMS Data
(2) Single tablet of abacavir, zidovudine and lamivudine
Source: HIV/AIDS Treatment Information Service, Rockville MD, IMS Data
December 3, 2003 7
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
HIV treatments are typically combinations of three or more drugs that are divided into three classes of
agents: nucleoside reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse transcriptase inhibitors
(NNRTIs); and protease inhibitors (PIs). NRTIs generally form the backbone of every HIV anti-retroviral
therapy regimen. Since physicians need to tailor therapies to suit individual patients, we argue that a
greater number of possible treatments may increase the overall need for resistance testing. We estimate
that there are approximately 25 additional HIV/AIDS drugs currently in clinical trials, eight of which are in a
new class of drugs called Entry Inhibitors.
A rapidly changing virus: factors underpinning the HIV/AIDS treatment market
A virus transmitted by an infected person to an uninfected person is, on average, 1000 generations removed
from the virus causing the initial infection. The speed at which the virus copies itself, and the relatively
large number of errors it makes in the process, makes finding drugs that the many variations of the
HIV responds to considerably challenging. The high error rate (incidence of mutation) is compounded by
the fact that the virus replicates quickly. It has been estimated that during replication of the virus, about
one error is made in every 10-4 to 10-5 DNA bases and that about 109 new virus particles are produced
every day. This translates to approximately 1 billion errors (mutations) per day as the virus makes copies
of itself, changing its genetic structure over time.
A high mutation rate enables the HIV virus to elude drug treatments by rapidly changing its genetic structure.
A large variety of different HIV variants exist within an infected patient, and, simply by chance, certain
variants may be less susceptible to drug therapies than others. When a particular drug is used, viral
strains susceptible to that drug are inhibited from replicating. However, virus variants that are less susceptible
to the particular drug continue to reproduce, resulting in the progressive establishment of resistant
HIV strains.
The population of viruses in a single patient becomes genetically more diverse over time. This is because
an HIV infection is comprised of many different ‘types’ or variations of the virus. When a patient starts taking
an anti-HIV drug, one HIV virus type may be more resistant than other types. While the anti-HIV drug
stops or slows replication of some HIV viruses, resistant viruses strains continue to multiply and, over time,
begin to outnumber treatment-sensitive strains. If a patient’s drug treatment regimen was not adjusted,
the resistant virus would continue to multiply, unchecked, in a patient’s body.
Table 5: The Mathematics of HIV Replication
New virus particles produced per day ~109 - 1010
Error rate of reverse transcriptase ~10-4 - 10-5 bases
Length of HIV genome ~104 bases
Likelihood of a new virus having
at least 1 error (mutation)
~30-50%
 chemical structure used by a virus to make copies of itself
 basic building blocks of DNA includes Cytosine, Guanine, Adenosine and Thymine that form a gene sequence
Sources: Medscape and Merriman Curhan Ford & Co
December 3, 2003 8
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Economic argument for resistance testing
Drug resistance to HIV/AIDS treatment has become a serious crisis. Per patient drug treatment costs can
exceed $25,000 annually as a patient progresses through therapy and their virus becomes increasingly
resistant to drug treatment. In designing an “optimal” treatment regimen, physicians often employ an
educated yet expensive trial-and-error process requiring different drug treatment combinations.
Historically, physicians have tended to treat patients based on assumptions about viral resistance to
drugs, without knowing to which drugs the HIV virus in particular patient’s body were resistant. It has
been common practice to change drugs in a treatment regimen, even when some drugs may still be effective.
This guesswork approach to treatment resulted in patients becoming more seriously ill, suffering
toxic side effects, and unnecessarily bearing the costs of ineffective drugs. To achieve long-term clinical
benefit, physicians must select drugs that best suppress viral replication and avoid drugs to which a patient’s
virus is resistant. Drug resistance testing is the key to identifying optimal treatments.
The economics of treating HIV/AIDS has changed. From 1996 to 2001, the cost of treating a patient
jumped from an average of $650 per month to $1,400, partly as a result of the increased use of various
three-drug cocktails. During roughly the same period, the proportion of drug cost to total treatment cost
had increased roughly ten-fold. Resistance is least likely to develop if treatment is based on a combination
of drugs. Over the last decade combination therapy for patients with advanced AIDS has only increased
life expectancy from 1.53 years to 2.91 years.
Clinical studies have demonstrated the economic benefits of HIV drug resistance testing based on qualityadjusted
life-years gained. In addition, qualitative assessments suggest that use of resistance testing is
likely to reduce the long-term costs of treatment as well as preserve future treatment options for the patient.
For example, if one assumes that the average monthly cost of a three-drug cocktail of antiretroviral
drugs is $1,400, avoidance of choosing even one ineffective drug for a period of just two months would
more than cover the cost of a resistance test. In addition, the development of resistance to one drug
often leads to the development of cross-resistance to other drugs in the same class.
The unnecessary development of cross-resistance can severely limit the patient`s future drug options. The
phenotypic resistance assay from ViroLogic includes an assessment of replication capacity, (RC) providing
physicians with a unique tool for evaluating drug options. If the replication capacity of a virus is low, patients
may be able to achieve clinical and immunologic stability on a simpler, less expensive regimen.
Such treatment strategies may allow physicians to reserve more “robust” treatment options for the future
and reduce the long-term costs of treatment. If resistance testing resulted in the avoidance of the
use of the newest drugs such as Fuzeon (approximately $25,000 per year), the savings to individuals —
and to the health care system — would be substantial.
The evolution of phenotypic testing
The resistance of the HIV virus to anti-viral drugs can be measured using genotypic and phenotypic assays.
Early phenotypic tests were slow, labor intensive, and not easily automated, rendering these tests
impractical for patient management. It is for this reason that genotypic tests were the first tests used on
a large scale to predict drug resistance.
Genotypic tests detect mutations in the underlying gene sequence, or genotype of the virus, and attempt
to associate them with drug resistance. However, genotypic tests measure resistance indirectly and require
subjective interpretations of test results. In contrast, phenotypic tests measure the ability of a virus
to replicate after exposure to a particular anti-viral drug and so eliminate much treatment plan guesswork
by providing the physician with direct information about the drug resistance of a patient’s virus. The most
comprehensive approach to resistance testing is to use both phenotypic and genotypic tests, as they provide
complementary information. The ViroLogic testing platform uses this approach.
December 3, 2003 9
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
The earliest phenotypic assays for HIV were developed in the late 1980s in response to HIV drug treatment
failures. These peripheral blood mononuclear cell (PBMC) tests required several lengthy incubation
periods and took four to six weeks to complete. The tests were not easily suited for automation, and thus
had limited throughput capability. In addition, PBMC test suffered deficiencies in accuracy and reproducibility.
By the mid-1990s the first recombinant virus assays (RVAs) for HIV drug resistance testing were
developed to address some of the limitations associated with PBMC assays. Current phenotyping assays
are not available as test kits for widespread distribution because they require a number of sophisticated
laboratory and analytical procedures. Therefore, only a small number of highly specialized clinical reference
laboratories have the methods and technical expertise to provide reliable phenotypic tests. In the
Unite States, these laboratories operate according to regulations specified by the Clinical Laboratory Improvements
Act (CLIA) under the jurisdiction of the Centers for Medicare and Medicaid Services (CMS).
A number of commercial phenotypic HIV drug resistance assays have been developed to help physicians
select individualized antiretroviral treatment regimens for their patients including Antivirogram® (Tibotec
Virco), PhenoSense™ HIV (ViroLogic), and Phenoscript™ (VIRalliance). Table 6 shows the current list of
commercially available HIV/Drug resistance tests. Each assay is performed using different protocols (RNA
extraction, amplification) that lead to the same general conclusions. However, validation studies comparing
the performance of the different assays demonstrate that the ViroLogic PhenoSense assay is more
accurate and sensitive than other competitive phenotypic assays.
ViroLogic sells its products through a direct sales force. In addition, the company sells its PhenoSense™
HIV product on a referral basis through competitors such as Laboratory Corporation of America, Quest
Diagnostics, and Specialty Labs. We believe that the opportunity that ViroLogic has to distribute
PhenoSense™ HIV, indirectly provides additional validation of the benefits of using PhenoSense™ HIV for
resistance testing.
Company Product List Price *
GENOTYPIC TESTS
Laboratory Corporation HIV GenoSureTM $618
Laboratory Corporation HIV GenoSureTM Plus (Virtual PhenotypeTM)
$667
Quest Diagnostics HIV-1 Genotype $460
Quest Diagnostics HIV-1 Virtual PhenotypeTM $460
Specialty Laboratory HIV-1 GenotypRTM PLUS $636
ViroLogic GeneSeqTM HIV $495
PHENOTYPIC TESTS
Specialty Laboratory HIV-1 PhenoscriptTM $950
Laboratory Corporation HIV-1 Phenotyping (ANTIVIROGRAMTM) $1,266
ViroLogic** PhenoSenseTM HIV $955
COMBINATION PHENOTYPIC/GENOTYPIC TESTS
ViroLogic PhenoSense GTTM $1,210
*In certain instances, a blood draw fee and/or other fees may also apply.
**ViroLogic has a direct sales force. In addition, Laboratory Corporation of America, Quest Diagnostics, Specialty Laboratory and other reference laboratories
offer ViroLogic’s PhenoSense HIV on a referral basis
Sources: Respective companies customers service departments
Table 6: Commercially Available HIV/AIDS Drug Resistance Tests
December 3, 2003 10
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
The ViroLogic testing solution
ViroLogic offers the most comprehensive
suite of HIV resistance test products, including
the only commercially available assay
that measures viral fitness, or the ability
of a virus to multiply in the presence of
a particular anti-viral drug. The company’s
phenotypic technology eliminates lengthy
virus culture steps using a genetically engineered
virus that replicates only once. The
technology makes the resistance tests more
consistent and accurate than alternative
HIV tests, and it shortens the time required
to complete testing. In addition, the tests
are automatically processed in large numbers,
making them practical for routine use
in clinical management of patients. The advantages
of ViroLogic’s testing platform include:
Rapid turnaround. ViroLogic`s phenotypic
assays can be completed in eight to ten
days, much faster than other phenotypic
resistance tests.
Measures replication capacity. ViroLogic`s
phenotypic assays are the only commercially
available tests that measure virus replication
capacity.
Direct, accurate measurement. ViroLogic`s
assays do not require a subjective
interpretation of data that may produce
questionable results because they measure
the degree of drug resistance and susceptibility
versus competing tests that only provide
a “yes” or “no” answer.
Reliable results. ViroLogic`s assays are accurate
and highly reproducible. This eliminates
the need to do repeat testing in order
to verify results.
In our opinion, ViroLogic’s assays are based on a technology platform that is practical for processing large
volumes of tests cost-effectively. In addition, quick turnaround and reliable results provide customers with
better and more timely information. The company’s PhenoSense technology works by means of a “resistance
test vector,” a strand of viral genes that replicates when it is introduced into a living cell. The resistance test
vector includes two key elements: a gene that produces a light emitting indicator (luciferase) which can easily
be detected and one or more genes derived from the patient’s virus. The genes derived from the patient’s
specific virus correspond to the targets of the anti-viral drugs to be tested. In the testing process, the patient
genes are attached to the test vector (Figure 1) and introduced into living cells in a test tube. Anti-viral
drugs are then added to the cells at varying concentrations, and the test vector completes a single round of
replication. The amount of light produced by luciferase is then measured (Figure 2), a direct assessment of
how sensitive a virus is to increasing concentrations of a given drug.
Resistance test
vector are
introduced into
cells to produce
virus
Cells are infected with
virus to measure drug
susceptibility
Protease inhibitors
are tested when the
virus is produced
Reverse transcriptase
inhibitors are tested when the
cells are infected
HIV-1 Resistance Test Vector
PR-RT luciferase
A resistance test vector is
assembled by inserting a gene
from the patient virus
Resistance test vectors contain a
firefly luciferase gene to measure
viral replication
Measuring Reduced Drug Susceptibility
A higher concentration of drug is required to inhibit the patient virus
% inhibition of virus replication
(luciferase activity)
Drug concentration (uM)
reference virus
patient virus
Figure 1
Figure 2
Source: company reports
Source: company reports
December 3, 2003 11
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
If the virus is sensitive to the drug being tested, no light is detected. If the virus is resistant to the drug,
light is detected. ViroLogic provides test results via reports with diagrams showing the amount of
luciferase corresponding to the amount of virus replication. Test results are direct quantitative measures
of drug resistance and are assessed based on clinical response data. In our opinion, PhenoSense technology
is easily scaleable and could be extended into other types of viral testing.
Current phenotypic tests provide a direct measure of susceptibility for all FDA-approved reverse transcriptase
and protease inhibitors, and they are being adapted to include new drugs and new drug targets as
they become available. The effort to establish assay cutoffs based on clinical response data is simplifying
the interpretation of phenotypic susceptibility assays and is essential for the development of highly predictive
genotypic algorithms. The interpretation of phenotypic test results using clinically relevant cutoffs
is expected to facilitate the selection of potent antiretroviral drug regimens while minimizing side effects,
both of which should result in improved treatment outcomes.
Resistance testing benefits drug developers
The potential market for improved anti-viral therapeutics is enormous. The HIV treatment market remains
relatively immature with only 20 HIV-specific marketed products supplying the global HIV-treated population.
The anti-HIV drug market is an estimated $5 billion, and the total anti-viral market is estimated at
approximately $8 billion. However, in the aggregate, pharmas invest approximately $30 billion annually
on R&D; and this amount has historically doubled every five years. The high cost of taking new drugs to
market is partly the result of a labor intensive trial and error process. In our opinion, ViroLogic assays
should be highly valued by HIV/AIDS drug developers who can use the company’s technology to separate
likely responders from non-responders in the clinical trials process.
For example, assays can significantly reduce clinical trial costs and drug development timeframes for
pharmaceutical companies because it allows them to conduct clinical trials more efficiently, thus allowing
them to enroll appropriate patients into their clinical trials. Enrolling the right patients initially saves drug
developers costs by preventing patients from receiving a treatment that will not work for them and by
preventing erroneous conclusions from being reached. This point is illustrated by a case in which AnorMED
Inc., a Canadian biopharmaceutical company developing drugs for HIV and cancer discontinued its Phase
Ib-IIa trial of lead candidate AMD-3100 in May of 2001 due to what it believed were adverse effects.
Based on a subsequent retrospective study using Virologic assays and a new test population the compound
was resurrected as a new target for HIV treatment. Subsequently, AnorMED reinitiated its clinical
program in 2002.
Resistance testing endorsed by U.S. Government
Over 80% of HIV/AIDS patients in the United States now have access to coverage for resistance testing.
This translates to more than $100 million in potential sales for the PhenoSense GT product alone. Currently,
48 state Medicaid programs, — including California, Florida and New York, the states with the largest
HIV/AIDS patient populations — had favorable coverage policies for drug resistance testing. Current
Procedural Technology (CPT) codes have been established to facilitate reimbursement of HIV drug resistance
testing. Guidelines issued by the U.S. Department of Health and Human Services in July 2003 recommend
that drug resistance tests be routinely used in designing drug treatments for HIV patients.
Guidelines for the use of drug resistance testing have been developed by several other agencies and expert
panels including the International AIDS Society-USA panel. Current treatment guidelines recommend
that drug resistance testing be used after treatment failure or an inadequate response to treatment in all
of the available treatment guidelines. In addition, resistance testing is recommended for guiding therapy
in pregnant women to minimize the risk of mother to child transmission. Medicare and nearly all private
payors, including Aetna U.S. Healthcare, the Blue Cross Blue Shield Organizations, Humana and United-
HealthCare pay for resistance testing.
December 3, 2003 12
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
New opportunities for growth
Entry Inhibitors. Since the development of the first HIV drug resistance assays, the understanding of the
mechanisms by which HIV attaches to and enters cells has advanced significantly. In order to enter and
infect cells, HIV must bind to either the CXCR4 (X4) or CCR5 (R5) chemokine receptors. The identification
of these co-receptors and their role in the HIV entry process has provided an opportunity for ViroLogic to
expand resistance test repertoire to include assays used to measure HIV resistance to entry inhibitors during
drug development and clinical trials. We expect the continued uptake in demand for the company’s Entry
Inhibitor assays (PhenoSense HIV Entry, GeneSeq HIV Entry, PhenoSense HIV Vaccine Entry) to make
significant contributions to revenue and earnings in 2004. Sales of these products have been incorporated
into our estimates.
HBV and HCV. The current pipeline of anti-HBV and anti-HCV drug candidates reflects the commitment of
many pharmaceutical companies to developing anti-viral treatments for chronic viral diseases in addition to
AIDS. Future HBV and HCV treatments are likely to involve the use of combination drug regimens, much
like those that are used to treat HIV infection. Since HBV and HCV replication dynamics resemble that of
HIV, drug resistant viruses are expected to emerge with continued drug treatment. We expect the launch of
GeneSeq HCV and PhenoSense HCV assays in 2003 and 2004, respectively for use in the development of
hepatitis C treatments to generate additional sales and earnings growth. In addition, we believe the company
can leverage its current testing platform to develop drug resistance tests for other diseases in therapeutic
areas including immunology and oncology.
Financial projections
In FY02 total revenue grew 38% with product revenue and contract revenue growth of 48% and 16% respectively.
Patient testing revenue and drug development revenue comprised approximately 73% and 27%
of product revenue, respectively, with growth of 48% and 16%. The company reported a loss of $1.38 for
FY02. In the most recent quarter, product revenues totaled $8.8 million and included revenue growth of
35% and 136% in the patient testing and drug development segments, respectively versus 31% and 37%
in the prior period. ViroLogic reported a loss of $0.02 for Q3-03 versus a loss of $0.24 in the prior period.
The loss narrowed due to higher gross margins and lower operating expenses.
We are forecasting EPS breakeven for Q4-03 on $9.6 million in revenues or revenue growth of 38% over
the prior period. We expect continued strength in the sales of the company’s drug development products in
Q4-03 and into FY04 and we are forecasting FY04 revenues and EPS of $45.3 million and $0.04. Going forward,
we expect sales to be driven by the launch of the GeneSeq HCV and PhenoSense HCV tests and continued
uptake in demand for the company’s Entry Inhibitor assays. In addition, we believe that higher volumes
of both patient testing and drug development testing will lead to FY04 gross margins of 55.1%, up
from our FY-03 forecast of 47.8%. These factors in combination with operating expenses spread over a larger
revenue base should result in sustainable EPS growth going forward.
Management
In our opinion ViroLogic, Inc. would benefit from superior scientific leadership. The management team includes
members who have held senior positions at Genentech and Dupont.
William D. Young, Chairman of the Board and CEO. William joined ViroLogic as Chairman of the Board
and CEO in November 1999. Prior to joining ViroLogic, he served at Genentech, Inc. for 19 years, most recently
as Chief Operating Officer, and served at Eli Lilly and Company for 14 years. He received his bachelor`s
degree in chemical engineering from Purdue University and his master`s of business administration
from Indiana University. In 2000, he was awarded an Honorary Doctorate of Engineering by his alma mater,
Purdue University.
December 3, 2003 13
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Tien Bui, Vice President of Sales and Marketing. Tien joined ViroLogic as National Sales Director in November
2000, was named Vice President of Sales in September 2001 and assumed the position of Vice
President of Sales and Marketing in November 2002. Before joining ViroLogic, Tien was the Virology Field
Director for DuPont Pharmaceuticals` Western Business Unit. Tien received her Bachelor`s of Science degree
in International Business from San Francisco State University and also studied abroad at The University of
Liege, Belgium.
Kathy L. Hibbs, Vice President, General Counsel. Kathy joined ViroLogic as Vice President, General
Counsel in April 2001. Kathy has also held General Counsel positions at Multitude, Inc and Varian Medical
Systems, Inc. She received her J.D. degree from the University of California, Hastings College of Law, and
her bachelor`s degree in political science from the University of California, Riverside.
Ken Hitchner, Vice President, Pharmaceutical Collaborations. Prior to joining ViroLogic in May of 1999,
Ken was Director of Project Management at Gilead Sciences. Before joining Gilead, Ken was Director of Product
Development and Global Project Leader at Genentech. Ken holds a Bachelors Degree in Zoology from
DePauw University and a Master Degree in Biology from San Francisco State University.
Christos J. Petropoulos, Ph.D., Vice President of Research and Development. Christos joined ViroLogic
in August 1996 and was named Vice President of Research and Development in November 1999.
From 1992 to 1996, Chris was a Scientist at Genentech, Inc where he directed the Molecular Virology, Molecular
Detection, and Research Virology Laboratories. Chris received his BS in zoology from the University of
Rhode Island and his PhD in molecular and cell biology from Brown University.
Jeannette Whitcomb, Ph.D., Vice President of Operations. Jeannette, Vice President of Operations
joined ViroLogic in 1996 and was a key member of the PhenoSense HIV development team. Prior to joining
ViroLogic, Jeannette was a Postdoctoral Fellow in Dr. Stephen H. Hughes` lab at the National Cancer Institute,
Frederick Cancer Research and Development Center. Jeannette received her BS in Biology from
Widener University in Chester, Pennsylvania and her Ph.D. in Microbiology and Immunology from Temple
University School of Medicine in Philadelphia.
Karen J. Wilson, Chief Financial Officer. Karen joined ViroLogic in January 2001. Prior to joining ViroLogic,
Karen held the position of Chief Financial Officer and Vice President of Operations for Novare Surgical
Systems, Inc. and served as a Senior Manager at Deloitte & Touche LLP. Karen is a certified public accountant
and received her B.S. degree in Business from the University of California at Berkeley.
December 3, 2003 14
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
FY-01 FY-02 FY-03E FY-04E Q1-02 Q2-02 Q3-02 Q4-02 Q1-03 Q2-03 Q3-03 Q4-03E Q1-04E Q2-04E Q3-04E Q4-04E
Product Revenue 17,815 24,530 32,309 43,604 5,493 6,430 5,672 6,935 6,551 7,786 8,759 9,213 9,354 10,939 11,334 11,977
% of Total Revenues 97.5% 97.1% 95.9% 96.2% 96.2% 96.6% 95.7% 99.5% 94.0% 97.9% 96.0% 95.6% 95.7% 96.3% 96.4% 96.6%
Contract Revenue 458 731 1,375 1,700 215 227 255 34 417 167 366 425 425 425 425 425
% of Total Revenues 2.5% 2.9% 4.1% 3.8% 3.8% 3.4% 4.3% 0.5% 6.0% 2.1% 4.0% 4.4% 4.3% 3.7% 3.6% 3.4%
Total Revenue 18,273 25,261 33,684 45,304 5,708 6,657 5,927 6,969 6,968 7,953 9,125 9,638 9,779 11,364 11,759 12,402
Yr/Yr %Chg 144.7% 38.2% 33.3% 34.5% 84.8% 39.6% 34.6% 15.9% 22.1% 19.5% 54.0% 38.3% 40.3% 42.9% 28.9% 28.7%
Cost of Product Revenue 11,845 14,589 16,866 19,596 3,425 3,761 3,463 3,940 3,819 4,268 4,403 4,376 4,368 4,966 5,112 5,150
Gross Product Margin 33.5% 40.5% 47.8% 55.1% 37.6% 41.5% 38.9% 43.2% 41.7% 45.2% 49.7% 52.5% 53.3% 54.6% 54.9% 57.0%
Yr/Yr %Chg 24.5% 20.9% 17.9% 15.2% 45.3% 32.4% 9.5% 14.6% 10.8% 8.9% 27.7% 21.6% 27.8% 20.8% 10.4% 8.6%
Operating Expenses
Research and Development 11,693 10,406 4,624 4,646 2,955 2,862 2,469 2,120 1,346 1,089 1,090 1,099 1,144 1,159 1,164 1,178
General and Administrative 11,376 10,550 9,094 9,093 2,744 2,638 2,279 2,889 2,466 2,375 2,113 2,140 2,171 2,273 2,293 2,356
Sales and Marketing 10,336 11,716 8,306 8,594 2,872 2,976 3,333 2,535 1,842 2,469 1,990 2,005 1,956 2,182 2,199 2,257
Total Operating Expenses 33,405 32,672 22,023 22,333 8,571 8,476 8,081 7,544 5,654 5,933 5,193 5,243 5,271 5,614 5,656 5,792
Yr/Yr %Chg 24.6% -2.2% -32.6% 1.4% 6.0% 8.7% -2.8% -18.1% -34.0% -30.0% -35.7% -30.5% -6.8% -5.4% 8.9% 10.5%
Operating Income (Loss) (26,977) (22,000) (5,205) 3,375 (6,288) (5,580) (5,617) (4,515) (2,505) (2,248) (471) 19 140 784 991 1,460
Interest Income 1,143 307 111 104 106 92 54 55 37 26 22 26 26 26 26 26
Interest Expense (466) (423) (152) (109) (91) (80) (75) (177) (52) (36) (32) (32) (30) (28) (26) (25)
Other Income 106 347 156 - 135 108 52 52 52 52 52
-
Pretax Income (Loss) (26,194) (21,769) (5,090) 3,370 (6,138) (5,460) (5,586) (4,585) (2,468) (2,206) (429) 13 136 782 991 1,461
Income Tax Provision - - - - - - - - - - - - - - - -
Net Income (Loss) (26,194) (21,769) (5,090) 3,370 (6,138) (5,460) (5,586) (4,585) (2,468) (2,206) (429) 13 136 782 991 1,461
Preferred Stock Dividend 2,603 11,528 3,816 880 3,068 258 249 7,953 2,622 506 413 275 220 220 220 220
Net Income (Loss) Attributable to Common (28,797) (33,297) (8,906) 2,490 (9,206) (5,718) (5,835) (12,538) (5,090) (2,712) (842) (262) (84) 562 771 1,241
Reported EPS ($1.43) ($1.38) ($0.30) $0.04 ($0.43) ($0.24) ($0.24) ($0.48) ($0.18) ($0.09) ($0.02) ($0.00) ($0.00) $0.01 $0.01 $0.02
Yr/Yr %Chg NM NM NM NM NM NM NM NM NM NM NM NM NM NM NM NM
Weighted Shares Outstanding 19,905 21,215 33,340 45,172 21,325 24,289 24,695 26,259 28,353 29,643 34,365 41,000 44,500 44,945 45,394 45,848
Fully Diluted Weighted Shares Outstanding 19,905 21,215 38,182 61,865 21,325 24,289 24,695 26,259 28,353 29,643 34,365 60,365 60,965 61,565 62,165 62,765
Sources: Company Reports and Merriman Curhan Ford & Co
Sean R. McKenna 415.248.5629
[e-mail]
ViroLogic, Inc.
Consolidated Income Statements
($ in thousands except for per share amounts)
Fiscal Year Ending Dec
December 3, 2003 15
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
FY-00 FY-01 FY-02 Q1-01 Q2-01 Q3-01 Q4-01 Q1-02 Q2-02 Q3-02 Q4-02 Q1-03 Q2-02 Q3-03
Current Assets
Cash & Cash Equivalents 12,623 1,399 10,559 5,695 6,174 10,189 1,399 10,207 4,460 3,045 10,559 9,047 7,763 7,748
Short-Term Investments 11,171 7,563 586 11,470 6,110 7,746 7,563 3,845 3,782 2,413 586 588 589 537
Accounts Receivable, net 2,404 4,562 4,924 2,668 3,215 3,143 4,562 4,560 5,552 3,739 4,924 4,399 4,390 5,109
Prepaid Expenses and Other 663 1,464 811 - - - 1,464 817 3,527 1,361 811 513 979 1,181
Inventory 449 956 958 691 835 823 956 1,005 1,325 1,193 958 837 746 965
Restricted Cash 1,050 100 257 800 800 600 100 100 100 150 257 257 426 426
Other Current Assets 489 1,671 125 891 1,238 1,681 1,671 678 295 1,325 125 126 108 342
Total Current Assets 28,849 17,715 18,220 22,215 18,372 24,182 17,715 21,212 19,041 13,226 18,220 15,767 15,001 16,308
Property and Equipment, net 13,234 18,381 10,961 13,328 15,208 18,473 18,381 18,118 12,527 11,710 10,961 10,171 9,602 8,927
Restricted Cash 979 950 950 1,000 900 900 557 557 450 450 350 350
Other Assets 585 855 855 745 920 890 855 864 738 741 855 977 1,039 1,220
Total Assets 43,647 37,851 30,486 37,238 35,450 44,545 37,851 41,094 32,863 26,234 30,486 27,365 25,992 26,805
Current Liabilities
Accounts Payable 1,865 2,304 831 3,010 2,025 2,917 2,304 1,968 1,387 1,615 831 1,232 1,563 1,117
Accrued Compensation 1,305 2,036 863 1,726 1,408 1,994 2,036 2,623 1,603 1,412 863 1,159 844 1,188
Accrued Liabilities 2,678 3,686 2,456 1,084 2,875 3,668 3,686 2,970 2,402 1,693 2,456 1,784 2,055 1,779
Deferred Revenue - 314 674 384 364 321 314 273 483 577 674 706 663 375
Convertible Promissory Notes 116 - 12,046 - - - - - - - 12,046 - - -
Current Portion of Capital Lease Obligations 398 977 1,173 504 732 756 977 1,068 1,102 1,129 1,173 1,038 842 620
Current Portion of Loans Payable 1,390 890 416 1,403 1,276 1,079 890 1,066 503 412 416 205 - 212
Total Current Liabilities 7,752 10,207 18,459 8,111 8,680 10,735 10,207 9,968 7,480 6,838 18,459 6,124 5,967 5,291
Long-Term Portion of Capital Lease Obligations 945 1,341 419 1,057 1,351 1,153 1,341 1,080 963 673 419 270 249 169
Long-Term Deferred Rent 288 - 345 281 388 234 - 516 - - 345 334 325 354
Other Long-Term Liabilities 1,019 1,604 - 656 2,893 1,567 1,604 650 616 351 - - - -
Redeemable Convertible Preferred Stock - 11,228 4,249 - - 11,457 11,228 14,666 12,103 12,098 4,249 4,249 4,249 3,880
Common Stock 20 21 28 20 20 20 21 23 25 25 28 29 32 39
Additional Paid-In Capital 88,772 93,226 107,925 88,676 89,291 92,673 93,226 99,931 102,694 102,699 107,925 119,683 120,651 122,961
Deferred Compensation (2,495) (875) (182) (1,976) (1,562) (1,164) (875) (637) (448) (297) (182) (99) (49) (25)
Accum Other Comprehensive Income (Loss) 178 94 7 231 88 125 94 30 23 26 7 7 6 3
Accumulated Deficit (52,832) (78,995) (100,764) (59,818) (65,699) (72,255) (78,995) (85,133) (90,593) (96,179) (100,764) (103,232) (105,438) (105,867)
Stockholder`s Equity 33,643 13,471 7,014 27,133 22,138 19,399 13,471 14,214 11,701 6,274 7,014 16,388 15,202 17,111
Total Liabilities and Stockholder`s Equity 43,647 37,851 30,486 37,238 35,450 44,545 37,851 41,094 32,863 26,234 30,486 27,365 25,992 26,805
Sources: Company Reports
Sean R. McKenna 415.248.5629
[e-mail]
ViroLogic, Inc.
Consolidated Balance Sheets
($ in thousands except for per share amounts)
Fiscal Year Ending Dec
December 3, 2003 16
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
FY-00 FY-01 FY-02 FY-03 Q1-01 Q2-01 Q3-01 Q4-01 Q1-02 Q2-02 Q3-02 Q4-02 Q1-03 Q2-03 Q3-03
Cash Flows from Operating Activities:
Net Income (Loss) (23,196) (26,194) (21,769) (5,103) (7,017) (5,881) (6,556) (6,740) (6,138) (5,460) (5,586) (4,585) (2,468) (2,206) (429)
Depreciation and Amortization 1,700 3,276 3,811 2,470 694 810 807 965 1,078 835 939 959 923 785 762
Non-cash Stock-Based Compensation 4,124 1,914 955 258 411 705 362 436 360 235 198 162 79 70 109
Provision for Doubtful Accounts 111 413 593 (156) 82 49 117 165 188 (188) 377 216 4 (4) (156)
Amortization of Deferred Gain on Lease Assignment - - (327) - - - - - - - (68) (259) (52) (52) 104
Amortization of Subtenant Advance - (325) (121) - - - - (325) (325) (2) - 206 - - -
Gain on Short-Term Investments (72) (164) - - - - (187) 23 - (51) 51 - - -
Changes in Operating Assets and Liabilities:
Accounts Receivable (1,965) (2,571) (955) (185) (346) (596) (45) (1,584) (186) (804) 1,436 (1,401) 521 13 (719)
Prepaid Expenses (358) (801) 653 (370) 162 (291) (542) (130) 647 (710) 166 550 298 (466) (202)
Inventory (162) (507) (2) (7) (242) (144) 12 (133) (49) (320) 132 235 121 91 (219)
Other Current Assets (374) 104 171 (217) 99 (56) 99 (38) (293) 166 (30) 328 (1) 18 (234)
Accounts Payable 408 439 (1,473) 286 1,145 (985) (24) 303 (336) (581) 228 (784) 401 331 (446)
Accrued Compensation 745 731 (1,173) 325 421 (318) 586 42 587 (1,020) (191) (549) 296 (315) 344
Accrued Liabilities 376 (981) (191) (449) (1,601) 458 162 - (706) 660 (1,061) 916 (833) 490 (106)
Deferred Revenue 35 198 360 (320) 268 (20) (43) (7) (41) 210 94 97 32 (43) (309)
Other Long-Term Liabilities 43 167 146 (31) - 66 (87) 188 61 (161) 76 170 (11) (9) (11)
Net Cash Provided By (Used In) Operating Activities: (18,585) (24,301) (19,322) (3,499) (5,924) (6,203) (5,339) (6,835) (5,153) (7,140) (3,341) (3,688) (690) (1,297) (1,512)
Cash Flows from Investing Activities:
Purchases of Short-Term Investments (35,702) (7,160) (13,415) (4,576) (1,340) (4,009) (1,212) (599) (8,062) 2,150 (1,544) (5,959) (1,032) (3,537) (7)
Maturities and Sales of Short-Term Investments 24,781 10,848 20,305 4,621 1,125 9,195 (200) 728 11,716 (2,094) 2,967 7,716 1,030 3,535 56
Restricted Cash (1,079) 1,029 350 (69) 279 - 150 600 - 343 (50) 57 (133) 64 -
Capital Expenditures (8,391) (7,777) (1,437) (375) (496) (698) (3,928) (2,655) (391) (688) (148) (210) - (349) (26)
Lease Assignment - - 3,793 - - - - - - 2,465 748 580 (122) 122 -
Tenant Improvement Reimbursement - (1,286) 1,286 - - - - (1,286) 1,286 - - - - - -
Advance from Subtenent - 2,600 - - - 2,600 - - - - - - -
Other Assets (10) (270) (187) (365) (160) (175) 30 35 (9) 67 (3) (242) - (184) (181)
Net Cash Provided By (Used In) Investing Activities: (20,401) (2,016) 10,695 (764) (592) 4,313 (2,560) (3,177) 4,540 2,243 1,970 1,942 (257) (349) (158)
Cash Flows from Financing Activities:
Principle Payments of Loans Payable 461 (1,345) (871) (204) (350) (395) (351) (249) (262) (522) (91) 4 (211) (205) 212
Principle Payments on Capital Lease Obligations 1,343 684 (958) (803) (74) (130) (174) 1,062 (170) (315) (263) (210) (284) (217) (302)
Net Proceeeds from the Issuance of Common Stock 31,954 1,006 3,603 2,882 12 2,894 (2,479) 579 4 1 304 3,294 1 1,110 1,771
Costs Related to Issuance of Preferred Stock 15,643 14,748 16,013 (423) - - 14,918 (170) 9,849 (14) 6 6,172 (71) (326) (26)
Net Cash Provided By (Used In) Financing Activities: 49,401 15,093 17,787 1,452 (412) 2,369 11,914 1,222 9,421 (850) (44) 9,260 (565) 362 1,655
Net Increase in Cash & Cash Equivalents 10,415 (11,224) 9,160 (2,811) (6,928) 479 4,015 (8,790) 8,808 (5,747) (1,415) 7,514 (1,512) (1,284) (15)
Cash & Cash Equivalents at Beginning of Period 2,208 12,623 1,399 10,559 12,623 5,695 6,174 10,189 1,399 10,207 4,460 3,045 10,559 9,047 7,763
Cash & Cash Equivalents at End of Period 12,623 1,399 10,559 7,748 5,695 6,174 10,189 1,399 10,207 4,460 3,045 10,559 9,047 7,763 7,748
Sources: Company Reports
Sean R. McKenna 415.248.5629
[e-mail]
ViroLogic, Inc.
Consolidated Statement Of Cash Flows
($ in thousands except for per share amounts)
Fiscal Year Ending Dec
December 3, 2003 17
Health Enabling Technologies & Services
ViroLogic, Inc. (VLGC) Buy
MERRIMAN
CURHAN
FORD & CO.
Publicly traded companies mentioned in this report: Bio Reference Laboratories Inc. (NASDAQ: BRLI, $17.79, NR),
Laboratory Corporation of America Holdings (NYSE: LH , $36.80, NR), Quest Diagnostics (NYSE: DGX, $74.12, NR), Specialty
Laboratories, Inc. (NYSE: SP, $15.80, NR)
Regulation Analyst Certification (“Reg. AC”):
All of the views expressed in this research report accurately rflect the research analyst`s personal views about any and all
of the subject securities or issuers. No part of the research analyst`s compensation was, is, or will be, directly or indirectly,
related to the specific recommendations or views expressed by the research analyst in the research report.
Merriman Curhan & Ford & Co. (“MEM”) expects to receive or intends to seek compensation for investment banking in
other business relationships with the covered companies mentioned in this report in the next three months.
Specific Disclosures:
Bolded disclosures refer to the subject company of this report.
(a) Within in the last twelve months, MEM has received compensation for investment banking services from
this company.
(b) MEM makes a market in this security and as such buys and sells from customers on a principal
basis.
(c) MEM and/or its officers, principals, employees, or owners own options, rights, or warrants to purchase
this security.
(d) An employee of MEM serves on the company’s Board of Directors (other than the research analyst).
(e) A research analyst and/or a member of the analyst’s household has a financial interest in the securities
of the subject company ( if applicable, the specific type of financial interest owned will be disclosed).
(f) the research analyst or a member of the analyst’s household serves on the company’s Board of Direc
tors.
(g) Within the last twelve months, MEM has managed or co-managed a public offering for this company.
(h) MEM or its affiliates beneficially owns 1% or more of an equity security of this company.
Key to Investment Rankings: Expected total share price return (inclusive of dividend reinvestment if applicable) relative
to the composite small to mid capitalization U.S. equities market.
This research has been prepared by Merriman Curhan Ford & Co, a wholly owned subsidiary of MCF Corporation. Some
companies Merriman Curhan Ford & Co. follows are emerging growth companies whose securities typically involve a higher
degree of risk and more volatility than the securities of more established companies. The securities discussed in Merriman
Curhan Ford & Co. research reports may be unsuitable for some investors depending on their specific investment objectives,
financial status, risk profile, or particular needs. Investors must make their own determination as to the suitability of
an investment in any securities referred to herein based on these factors and their own investment strategy. This research
report is not a recommendation that any particular investor should purchase or sell any particular security in any amount
or at all, and is not a solicitation of any offer to purchase or sell from or to any particular investor.
The information contained herein is based on information obtained from sources believed to be reliable but is neither allinclusive
nor guaranteed by Merriman Curhan Ford & Co. No independent verification has been made as to the accuracy or
completeness of the information. Opinions, if any, reflect our judgment at the time the report is first published and are
subject to change without notice. Merriman Curhan Ford & Co. does not undertake to advise you of changes in its opinion
or information.
Member NASD / SIPC. Copyright © 2003. All rights reserved.
Additional Information Supporting the Statements in this Report is Available Upon Request.
Rating %
Universe
No. of
Stocks
Description % Investment Banking
Services Provided
Buy 67% 52 Outperform the market over the next 12 months.
Initiate or increase position.
10%
Neutral 28% 22 Perform in line with market over the next 12
months. Maintain position or take no action.
0%
Sell 5% 4 Underperform the market over the next 12
months. Sell or decrease position.
0%

[heikekarina]

ViroLogicResearch.pdf

[heikekarina]

heute verkaufen wohl die ersten zittrigen Kleinanleger in USA. Ob das mal nicht zu früh ist. Man muss sich auch mal in Geduld üben können. Die grossen Pakete der vergangenen Tage bleiben in fester Hand

[heikekarina]

und wieder mal die Shortis am Werk

[heikekarina]

so, wie ich es sehe bekommen auch hier einige mächtig Angst. Wird Zeit gleich Morgen ein Abstauberlimit zu legen.

[heikekarina]

das gibt leckere NK-Gelegenheiten.

[wissi71]

Seh ich auch so.

[heikekarina]

die Amis, wollen mit Gewalt VLGC um die 2,50$ sehen. Mal sehen ob es klappt

[MaxLubin]

#176
ich meine nicht das es unter 2,5$ geht. Montag fällt immer der Käufer... Montag=Umsatzlos, aber Di. sollte wieder ein Stück nach oben gehen ..

[wissi71]

Halten sich aber momentan noch ganz wacker.

[MaxLubin]

und hier ist zu sehen ,wie schön gekauft wird ..
kleine Stücke raus und 57000 rein ..

14:48:07 2.690 100 Cincinnati at Ask
14:46:28 2.707 57000 Nasdaq-NM
14:43:20 2.672 100 Nasdaq-NM
14:43:17 2.672 100 Cincinnati
14:43:09 2.690 100 Nasdaq-NM at Bid
14:43:05 2.690 100 Nasdaq-NM at Bid
14:43:05 2.690 100 Nasdaq-NM at Bid
14:43:05 2.690 100 Nasdaq-NM at Bid
14:43:03 2.700 3400 Pacific at Ask
14:40:31 2.680 100 Nasdaq-NM

[heikekarina]

@MaxLubin

die Märkte haben sich schön gedreht.

Ich meinte nicht das es unter die 2,50$ geht, weil ein Ausverkauf stattfindet, sondern so, wie Du es ja anhand der Trades sehr schön dagestellt hast.
Ich werfe kleine Stückzahlen auf den MArkt, um unten grössere Pakete abzustauben.
Ich denke das es schon Mittwoch wieder in Richtung 3$, wenn nicht sogar darüber gehen kann. Wir werden es sehen.

Man muss sich auch mal in Geduld üben können

[heikekarina]

Realtime 2.81$, allerdings liegen 11 US-Cent an Spread dazwischen. Daversuche immer noch einige preiswerter einzusteigen. Mals sehen wer bei den Amis die stärkeren Nerven hat.
Allgemein gesehen, verfahren die nicht nur an der Börse aggresiver wie unser eins in Deutschland. Lese ich so einige Posting in den einschlägigen Amibords, dann überkommt einem das eisige Grauen. Gewalt, Beleidungen usw. scheint in deren Vokabular nichts ausser gewöhnliches zu sein. Bei W:0 wären bereits 90% aller User gesperrt.

[heikekarina]

Ask bei 2,83$

[heikekarina]

Ask 2.85$

Nachbörslich bereits 2.95$

[Intrader78]

was für ein rebound!!!!

[heikekarina]

ja, selbst die Amis scheinen euphorisch. Kurse über 3$ sind anscheinend kein Spuk mehr bei denen. Einige sprechen bereits von über 5$ auf Sicht Ende Januar 04.
4$ bis 4.50$ bis Ende des Jahres

[Bullebio]

@ heikekarina

hallo erstmal.
ich muß offen gestehen, dass ich heute auch etwas panik bekommen habe. ich habe 1/3 abgebaut, um freie liguidität für biophan zu bekommen.
ich bin trotzdem noch sehr positiv gestimmt, was VLGC betrifft. der heutige rebound vom tagestief bei 2,56$ sagt ja schon alles. und schlußkurs auf tageshoch. so muß es sein. sauber halt.

tschau

[robby13]

Phsychologisch ist aktuelle Situation völlig normal , die Korrektur schüttelt die schwachen Hände aus dem Markt , andere greifen anschließend wieder beherzt zu.
Die Ernte werden jene Anleger einfahren , welche auch mal 20 oder 30% Vola abkönnen. Vielleicht sollte man nicht jede marktkonforme Bewegung eines spekulativen Wertes als den Untergang des Abendlandes betrachten. Fundamentals zählen !
robby

[Dolocher]

Ich glaube das wir bis zu den Zahlen auf dem Niveau von 3,00 US$ + - 20% einpendeln werden,sollte VLGC hier bereits in die Gewinnzone fahren(wovon ich fest überzeugt bin) sind die 4-5$ wirklich schneller Realität,als das die meisten(ich auch) gedacht hätten.Aber ich werde mich nicht Beschweren
Momentan auch keine News!

[heikekarina]

@Dolocher

wann, kommen die Zahlen? Danke!

Ansonsten, schliesse ich mich nur zu gerne deiner Meinung an

[Dolocher]

Leider gibt es dazu nirgendwo einen genauen Termin,aber da bei VLGC das Geschäftsjahr=Kalenderjahr ist,glaube ich das wir die Zahlen so um den 3-5 Januar sozusagen als nachträgliches Weihnachtsgeschenk bekommen.
Ein Verlust von 0,01$/Aktie im 3.Quartal sollte sich in einen Gewinn von (meine Schätzung) 0,05-0,07 $ verwandeln,so das wir auf Jahressicht beim Nettoverlust sogar etwas unter den Schätzungen von,0,23US$ liegen sollten und das nächste Jahr wird schwarz !

MfG

[wissi71]

Schön wär es.... und würde auch dem Kursverlauf ganz gut tun.

[heikekarina]

wir wollen geduldig bleiben

[Dolocher]

Nachdem wir uns von unter 0,90US$ bis knapp 3,00$ geduldig hochgearbeitet haben sollten wir die nächsten Monate auch noch geduldig bleiben,es sollte sich auszahlen

[wissi71]

Genau! Da hast du recht!
Allen ein schönes WE!!

[linklink]

VLGC ViroLogic, Inc.

Symbol Last Trade Date Change Open High Low Volume
VLGC 2.8 Dec-12-2003 0.05 2.75 2.97 2.7 949,400

Analysis


Overall Very Bullish
Short Very Bullish
Intermediate Very Bullish
Long Very Bullish

Support/Resistance Type Value Conf.
resist. 3.19 2
supp 2.78 3
supp 2.65 2
supp 2.47 4
supp 2.24 4
supp 2.11 2
supp 1.72 9
supp 1.57 8
supp 1.39 2
supp 1.32 6
supp 1.25 5
supp 1.14 3
supp 1.05 2

[wissi71]

Und warum passiert beim Kurs nicht viel??

[heikekarina]

Nerven behalten. Es betseht keinerlei Verkaufsdruck bei den Amis. Alle, die in den vergangenen Wochen eingesammelt haben, halten ihre Stücke fest in den Händen. Die 3$ Marke braucht noch ein paar Tage, bis die endgültig geknackt sind

[wissi71]

Sieht ganz so aus, kaum Umsätze im Vergleich zu den vergangenen Handelstagen.
Na dann schaun wir mal, wie das so weiter geht...

[claudi34]

viele instis im ami-land (vor allem fonds) haben ihre ordenbücher schon geschlossen und haben angesichts der anstiege der vergangenen wochen auch keine veranlassung zum "window-dressing".
was mich positiv stimmt für VLGC: manche fonds verkaufen ihre highflyer, um fürs neue jahr neue anleger zu gewinnen.
mit kursgewinnen von 80 bis 100 prozent kann man ja schön auf die pauke hauen. von "advertise-sales" ist hier nichts zu sehen. das bedeutet, dass VLGC ein noch signifikantes kurspotential eingeräumt wird.
schönen abend.
lg.
aus münchen

ich für meinen teil bleib sicher bis feb. long. mal schauen, was passiert, wenn die fonds frisches geld mobilisieren und die nächsten zahlen anstehen

[claudi34]

viele instis im ami-land (vor allem fonds) haben ihre orderbücher schon geschlossen und haben angesichts der anstiege der vergangenen wochen auch keine veranlassung zum "window-dressing".
was mich positiv stimmt für VLGC: manche fonds verkaufen ihre highflyer, um fürs neue jahr neue anleger zu gewinnen.
mit kursgewinnen von 80 bis 100 prozent kann man ja schön auf die pauke hauen. von "advertise-sales" ist hier nichts zu sehen. das bedeutet, dass VLGC ein noch signifikantes kurspotential eingeräumt wird.
schönen abend.
lg.
aus münchen

ich für meinen teil bleib sicher bis feb. long. mal schauen, was passiert, wenn die fonds frisches geld mobilisieren und die nächsten zahlen anstehen

[heikekarina]

um die 2,70$ wird sich gerne eingedeckt

[heikekarina]

"Certain statements in this press release are forward-looking, including statements relating to anticipated growth in sales of testing products and ongoing benefits from cost reduction measures, expectations regarding 2003 and 2004 guidance, the development of new technology, the receipt of non-dilutive grants, projected operating results, continued acceptance of the Company`s products for patient testing and increasing demand from vaccine and drug development partners. These risks and uncertainties include, but are not limited to, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission."

[wissi71]

WIr hatten heut schon niedrigere Kurse...

[heikekarina]

das lag aber nur daran, das Amgen negative Meldungen gebracht haben.
Wichtigste aber ist, das die Märkte (Dow, Nasdaq, und Bio)
mitspielen. Nach wievor sind die Märkte sehr volatil. Alles wartet immer noch auf die versprochene Rally

[heikekarina]

http://www.stockta.com/cgi-bin/candle.pl?symb=VLGC&size=anal…

[heikekarina]

http://www.stockta.com/cgi-bin/analysis.pl?symb=VLGC&num1=3&…[IMG][/URL][/url]

[heikekarina]

Time Price Volume Exchange Info


16:06:10 2.850 11200 Nasdaq-NM
16:00:23 2.750 36000 Nasdaq-NM
15:59:59 2.880 2200 Pacific
15:59:58 2.870 500 Cincinnati
15:59:56 2.900 400 Cincinnati at Ask
15:59:56 2.900 6900 Cincinnati at Ask
15:59:56 2.900 1000 Cincinnati at Ask
15:59:53 2.879 100 Nasdaq-NM
15:59:52 2.880 200 Nasdaq-NM
15:59:51 2.880 1000 Cincinnati

[robby13]

KAUAI, Hawaii, Dec 17, 2003 /PRNewswire-FirstCall via Comtex/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today a presentation on the Company`s development of a novel Hepatitis C virus (HCV) drug susceptibility assay with applications in drug discovery and development. The findings were presented by Neil Parkin, Ph.D., Scientific Director of Research at ViroLogic, at the 5th biennial HepDART meeting "Frontiers in Drug Development for Viral Hepatitis" held in Kauai, Hawaii, December 14-18.

"Recent research advances have boosted understanding of Hepatitis C virus replication and provided the biopharmaceutical industry with several new targets for potential therapeutic intervention," said Bill Young, ViroLogic`s Chairman and Chief Executive Officer. "The HepDART presentation illustrates how ViroLogic`s expertise in virology and assay development can be applied to facilitate the development of therapeutics for the treatment of this serious chronic disease."

The study entitled, "Sequence Analysis of NS5B in Genotype 1 HCV: Extensive Sequence Variability and Naturally Occurring Polymorphisms Which May Affect Polymerase Inhibitor Activity" characterized the natural genetic variation in HCV polymerase (NS5B) using ViroLogic`s newly developed genotyping assay. The assay is currently available to biopharmaceutical companies for generation of clinical data for evaluation of a promising new class of anti-HCV drugs that target the viral polymerase.

Dr. Parkin also described the Company`s ongoing effort to assemble a large database of complete genotype 1 NS5B sequences, which has already uncovered significant diversity. By mapping the regions of genetic variability to the structure of the polymerase, drug developers may be able to target areas of least variation for drug development and predict potential baseline variability in viral susceptibility to candidate anti-HCV drugs. ViroLogic is also developing a phenotypic assay to assess the effect this natural variation has on drug susceptibility.

About Hepatitis C

Hepatitis C is one of the most common chronic blood-borne infections in the United States. According to the U.S. Centers for Disease Control and Prevention, approximately 3.9 million Americans are infected with HCV. Currently, no vaccine is available to prevent new HCV infections. Left untreated, chronic HCV infection often leads to end stage liver disease and is the leading reason for liver transplantation in the United States. In contrast to the current treatment of chronic HCV infection, a combination of interferon and ribavirin, the next generations of anti-HCV drugs are designed to target specific viral proteins and directly block critical steps in the HCV replication cycle.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.virologic.com.

Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from physicians or from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

SOURCE ViroLogic, Inc.


CONTACT: Karen Wilson, CFO of ViroLogic, Inc., [phone], or
[e-mail]

URL: www.prnewswire.com


Copyright (C) 2003 PR Newswire. All rights reserved.

-0-



KEYWORD: Hawaii
INDUSTRY KEYWORD: HEA
MTC
BIO
SUBJECT CODE: SVY
TDS

[heikekarina]

sieht heute sehr gut aus

[wissi71]

Oh ja, find ich auch!!

[robby13]

Time Price Volume Exchange Info


10:51:59 3.250 200 Pacific at Ask
10:51:55 3.250 700 Nasdaq-NM at Ask
10:51:31 3.250 100 Cincinnati at Ask
10:51:30 3.250 100 Pacific at Ask
10:51:30 3.250 100 Pacific at Ask
10:51:30 3.250 100 Pacific at Ask
10:51:30 3.250 100 Pacific at Ask
10:51:30 3.250 100 Pacific at Ask
10:51:30 3.230 100 Nasdaq-NM
10:51:30 3.240 100 Nasdaq-NM

Gruß
robby

[Dolocher]

Da bin ich mal 2 Tage nicht da,schon läuft VLGC auf 3,40...ich werde jetz öfter verreisen !

Jetzt kann es sehr schnell auf 4-4,50 US $ gehen,da es hier kaum Widerstände gibt und spätestens nach den Zahlen sollten wir die 4,00 US$ knacken.

[CutPall]

@ Dolocher,
wie wärs mit einer Weltreise, so für 12 Monate, dann zurückkommen und steuerfreie Gewinne realisieren
Hätte nicht gedacht, dass wir in diesem Jahr die 3$ knacken.

[Intrader78]

schlußkurs 3,48$

Da kommt Freude auf!!! Morgen gehts weiter nach oben.

[Dolocher]

@ CutPall
ich werde darüber nachdenken... aber nur unter der Bedingung das der Kurs dann bei mind. 10US$ steht

MfG

[CutPall]

2 Tage = 20%
1 Jahr = 365 Tage = 3650%

Da würde ich dir die Reise sogar finanzieren

[wissi71]

Ich sponsor auch was!

[Dolocher]

Ausgehend von 3,30 US$ hätten wir dann einen Kurs von 123,75 US$/Aktie in 12 Monaten...
dann bin ich Millionär und setzt mich zur Ruhe...

[heikekarina]

Leute,

fängt das jetzt mit den Halluzinatinen an?

[heikekarina]

Last 10 trades
verdammt ruhig Heute. Nervös?

Time Price Volume Exchange Info


12:40:33 3.300 10000 Nasdaq-NM at Bid
12:39:56 3.300 100 Pacific at Bid
12:39:56 3.300 1100 Pacific at Bid
12:39:56 3.300 1200 Pacific at Bid
12:39:56 3.300 100 Pacific at Bid
12:39:56 3.300 900 Pacific at Bid
12:39:52 3.300 800 Pacific at Bid
12:39:49 3.300 900 Pacific at Bid
12:39:43 3.300 1000 Pacific at Bid
12:39:36 3.301 100 Nasdaq-NM

[heikekarina]

At 12:43PM ET: 3.34

[heikekarina]

hmm, Morgen Hexensabatt. Hoffentlich bleibt VLGC stabil. Die ersten verkaufen wohl aus reiner Nervosität. Morgen werden die nächsten folgen. Nicht weiter schlimm, denn Konsolodierungen werden kommen

[heikekarina]

auf 3 Monatssicht, sollte der derzeitige Kurs sich halten. Ansonsten meine ich das VLGC bis auf 2,80$ zurück kommen könnte. Wird diese Marke unterschritten sogar bis 2,50$.
We will see

[robby13]

reine Kaffeesatzleserei.......

[MaxLubin]

#223 .. immer gut drauf und jetzt? Hast du grund dafür, dass wir zu 2,80$ kommen könnten, oder reine Gefühlsache ...

[Intrader78]

#223
ouh ouh da hats aber jemand plötzlich nötig!!!!

[heikekarina]

natürlich reines Bauchgefühl. Genauso, wie ich vor Monaten Virologic wie Sauerbier angepriesen habe. Da bin ich von den meisten ausgelacht worden. Ich bleibe selbstverständlich weiter positiv gestimmt. Ausserdem habe ich nur vom 3 Monatschart geschrieben. Langfristchart, sagt mir nur positives. Also, schön die Finger vom VK-Buttom lassen.

[robby13]

Wall Street News Alert -- Attractive Stocks to Watch!

WESTON, Fla., Dec 19, 2003 (PRIMEZONE via COMTEX) -- Wall Street News Alert`s "stocks to watch" this morning are: Y3K, Inc (OTCBB:YTHK), Women First HealthCare (Nasdaq:WFHC), ViroLogic Inc. (Nasdaq:VLGC) and Applied Signal Technology (Nasdaq:APSG).

Aggressive investors should be watching Y3K, Inc (OTCBB:YTHK) this morning! Yesterday after the markets closed, the company issued a press release announcing the completion of its customized MarketPortal software for Consumer First, a national financial services, consumer marketing company with a nationwide network of merchants and customers! The custom MarketPortal software is part of a development and licensing agreement that calls for Y3K to provide customized MarketPortal and Affiliate Tracker software that will allow Consumer First to aggregate its thousands of merchants in an online shopping network.

This could be great news for investors! The press release states that, according to an agreement, Y3K receives an annual fee from every business that joins the network, plus a percentage of all transaction fees. "The completion and operation of the customized software for Consumer First means that we will begin to immediately generate revenue," stated King Cole, President of Y3K. "Based on current growth trends of Consumer First, this contract is projected to result in revenue of $3.9 million dollars for Y3K over the course of 2004, with the potential for $300,000 during the first quarter. This will prove to be a very lucrative partnership for both companies."

Keep your eye on this one! Y3K and the Consumer First Executive Team are now jointly developing a training program for the rapidly growing 10,000 member national sales force. The sales force will begin recruiting additional businesses for the Consumer First online shopping portal at the start of 2004, and consumers will be able to shop in the robust shopping environment shortly thereafter. The Consumer First model is an historical first in which consumers receive direct benefits from the merchants when they spend at any of the thousands of businesses within the national network.

Consumer First has created an affiliation with both Visa and MasterCard and also have their own Consumer First Card. Consumer First works with a number of major affinity groups including national PTA, major universities and major credit unions and their rapidly growing merchant base includes national major chains such as Pep Boys and AAMCO. Consumer First has access to over 14 million credit card holders, and has 10,000 member/distributors. The stock closed yesterday at just over Eight Cents a share.

Stocks showing interesting activity yesterday were: Women First HealthCare (Nasdaq:WFHC) down 3.75% on 517,000 shares traded, ViroLogic Inc. (Nasdaq:VLGC) down 2.16% on 1,406,500, and Applied Signal Technology (Nasdaq:APSG) down 1.26% on 191,400 shares traded.

Commentary: The Wonderful World of Wireless

"Look for a new device, replacing the old bar code system, to keep track of anything. The new RFID (radio frequency identification tag) will become the norm soon. It will track things like luggage, groceries, mail, retail purchases, etc. It works on radio frequency, like the fast lane in through a tollbooth, and will change a lot of the way we do things soon," stated Sonja Rudd in Wall Street News Alert`s daily commentary continued at: www.WallStreetNewsAlert.com.

WSNA`s email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 11 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at www.wallstreetnewsalert.com and select the "join now" button.

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company`s publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies` discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. WSCF has previously been compensated One Hundred and Sixty Thousand shares and Twenty-Five Thousand Dollars by a third party (Ashley Inc) who is non-affiliated, for services previously performed, and subsequently Twenty Thousand Dollars by the company. WSCF has recently been compensated Fourteen Thousand Dollars by the company, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF`s services for a company may cause the company`s stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF`s selling of a company`s stock may have a negative effect on the market price of the stock. Market commentary provided by Sonja Rudd.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies` annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

SOURCE: Wall Street Capital Funding LLC

INVESTMENT OPINION

By Staff
CONTACT: Wall Street News Alert
Email: [e-mail]
URL: www.wallstreetnewsalert.com



(C) 2003 PRIMEZONE, All rights reserved.

-0-



INDUSTRY KEYWORD: Advertising
SUBJECT CODE: INVESTMENT OPINION
Analyst Recommendations

STOCK SYMBOLS: [(ythk)] [(wfhc)] [(vlgc)] [(apsg)]

[heikekarina]

sieht doch mal wieder gut aus. VLGC entwickelt sich immer mehr zu einem schönen und stabilen Wert. Was hatte ich gestern nur für Gedanken? Wahrscheinlich der weihnachtsstress.
Übrigens, habe ich meine Senatorposition heute massiv aufgestockt. Auch dieses Pferdchen lernz nach anfänglichen Schwierigkeiten das Laufen. Nur am Rande erwähnt.

[robby13]

hi , n amzn - Put wäre vielleicht auch ne überlegenswerte Investition !
Bzgl. vlgc; bei Biotechwerten jener Sparte ist die Bemühung irgendeiner Charttechnik immer ziemlich müßig....
Grüße vom Robby

[claudi34]

hi, ich denke auch dass vlgc relativ fest ist.
heute ist schließlich hexensabbat in den usa und da stellen die trader normalerweise immer glatt. davon ist noch nix zu merken.
zu heike: senator ist gut gelaufen, das wunder von bern wird dem kurs weiter flügel geben. ich für meinen teil bleib aber bei iem. die aktie ist sowas von unterbewertet.
lg

[robby13]

fast alle dt. Medienwerte ( im Depot ) erachte ich als einen Ritt auf der Rasierklinge. Senator wird auf 0,80€ fallen, in Kürze.
Broadnet , meinetwegen...., mit spitzen Fingern.
robby

[claudi34]

hast recht robby, das sind heiße eisen. aber solche haben auch die chance auf überproportionale kursgewinne.
wie du vermutlich weißt, sind medienwerte meine persönlichen favoriten (weil ich mich ein wenig auszukennen glaube). aber außer IEM und highlight habe ich keinen dt. wert im depot und auch nicht vor, mir einen weiteren zu kaufen.
lg. aus münchen
schönes wochenende

[MaxLubin]

hier eine Analyze von VectorVest ...


VectorVest Stock Analysis of Virologic Inc as of 12/19/2003

Thank you for requesting an analysis of Virologic Inc from VectorVest.
The ticker symbol for Virologic Inc is VLGC. VLGC is traded on the
NASDAQ - (O)

Analysis Summary
VLGC is overvalued compared to its Price of $3.28 per share, has below
average safety, and is currently rated a Hold.

In-Depth Analysis
Business: VIROLOGIC INC, (VLGC) conducts R&D on products to improve
treatment of viral diseases. VLGC has developed a way of measuring
impact of genetic mutations in viruses on their resistance to drugs and
is using it to test various disease viruses.

Price: VLGC closed on 12/19/2003 at $3.28 per share

Value: Value is a measure of a stock`s current worth. VLGC has a
current Value of $0.57 per share. Therefore, it is overvalued compared
to its Price of $3.28 per share. Value is computed from forecasted
earnings per share, forecasted earnings growth, profitability, interest,
and inflation rates. Value increases when earnings, earnings growth rate
and profitably increase, and when interest and inflation rates decrease.
VectorVest advocates the purchase of undervalued stocks. At some point
in time, a stock`s Price and Value always will converge.

RV (Relative Value): RV is an indicator of long-term price appreciation
potential. VLGC has an RV of 0.36, which is very poor on a scale of 0.00
to 2.00. This indicator is far superior to a simple comparison of Price
and Value because it is computed from an analysis of projected price
appreciation three years out, AAA Corporate Bond Rates, and risk. RV
solves the riddle of whether it is preferable to buy High growth, High
P/E stocks, or Low growth, Low P/E stocks. VectorVest favors the
purchase of stocks with RV ratings above 1.00.

RS (Relative Safety): RS is an indicator of risk. VLGC has an RS rating
of 0.59, which is poor on a scale of 0.00 to 2.00. RS is computed from
an analysis of the consistency and predictability of a company`s
financial performance, debt to equity ratio, sales volume, business
longevity, price volatility and other factors. A stock with an RS rating
greater than 1.00 is safer and more predictable than the average stock
in the VectorVest database. VectorVest favors the purchase of stocks of
companies with consistent, predictable financial performance.

RT (Relative Timing): RT is a fast, smart, accurate indicator of a
stock`s price trend. VLGC has a Relative Timing rating of 1.82, which is
excellent on a scale of 0.00 to 2.00. RT is computed from an analysis
of the direction, magnitude, and dynamics of a stock`s price movements
over one day, one week, one quarter and one year time periods. Once a
stock`s price has established a strong trend, it is expected to continue
in that trend for the short-term. If a trend dissipates, RT will
gravitate toward 1.00. RT will explode from bottoms, dive from tops, and
reflect changes in price momentum. VectorVest favors the purchase of
stocks with RT ratings above 1.00.

VST (VST-Vector): VST is the master indicator for ranking every stock
in the VectorVest database. VLGC has a VST rating of 1.19, which is good
on a scale of 0.00 to 2.00. VST is computed from the square root of a
weighted sum of the squares of RV, RS, and RT. Stocks with the highest
VST ratings have the best combinations of Value, Safety and Timing.
These are the stocks to own for above average, long-term capital
appreciation. VectorVest advocates the purchase of safe, undervalued
stocks rising in price. The efficacy of this indicator was demonstrated
in a study conducted at the University of Chicago which showed that high
VST stocks outperformed the S&P 500 by 583.1% over the six year period
from 1996 through 2002 <http://www.vectorvest.com/Performance2.htm> .

CI (Comfort Index): CI is an indicator which reflects a stock`s ability
to resist severe and/or lengthy price declines. VLGC has a CI rating of
0.76, which is poor on a scale of 0.00 to 2.00. CI is quite different
from RS in that it is based solely upon a stock`s long-term price
history. VectorVest advocates the purchase of high CI stocks.

GRT (Earnings Growth Rate): GRT reflects a company`s one to three year
forecasted earnings growth rate in percent per year. VLGC has a
forcasted Earnings Growth Rate of 13.00%, which VectorVest considers to
be good. GRT is computed from historical, current and forecasted
earnings data. It is updated each week for every stock in the VectorVest
database. GRT often foretells a stock`s future price trend. If a stock`s
GRT trend is upward, the stock`s price will likely rise. If GRT is
trending downward, the stock`s Price will probably fall. VectorVest
favors the purchase of stocks whose GRT is rising and is greater than
the sum of current inflation and interest rates, (7.43%).

Recommendation (REC): VectorVest gives a Buy, Sell, Hold recommendation
on every stock, every day. VLGC has a Hold recommendation. REC reflects
the cumulative effect of all the VectorVest parameters working together.
These parameters are designed to help investors buy safe, undervalued
stocks rising in price. They also help investors avoid or sell risky,
overvalued stocks falling in price. VectorVest recommends that investors
buy high VST-Vector, Buy-rated stocks in rising markets.

Stop (Stop-Price): Stop is an indicator of when to sell a long position
or cover a short position. VLGC has a Stop of $2.33 per share. This is
$0.95 below VLGC`s current closing Price. A stock`s Stop is computed
from a 13 week moving average of its closing prices, and is fine-tuned
according to the stock`s fundamentals. High RV, high RS stocks have
lower Stops, and low RV, low RS stocks have higher Stops. In the
VectorVest system, a stock gets a `B` or `H` recommendation if its Price
is above its Stop and an `S` recommendation if its Price is below its
Stop.

EPS (Earnings per Share): EPS stands for leading 12 months Earnings Per
Share. VLGC has a forecasted EPS of $0.01 per share. VectorVest
determines this forecast from a combination of recent earnings
performance and traditional fiscal and/or calendar year earnings
forecasts.

P/E (Price to Earnings Ratio): P/E is a popular measure of stock
valuation which shows the dollars required to buy one dollar of
earnings. VLGC has a P/E of 328.00. This ratio may be deemed to be high
or low depending upon your frame of reference. The average P/E of all
the stocks in the VectorVest database is 40.45. P/E is computed daily
using the formula: P/E = Price/EPS.

EY (Earnings Yield): EY reflects earnings per share as a percent of
Price. EY is related to P/E via the formula, EY = 100 / (P/E), and may
be used in place of P/E as a measure of valuation. EY has the advantages
that it is always determinate and can reflect negative earnings. VLGC
has an EY of 0.32 percent. This is below the current average of 2.47%
for all the stocks in the VectorVest database. EY equals 100 x
(EPS/Price).

GPE (Growth to P/E Ratio): GPE is another popular measure of stock
valuation. It compares earnings growth rate to P/E ratio. VLGC has a GPE
rating of 0.04. High growth stocks are believed to be able to justify
high P/E ratios. A stock is commonly considered to be undervalued when
GPE is greater than 1.00 and overvalued when GPE is below 1.00.
Unfortunately, this rule of thumb does not take into account the effect
of interest rates on P/E ratios. The operative GPE ratio of 1.00 is
valid when and only when interest rates equal 10%. With long-term
interest rates currently at 5.63%, the operative GPE ratio is 0.32.
Therefore, VLGC may be considered to be overvalued.

DIV (Dividend): VectorVest reports annual, regular, cash dividends as
indicated by the most recent payments. Special distributions, one-time
payments, stock dividends, etc., are not generally included in DIV. VLGC
does not pay a dividend.

DY (Dividend Yield): DY reflects earnings per share as a percent of
Price. VLGC does not pay a dividend, so it does not have a Dividend
Yield rating. . DY equals 100 x (DIV/Price). It is useful to compare DY
with EY. If DY is not significantly lower than EY, the dividend payment
may be in jeopardy.

DS (Dividend Safety): DS is an indicator of the assurance that regular
cash dividends will be declared and paid at current or at higher rates
for the foreseeable future. VLGC does not pay a dividend, so it does not
have a Dividend Safety rating . Stocks with DS values above 75 typically
have RS values well above 1.00 and EY levels that are much higher than
DY.


DG (Dividend Growth Rate): Dividend Growth is a subtle yet important
indicator of a company`s financial performance. It also provides some
insight into the board`s outlook on the company`s ability to increase
earnings. VLGC does not pay a dividend, so it does not have a Dividend
Growth rating .

YSG (YSG-Vector): YSG is an indicator which combines DIV, DY and DG into
a single value, and allows direct comparison of all dividend-paying
stocks in the database. VLGC does not pay a dividend, so it does not
have a YSG rating . Stocks with the highest YSG values have the best
combinations of Dividend Yield, Safety and Growth. These are the stocks
to buy for above average current income and long-term growth.

Open: VLGC opened trading at a price of $3.35 per share on 12/19/2003.


High: VLGC traded at a High price of $3.40 per share on 12/19/2003.


Low: VLGC traded at a Low price of $3.25 per share on 12/19/2003


Close: VLGC closed trading at price $3.28 per share on 12/19/2003.
(Close is also called Price in the VectorVest system)

Range: Range reflects the difference between the High and Low prices for
the day. VLGC traded with a range of $0.15 per share on 12/19/2003.

$Change: VLGC closed down 0.06 from the prior day`s closing Price.

%PRC: VLGC`s Price changed -1.80% from the prior day`s closing price.


Volume: VLGC traded 421,100 shares on 12/19/2003.

AvgVol: AvgVol is the 50 day moving average of daily volume as computed
by VectorVest. VLGC has an AvgVol of 1,431,200 shares traded per day.


%Vol: %Vol reflects the percent change in today`s trading volume as
compared to the AvgVol. %Vol equals 100 x (Volume/AvgVol). VLGC had a
%Vol of -70.58% on 12/19/2003

Sales: VLGC has annual sales of $31,000,000

Sales Growth: Sales Growth is the Sales Growth Rate in percent over the
last 12 months. VLGC has a Sales Growth of 19.00% per year. This is very
good. Sales Growth is updated each week for every stock. It is often
useful to compare Sales Growth to Earnings Growth to gain an insight
into a company`s operations.

Sales Per Share (SPS): VLGC has annual sales of $0.79 per share. SPS can
be used as a measure of valuation when comparing stocks within an
Industry Group.

Price to Sales Ratio (P/S): VLGC has a P/S of 4.13. This ratio is also
used as a measure of valuation. Here, too, it is useful when comparing
stocks within an Industry Group.

Shares: VLGC has 39,000,000 shares of stock outstanding.

Market Capitalization: VLGC has a Market Capitalization of $128,000,000.
Market Capitalization is calculated by multiplying price times shares
outstanding.

Industry Group: VLGC has been assigned to the Drug (BiomedicalGenetic)
Industry Group. VectorVest classifies stocks into over 200 Industry
Groups and 40 Business Sectors.

Business Sector: VLGC has been assigned to the Drug Business Sector.
VectorVest classifies stocks into over 200 Industry Groups and 40
Business Sectors.

The basic strategy of VectorVest is to buy Low risk, High reward stocks.
We suggest that Prudent investors buy enough High Relative Value, High
Relative Safety stocks to keep the overall RV and RS ratings of their
portfolios above 1.00. As you do this, you`ll find that your risk will
go down and your investment performance will improve.


Graph

Virologic Inc


Drug (BiomedicalGenetic)

[heikekarina]

schön stabil unsere VLGC. Dieser Wert macht wirklich Freude

[Dolocher]

Toll,noch mal 5% vor Weihnachten...so macht das richtig Spass

[robby13]

Hallo liebe Virologic - Gemeinde !

Will mich hiermit in meinen wohlverdienten Weihnachtsurlaub verabschieden. Natürlich möchte ich mich auf diesem Wege für alle Beiträge hier im vlgc - Thread bei Euch bedanken. Sicher treffen wir uns in 04 in aller Frische hier wieder , oder ??! Verkaufskurse haben wir noch lange nicht !

So , ich wünsche Euch allen ein besinnliches und schönes Weihnachtsfest mit Eurer Familie ! ( und zweigt mal zusätzlich 200€ aus den vlgc - Gewinnen für Geschenke ab
)

Viele Grüße vom robby

[heikekarina]

Robby13

wünsche Dir ebenfalls ein schönes Weihnachtsfest und einen guten rutsch in das neue Jahr.
Allen anderen hier im Board natürlich auch.
Auf das uns VLGC uns in 04, genauso viel Freude bereitet, wie in den vergangenen Wochen.

[BaronOppenSAL]

danke ebenso, wünsch ich auch.....

[claudi34]

wünsche euch allen ein frohes fest, stressfreie feiertage und ein prall gefülltes konto im nächsten jahr.
verkaufskurse sehe ich noch nicht, die amis sind noch immer recht bullish.
lg aus münchen

[Bullebio]

@ all

in der nachbörse:

16:08 uhr 80.000st zu 3,48$


bin mehr als zufrieden mit der entwicklung von VLGC. ist ein herrlicher weihnachtstraum.

dabeibleiben ist alles, dass die 10$ im verlauf 2004 zu sehen sind.

ich wünsche allen ein frohes weihnachtsfest. leider habsch dienst, aber was solls!!

[hevchen]

hallo,

möchte noch virologic nachkaufen. ist das bei dem kursanstieg bis jetzt noch sinnvoll?

gruss

hevchen

schöne weihnachten

[Bullebio]

@ hevchen

das ist deine entscheidung. mein kursziel ende 2004 liegt bei 10$. ob sich da noch ein einstieg bei 3,45$ lohnt, obliegt deiner verfassung.

tschau

[Dolocher]

An dieser Stelle möchte auch ich allen hier im Board schöne Feiertage wünschen und bedanke mich auch mal,das es hier bei VLGC ohne gegenseitige Beschimpfungen und Beleigungen abgeht,was ja leider schon Seltenheitswert hat und wünsche allen auch einen erfolgreichen Start ins neue Jahr.

@hevchen

Das hängt vor allem davon ab,wie Dein Anlagehorizont aussieht.Auf Jahressicht sind die aktuellen Kurse zum Einstieg noch ok,ausserdem rechne ich mit guten Quartalszahlen und dem Sprung in die Gewinnzone,so das wir durchaus potenzial nach oben haben.Auch wenns schön wäre,glaube ich im nächsten Jahr noch nicht an die 10,00$ aber auf 6-8$ sollte VLGC m.E. schon laufen,was immer noch 100% vom aktuellen Kurs wären.Eine Garantie gibts dafür allerdings nicht

MfG

[heikekarina]

@Dolocher

auch Dir ein schönes Weihnachtsfest und einen guten rutsch in das Jahr 2004.
Und das unsere VLGC in 04 weiter so schön performt.
Schön den Finger vom VK-Buttom lassen, ja?

[MaxLubin]

ich möchte auch allen hier im Board schöne Feiertage wünschen und nur das beste in 2004 ...

[MaxLubin]

14:27:22 3.590 1000 Nasdaq-NM at Ask
14:26:54 3.590 1300 Cincinnati at Ask
14:26:54 3.578 1100 Cincinnati at Ask
14:26:54 3.590 100 Cincinnati at Ask
14:26:54 3.580 200 Pacific
14:26:54 3.580 300 Cincinnati
14:26:54 3.578 1400 Cincinnati
14:26:53 3.590 100 Pacific
14:26:34 3.550 150000 Nasdaq-NM
14:25:38 3.590 100 Pacific at Ask

...da ist jemandem egal ,dass heute 23.12.ist!

[wissi71]

Auch von mir allen ein frohes Fest sowie alles erdenklich Gute für 2004!
Ich würde mich sehr freuen, wenn es weiterhin in diesem Thread so nett und objektiv zugeht. Auch vielen Dank für Infos!!

[Intrader78]

Schlußkurs heute 3,70$

Nach aktuellem Umrechnungskurs macht das 2,98 EUR

Würde mich gar nicht mehr wundern wenn wir heuer die 4$ nachahltig überschreiten!!

Euch allen, auch von mir schöne Weihnachten.

[Bullebio]

@ all

ich wünsche euch ein Frohes Weihnachtsfest!!!

ich denke, die VLGC Gewinne kommen von alleine.
mit VLGC macht börse wieder spaß!!

bei 10$ lade ich euch alle rechtherzlich ein!!

tschau

[rockmaster]

schöne weihnachten allen !
bin seit ca 1,5 jahren in virologic und verfolge sitdem auch die postings auf w.o.
neben der kursentwicklung ist besonders die faire diskussion und gute information bei diesem wert bzw thread erfreulich - findet man so nicht überall! weiter so !!
gruß rockmaster....

[Dolocher]

3,81 US$ (52 Wochen-hoch)ist ein tolles Weihnachtsgeschenk im Januar sehen wir die 4 vorm Komma


@heikekarina
in Sachen VLGC habe ich meinen VK-Button vorerst demontiert
Bevor ich nicht die 8US$ gesehen habe,werde ich keinen Gedanken an einen Verkauf verschwenden

Wenn wir im Januar gute Zahlen sehen,könnte sich der momentan recht steile Aufwärtstrend sogar noch einmal fortsetzten,bevor wir dann mal eine,wahrscheinlich längst fällige Konsolidierung sehen um dann mit neuem Schwung durchzustarten.

[heikekarina]

Ein frohes und gesundes Jahr 2004, wünscht allen Heikekarina.

Die 3€ sind erobert.

Allen investierten weiterhin viel Erfolg mit diesem Wert. Und bitte nicht gleich die Nerven verlieren, wenn es mal zu einer Konsolodierung kommt. Auch Virologic, wird nicht davon verschont bleiben. Trotzdem, bleibe ich weiterhin dabei.

[wissi71]

Auch von mir alles Gute und maximale Erfolge für 2004!

Hoffe natürlich, dass Viro weiterhin ein Teil unseres Erfolges sein wird.

[heikekarina]

sie bleibt es, auch wenn es hier und da kleinere Rücksetzer geben wird.

[Bullebio]

heute über 4$??????????

realtime 3,98$

sieht fantastisch aus............

[wissi71]

Und die 4 $ haben wir auch schon gesehen...

[heikekarina]

VLGC macht einen wirklich glücklich

@wissi71 hast Du noch deine ITXC? Ich ja. Mal schauen wohin die noch laufen

@Bullebio
was sagst Du zum heutigen Verlauf von BIPH?

mal was in eine ganz andere Richtung. Hat jemand von euch Mount10? da wird auch seit Tagen immer wieder der Kurs gedeckelt. Auf Xetra werden über den Tag verteilt immer wieder kleinere Order eingestellt. Ich denke das hier in Kürze der Start beginnt. Ich selber bin seit Anfang Dez.03 investiert, und habe in der letzten Woche noch einmal aufgestockt. Schaut euch den Wert ruhig mal an. KGV 12. In einer der letzten EamS im Dez.03, wird Mount10 als klassischer Reboundkandidat genannt.

[Bullebio]

@ heike

VLGC wird heute wahrscheinlich nicht über die 4$ marke schließen. aber die sehen wir diese woche noch. haben ja ein paar tage lang konsolidiert.

zu BIPH

erstaunlich der rebound. einige schwache hände sind jetzt aus dem markt, jetzt kann es richtung 0,66$ gehen.
immer schön langsam.


schau dir mal Q-Soft an. KGV von 4 dieses jahr.
hat eine markt cap von 2,6mio euro.

könnte schnell mal übernommen werden bzw. nach oben ausbrechen.

[heikekarina]

@Bullebio

zu VLGC

ob die über 4$, oder leicht unter 4$ schliessen, das sollte uns wirklich nichts ausmachen dürfen. Ich war allerdings angenhem überrscht das die Konsolodierung so moderat ausgefallen ist.

zu BIPH

starker Rebound, sehr stark. Es ist zum verzweifeln wieviel zittrige Hände es doch gibt. Bin weiterhin sehr positiv eingestellt.

zu Q-Soft

stell doch bitte kurz die WKN ein. Danke

[Bullebio]

Q-Soft

WKN 617594

ein heißer nischenplayer im softwarebereich mit einem

KGV 4
KUV 0,1

einfach lächerlich.

[wissi71]

# heikekarina

Hallo Heike, klar hab ich noch meine ITXC. ... und es sieht gut aus mit ihnen. Bin auch mit meiner Orchid bio gut gefahren, obwohl ich schon fast die Nase voll von denen hatte. Und ebenfalls eine Xybernaut stellt heute einen zufriedenen Kursverlauf dar.
Kann gern alles so weiter gehen....

Euch allen gute Kurse!

[Dolocher]

@ wissi71

ich glaube Xybernaut wird uns auch übers Jahr 2004 hinaus noch viel Freude bereiten und der Kursrückgang der letzten Wochen war nicht gerechtfertigt und unbegündet.Wenn sich die News der letzten Wochen nur halbwegs in Umsatz verwandeln,kannst Du Dir die XYBR-Aktien vergolden lassen

Virologic hingegen traue ich in diesem Jahr noch 6-8$ zu evtl sogar die 10$,mehr kann man m.E. im Moment nicht erwarten,es sei denn das Geschäft und die Gewinne entwickeln sich noch besser als bisher schon.(Bin ich jetzt schon ein Basher?)

Da es bei VLGC momentan keine News gibt,gehe ich auch von einem ordentlichen 4. Quartal 2003 aus, wobei die genauen Zahlen wohl erst Ende Januar/Anfang Februar veröffentlicht werden und nicht schon Anfang Januar,aber die 4$ werden im Januar trotzdem fallen.

Ich wünsche Euch allen auf jeden Fall viel Erfolg für 2004!

MfG

[Bullebio]

leider haben wir die 4$ nicht auf anhieb geschafft, aber wie heißt so schön:

ich bin jung, ich kann warten.


in der nachbörse:

16.13uhr 3.93$ 34200st
16.05uhr 3.90$ 10000st

[Dolocher]

Immerhin ein neues 52 Wochen-Hoch

[wissi71]

@ Dolocher

Ich denke und hoffe auch, dass Xybernaut in diesem Jahr noch um einiges zulegen wird. Bin bei dieser Aktie ohnehin auf ein Langzeit-Spiel aus.
Fand den Bericht im TAIPAN sehr überzeugend, was mich zum Einstieg motiviert hat.

Von der Stärke von Virologic bin ich schon regelrecht fasziniert. Aber auch eine ITXC schlägt sich sehr gut.

Grüsse an dich und an alle Investierten!

[Intrader78]

3,52 $

das soll am einer verstehen. Die ganzen Tage eine der stabilsten Aktien am MArkt und nun im Intraday dieser Mist!!

[CutPall]

-9,61%
Solche Veränderungen kannten wir bisher nur mit positiven Vorzeichen. Jetzt kriegen wir wohl die Korrektur, der kurzfristige Aufwärtstrend dürfte jetzt gebrochen sein.
Ts ts, und das alles innerhalb von 2 Handelstunden.

[Dolocher]

Was mir dabei auffällt,ist,das heute mehr Instis bei VLGC am Werke waren als Durchschnittlich im letzten Monat.Muss nichts zu sagen haben,ist aber auffällig.
Ich vermute als die 3,60 nach unten durchbrochen wurde,sind schon die ersten SL`s ausgelöst worden,dann hat man auch ganz schnell mal 10% Verlust innerhalb weniger Stunden.Mal sehen was die nächsten Tage bringen,von VLGC jedenfalls gibt es keine News,weder positiv,noch negativ und das ist eigentlich positiv
Ich bin zwar bis Mi nicht im Lande und auch ohne Internetanschluss,verzichte aber auf einen SL und denke das diese Korrektur am Ende doch besser ist,als die eher verhaltenen Bewegungen in letzter Zeit und nach einem reinigenden Gewitter scheint auch wieder die Sonne

Ich wünsche schon einmal ein schönes Wochenende,Kursziel bleibt weiterhin 6-8$!

MfG

[wissi71]

So ein Mist!! Was ist denn hier nur los?? Hat jemand ne Erklärung für den Absturz??

[turbos1]

Ein Glück , dass ich rechtzeitig bei 2,90 Euro verkauft habe.

[Intrader78]

so eine Schei..! Die brechen ja seit Gestern voll weg. Im Moment siehts nach SL abbraten von nem Zockerteam aus. Ma sehrn obs die Tage mit größen Stückzahlen wieder hoch geht!! Bisher keine News bekannt!!

[heikekarina]

Es gibt 0 News. Lasst euch nicht Nervoes machen.
Da werden wohl geziel SL ausgelöst.

[heikekarina]

hat sich jemand von euch mal die Mühe gemacht, und sich den 3 Monatschart angesehen? Wahrscheinlich nicht. Macht das mal, bitte. Das wurde bewusst gemacht.

[MaxLubin]

12:51:35 3.150 500 Nasdaq-NM at Ask
12:51:35 3.150 1900 Nasdaq-NM at Ask
12:51:35 3.150 4000 Nasdaq-NM at Ask
12:51:33 3.140 1300 Nasdaq-NM
12:51:32 3.140 100 Nasdaq-NM at Ask
12:51:32 3.140 2300 Cincinnati at Ask
12:51:10 3.140 100 Nasdaq-NM at Ask
12:51:00 3.140 600 Nasdaq-NM at Ask
12:51:00 3.140 3500 Nasdaq-NM at Ask
12:50:59 3.140 3000 Cincinnati at Ask

Was für ein Spiel Heute

[wissi71]

@ heikekarina

Es sieht ganz so aus, als ob du recht hast. Der jetzige Kurs liegt erheblich über den Tagestiefstständen.

[heikekarina]

Ich hoffe es

[CutPall]

Als ersten Haltepunkt können wir wohl die 3$ festhalten. Intraday haben wir sie heute geküsst und es ging wieder aufwärts. Mal schauen ob sie den nächsten Test standhält.
Nutzt eigentlich jemand von euch die Chance zum Nachkaufen ?

[heikekarina]

ich konnte heute Nachmittag nicht anders. Ich musste kaufen

[wissi71]

Und ich hätte es tun sollen! Der Gedanke zum Nachkauf war erst mal da. Schaun mer mal, wie es weiter geht...

[MaxLubin]

... Nachgekauft, ob sich des gelohnt hat na mal sehen

[heikekarina]

15% mit Nachkauf ist doch nicht schlecht, oder. Nachkauf eng abgesichert. Die alten bleiben ohne SL im Depot.

[CutPall]

Ich selber bin leider schon voll investiert, natürlich nicht nur in VLGC. Ansonsten hätte ich wohl bei knapp über 3$ meine neuen Kauforders plaziert. Ich denke, wir werden die nächsten Wochen zwischen 3$ und 4$ hin und her pendeln. Vielleicht hab ich ja bis zum möglichen neuen Test der 3$-Marke wieder Spielgeld

[heikekarina]

der Nachkauf von Gestern ist durch mein SL gefallen.
GHabe mir am Montag BIOPHAN TECHNOLOGIES INC (OTCBB)
in mein Depot gelegt. Am ASnfang muss ich sagen, war
mir mehr als mulmig. Dienstag, habe ich noch mal eine Schippe drauf gepackt. Da wurde mir noch mulmiger.
JKetzt gewinne ich immer mehr Freude an diesen Wert.
Die Umsätze sind in USA sehr hoch. Vielleicht hat der eine oder andere Interesse sich diese Aktie näher zu betrachten.

[heikekarina]

BIOPHAN TECHNOLOGIES INC (OTCBB)

ich bin neben VLGC begeistert

[heikekarina]

geht doch

[CutPall]

Dann war ja heute ein Spitzentag für dich:
Biophan 40%
Vlgc immerhin lumpige 6%

Glückwunsch !

[heikekarina]

CutPall

danke

Auch heute ist wieder so ein Tag

Virologic +8,xx%
Biopharm +23,68%
Nanopierce, endlich ausgebrochen bereits über 40%

trotz allem , sollte man nie die Realität verlieren. Es wird Tage der Konsolodierungen geben.

[heikekarina]

VLGC, eine Freude

[heikekarina]

@all

schaut doch bitte bei NPCT WKN 916132 vorbei. Das sieht nach Ausbruch aus.

Und haltet mir VLGC hoch

[Intrader78]

eha, na ma sehn obs diese Woche mit den 4$ klappt, wenn nich dann eben nächste

Tja da wurden die ltzten Tag nur ein par SL´s und Zittrige verabschiedet!! Alles wieder beim alten!! Wenn erst mal News kommen gehts auf zu neuen HÖHEN!!

[heikekarina]

da sind se ja wieder die 3€

[turbos1]

Lohnt es sich noch zu kaufen ?

[heikekarina]

wenn Du long eingestellt bist, dann denke ich, ist es ok.

[Dolocher]

So,bin auch wieder da,und sehe das ihr eine recht turbulente Woche hattet Ich verstehe nur das Geschrei nicht,nachdem wir so lange auf die Konsolidierung gewartet haben,war das doch eigentlich keine Überraschung und auch nicht übertrieben.
Das positive ist,das nun alle Angsthasen und alle die zu eng abgesichert hatten drausen sind und sich nun entscheiden müssen ob sie neu einsteigen oder dem Kurs hinterher sehen.Wie auch immer,ich sehe momentan keinen Grund das Kusziel aufzugeben und glaube das wir vom momentanen Niveau immer noch 100% Potenzial haben


@heikekarina

Herzlichen Glückwunsch zu Deiner Entscheidung für CYGN(habs im Forum gesehen),ich habe mit diesem Wert nach einem anfänglichen Verlust in den letzten 2 Jahren schon sehr viel Geld verdient,da man hier sehr gut traden kann.Vor den Zahlen unbedingt SL setzten,sonst kann es bei dieser Aktie ganz schön in die Hose gehen.

MfG

[heikekarina]

@Dolocher

Danke für die Blumen. Ich versuche vorsichtig zu sein.

[MaxLubin]

so und jetzt wird schon langsam Zeit für ne Nachricht

[heikekarina]

ja wäre nicht schlecht. Aber unser Baby hält sich wacker

[wissi71]

Und wie geht es weiter mit unserem Baby???
Der Wochenschluss sah nicht so toll aus...

[heikekarina]

Ruhe bewahren

[MaxLubin]

#299 eben, die letzte möglichkeit nachzukaufen, wer noch Heute kauft tut nur gut, weil Morgen wird schon zu spät! Tik, tak da kommt ne Meldung raus und booommmm

[Intrader78]

@MAxLubin

tja fragt sich nur BOm in welche Richtung. Die Amis denken da anscheinend anders als zu. Geht weiter nach unten!!!

[Dolocher]

Da es momentan nichts Neues von VLGC gibt wird sich der Kurs auf dem aktuellen Niveau mit leichten Schwankungen einpendeln.Neue Impulse wird es wohl erst nach den Zahlen geben,wobei ich bekanntermassen von recht guten Zahlen ausgehe,evtl. schon dem Sprung in die Gewinnzone,was der Aktie wieder neuen Schwung geben sollte.Die momentanen Verkäufer werden wohl Anleger sein,welchen die aktuelle Konsolidierung etwas zu lange dauert und deshalb die Geduld verlieren oder sie spekulieren auf weitere Rücksetzer um günstiger wieder einzusteigen.
Ich kann momentan aber keine Gründe finden,die für grössere Verluste in absehbarer Zeit sprechen,allerdings geht nach oben bis zu den Zahlen auch nicht viel

[heikekarina]

@Dolocher

ganz deiner Meinung

[heikekarina]

mal schauen wie lang die Konsolodierung anhält.

[MaxLubin]

festhalten, 1,2,3 ..... und los geht´s

[Dolocher]

+7,69%
Sollten wir die 4,00 noch vor den Zahlen wieder sehen!?
Mal sehen ob die Konsolidierung schon beendet ist,war ja reichlich überkauft...

[MaxLubin]

USA 3,84$ und FRA. 2,90€ ,also sofort draufzahlen sonst wird nix!

[MaxLubin]

12:35:44 3.950 140000 Nasdaq-NM
12:30:47 3.890 600 Nasdaq-NM at Ask
12:30:47 3.843 300 Cincinnati
12:30:44 3.870 100 Pacific
12:29:09 3.890 3300 Nasdaq-NM
12:29:08 3.860 1600 Pacific
12:11:07 3.830 300 Nasdaq-NM at Bid
12:11:00 3.850 5000 Nasdaq-NM at Ask
12:10:51 3.830 5000 Nasdaq-NM
12:09:12 3.800 100 Boston at Bid

[MaxLubin]

4,04$

[heikekarina]

was soll ich schreiben?

...ich freu mich

[heikekarina]

4,06

[MaxLubin]

echt?

[heikekarina]

ask 4,11

[wissi71]

Wär gut, wenn meim heutigen Schlusskurs schon ne 4 vor dem Komma steht, denk ich...

[Dolocher]

SK 4,00...Punktlandung

Ich hoffe alle Angsthasen,welche ihre Anteile in den letzten Tagen verkauft haben,werden sich in den nächsten Wochen richtig ärgern

[MaxLubin]

Gerüchte: VLGC 0.22$ gewinn pro Anteil ...

[Intrader78]

...wenn das annähernd stimmen würde.Gibts kein halten mehr!!

[Dolocher]

@maxlubin

Gibts dafür `ne Quelle?
Das wäre etwa das dreifache der bisherigen Schätzungen immerhin hatten wir im letzten Quartal noch Verluste,und nun gleich 0,22$?!
Das wäre wirklich mehr als erfreulich.

[heikekarina]

wo ist die Quelle??????

[MaxLubin]

Ouelle? hier... www.quelle.de
Gut, in einem Ami board wurde 0.20$ gesagt ...

[Intrader78]

töröööööööööööööööö :O

[Dolocher]

Immer aktuelle Börsennachrichten...meine Quelle

Na,mal sehen was tatsächlich rauskommt,in den Ami-Boards ist es ja (noch schlimmer als bei WO) Volkssport durch derlei Gerüchte ein wenig am Kurs zu drehen

Ich hoffe(und glaube) zumindest,das wir in dieser Woche nachhaltig die 4$ knacken,das muss doch nun endlich mal möglich sein.

[Intrader78]

4,19 $

so was schönes !!! Auf geht´s!!! Die 5$ naht!!!

[rockmaster]

4,24 USD !! + 8% , geht wieder steil nach oben mit Virologic !!

[rockmaster]

sieht doch ganz gut aus:

http://www.stockta.com/cgi-bin/opinion.pl?symb=VLGC&num1=5&m…

Composite Indicator
Trend Spotter (TM) Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 878955

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Buy

Medium Term Indicators Average: 100% - Buy
50-Day Average Volume - 1394948

Long Term Indicators
60 Day Commodity Channel Index Buy
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 100% - Buy
100-Day Average Volume - 1227711

Overall Average: 96% - Buy

Price / Support/ Pivot Point/ Resistance

3.93 / 3.74 / 3.96 / 4.18

[Dolocher]

4,24$ SK

Achtung!

ViroLogic Announces Fourth Quarter and Year End 2003 Earnings Conference Call; Tuesday, February 10, 2004 at 5:00 p.m. ET, 2:00 p.m. PT

[wissi71]

# Dolocher

Danke für die Q-Zahlen-Info!!
Wollte schon fragen, wann es soweit ist.
Mit welchem Kursverlauf bis dahin sollte man denn rechnen??

Grüsse an alle Investierten

[ollihat]

Für Anhänger von Point and Figure Charts:

VLGC ist gestern aus dem Triple Top nach oben ausgebrochen.

Quelle: StockCharts.com

Deren nächstes Kursziel ist 5.38 $

[Dolocher]

Wenn ich mir so den gestrigen Tag noch mal ansehe,kann ich mich des Eindrucks nicht erwehren,das wir diesen kleinen Anstieg einem Institutionellen Anleger zu verdanken haben,da hier sehr konsequent alles vom Markt gekauft wurde,was auch nur in die Nähe der 4$ Marke kam.
Da ich persönlich recht optimistisch für die Zahlen bin,sei mir hier die Vermutung gestattet,das auch der gestrige Tag im Zusammenhang mit der Veröffentlichung der Quartalszahlen zu sehen ist,zumal diese intern schon seit geraumer Zeit bekannt sein dürften.Wie gesagt,es ist nur eine Vermutung von mir!

Passend zum Thema stelle ich für alle Interessierten hier mal einen Link zu den aktuellen Top-Holders rein:

http://finance.lycos.com/qc/research/topholders.aspx?symbols…

Auffallend ist jedenfalls das zunehmende Interesse seit September 2003,was sich mit dem Kursverlauf und den gestiegenen Umsätzen deckt.

[MaxLubin]

#328 ... der kurz hält sich bis jetzt sehr gut, aber ich sehe da ein rückschlag bis zu 3.90$ ...

[wissi71]

Wow! Unser Baby marschiert weiter gen Norden...

[heikekarina]

The current wave of accumulation has outlasted all overhead resistance from sellers and driven VLGC to a new fifty-two week high at 4.350. This preponderance of buying makes the stock one to watch for continued upside momentum. Further demand from investors could bring more new highs. The last trade for VLGC was 4.330 on volume of 453,800 shares traded. In the short term, VLGC may consolidate briefly before resuming its current uptrend.

A Moving Average describes a stock`s price trend with respect to a specific time frame. To calculate a 10-day moving average, the closing prices for the most recent ten days are added together and then divided by ten. This renders the Average price of the stock for the most recent ten sessions. By calculating this average daily using only the most recent data, the average "moves" in conjunction with the underlying stock price. The moving average provides a reliable reference for tracking both trends and performance.

VLGC shows a substantial positive divergence from its 200-day moving average line of more than 75%. Generally, the greater the difference between a stock`s price and this important long-term technical indicator, the steeper will be that stock`s long-term uptrend. A divergence this large from the 200-day line ranks in the top five percent of the market and is a bullish indication of long-term strength for VLGC.

A positive divergence of more than 25% from the 50-Day Moving Average Line confirms that VLGC has recently been under accumulation. Monitor the stock`s performance relative to this significant intermediate term indicator. Some investors would consider VLGC somewhat over-extended in its current price range because the stock is trading so far above its 50-day line. If VLGC soon falls to profit taking or broader market momentum, as it converges with the 50-day line look for support in that range or a turn upward as indication of strength in its overall trend.

VLGC has exhibited short-term momentum as implied by its positive divergence from the 10-Day Moving Average Line. Be advised that a pullback or consolidation on profit taking could soon be in order following any additional gains the stock might post in the near-term. If VLGC is also above its 50 or 200-day moving average line, this is technical indication of a long-term uptrend for the stock.

Monitoring a stock`s price in relation to its moving average lines is an effective means of understanding the dynamics of its price trend. When considered with other technical indicators, moving average lines offer powerful insight into price movements. If VLGC is below its 50 or 200-day moving average line, the stock has recently been down trending and the break above the 10-day line could be first indication of a possible recovery.


Comparing cash flow ratios, measures of debt coverage and company growth reveals that VLGC could be in a questionable financial position relative to some benchmarks of liquidity and equity. This company scores in the bottom half of the market for Fundamental Rank, a composite of popular balance sheet measures. Both fundamental and value-based investors alike might avoid this one. However, the company could be a potential leader of its industry. Aggressive growth for a company often involves incurring sizeable financial risk. Confer earnings estimates reports and projected growth rates to see what industry professionals expect in the years to come for VLGC.

A "Price Gap" represents a range of prices on a stock chart in which no trading takes place. This occurs when a stock opens for trading at a lower price than the previous day`s close and then does not trade above that mark again. Negative opening gaps are bearish indication of weakness in investor demand. If this move lower is accompanied by surging volume, or is through a point of previous support, it could be early indication of a new downtrend.

VLGC shows a negative opening gap of greater than 5% with its most recent open. Examine news or events to uncover what may have prompted this heightened selling pressure. If no news corresponds with this decline, keep a watchful eye as more weakness could follow.

[heikekarina]

VLGC: New 52-Wk High @ $4.270 up 0.71% [delayed]

Ridgeland, MS, JAN 27, 2004 (EventX/Knobias.com via COMTEX) -- This is the 2nd 52 WEEK HIGH alert for VLGC in the past 7 calendar days.

The share price for ViroLogic Incorporated (NASDAQ NM: VLGC) reached a new 52-week high today, trading at $4.270, up $0.030 (0.71%) from its previous close of $4.240.

The Company`s previous 52-week high of $4.250 was set yesterday on January 26, 2004.

One year ago, the Company`s shares closed at $0.870. The price has climbed more than 390 percent since then.

At the time of this alert, the stock had traded 348,800 shares via 593 trades, 60.04% below it`s 20day average of 872,885 shares.

This new 52-week high currently puts the stock:

14.82% above its 20day Moving Average of $3.719

38.88% above its 50day Moving Average of $3.075

85.67% above its 100day Moving Average of $2.300

The Company last released news on January 26, 2004 (yesterday):

"ViroLogic Announces Fourth Quarter and Year End 2003 Earnings Conference Call; Tuesday, February 10, 2004 at 5:00 p.m. ET, 2:00 p.m. PT"

VIROLOGIC INCORPORATED

A biotechnology company developing, marketing and selling innovative products to guide and improve treatment of viral diseases. It developed a practical way of directly measuring the impact of genetic mutations on drug resistance.

GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by at least 10 minutes. To get all Knobias alerts in real-time daily, visit www.knobias.com/cmtx

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.


CONTACT: Knobias.com, LLC
601-978-3399
601-978-3675
[e-mail]
www.knobias.com/cmtx

[Dolocher]

Tja,nicht mal unsere VLGC ist getern von der negativen Stimmung nach der Bekanntgabe der FED-Entscheidung verschont geblieben.Aber andere Werte hat es noch viel schlimmer erwischt(z.B. CYGN) aber es geht ja schon wieder Richtung Norden und wenn die 4$ im Tagesverlauf halten,sehe ich die Tage bis zu den Zahlen recht positiv.

[Dolocher]

Grants/contracts
Grants/contracts

ViroLogic is awarded three SBIR grants for HIV tools

A Medical Device Daily Staff Report

ViroLogic (South San Francisco, California) has been awarded three Small Business Innovation Research (SBIR) grants from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (Bethesda, Maryland), for more than $3 million over three years.

The grants will support the development of analytical and database tools to facilitate the identification and characterization of drug-resistant strains of HIV and assays that will aid in the preclinical and clinical evaluation of the next generation of anti-viral therapeutics.

“These grants validate our leadership in HIV drug resistance and provide a non-dilutive means to fund the company’s research and development efforts,” said Bill Young, ViroLogic’s chairman and chief executive officer. “We will use the funds to create new technology designed to aid in the development of novel antiretroviral drugs that target specific steps in the life cycle of HIV and other viruses.”

The largest of the awards, a three-year Phase II grant in excess of $2 million, will support further development of two HIV entry assay technologies.

ViroLogic said it is advancing individualized medicine by developing and marketing products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis

[wissi71]

Schade! Leider haben die $ $ nicht gehalten...
Was sagen unsere Charttechniker dazu??

[wissi71]

Meinte natürlich die 4 $.

[MaxLubin]

KZ 3.65$

[Dolocher]

Die nächste "nennenswerte" Unterstützung sehe ich bei c.a. 3,50$,allerdings gehe ich,wie schon weiter oben erwähnt eher von einer positiven Entwicklung aus,und zwar aus folgenden Gründen:

1. Fundamental ist bei VLGC alles in Ordnung und dieser Verlust der letzten Tage hatte nach meiner Ansicht nichts mit VLGC selbst zu tun,sondern war eher eine Folge der Allgemeinen Panik und Angst vor einer baldigen Zinserhöhung,nachdem Greenspan in seiner Rede den Hinweis auf einen "Beträchtlichen Zeitraum" der Zinsstabilität strich,was im Klartext nichts anderes als eine Zinserhöhung,m.E. noch im ersten Halbjahr 2004 bedeutet,weil ja die Wahlen anstehen.

2. ist der Aufwärtstrend nicht gebrochen worden,auch wenn es ganz knapp war

3. stehen bei Virologic am 10.02. die Zahlen ins Haus,welche schon heiss diskutiert werden und natürlich jede Menge Spekulanten anziehen,vor allem in USA.
Die Mehrheit geht von guten bis sehr guten Zahlen aus, so das hie noch einige Versuchen werden,das aktuelle Niveau nochmal zum Einstieg oder Nachkauf zu nutzen,denn falls der Gewinn höher als 0,02-0,03 $ ausfallen sollte,geht es weiter nach Norden

4. werte ich das steigende Interesse durch Instis auf jeden Fall als ein positives Signal,obwohl auch diese sich täuschen können

5.denke ich,das man sich von solchen Kursreaktionen nicht verrückt machen lassen sollte,denn wer in VLGC investiert,sollte dies schon langfristig tun und da gehören Rückschläge nun mal dazu,Microsoft erging es nicht besser
Dafür hat man bei VLGC das gute Gefühl,bereits jetzt bei einem zukünftigen Marktführer in diesem Segment investiert zu sein.

Fazit: kurzfristig sind m.E. noch Schwankungen von bis zu 15% drin,langfristig jedoch wird die Aktie weiterhin gutes Geld verdienen,mein Kursziel bis Jahresende daher weiterhin 6$-7$

Genau wie Wissi bin ich natürlich an weiteren Meinungen interessiert und lasse mich gegebenenfalls auch eines Besseren belehren

MfG

[heikekarina]

ich sehe keinen Grund mir Sorgenfalten stehen zu lassen. Das wir uns Seitwärts bewegen, dürfte mittlerweile jedem aufgefallen sein. Ein anderer Faktor ist totz bullisher Börse, das diese volatil bleibt.
Ansonsten schliesse ich mich Dolocher gerne an

[wissi71]

# Dolocher

Danke, dass du an mich denkst!

Ich finde deine Zusammenfassung ganz gut und denke - und hoffe natürlich auch - dass du recht behältst.
Ich meine, der Kursverlauf vom Freitag gibt dir bereits Recht. Viro hat wieder Richtung Norden eingeschlagen, auch wenn wir weit von den Tageshöchstständen entfernt geschlossen haben. Ich halte den Kursverlauf trotzdem -insgesamt gesehen - bisher für sehr beeindruckend mit seiner relativen Stärke. ( Bin ja erst seit November 03 dank!! heikekarina investiert. )

Schöne Sonntag an alle Investierten!

[heikekarina]

wiss71

freut mich das Du dabei bleibst

[wissi71]

Na klar doch; kann euch doch nicht allein lassen
Allerdings find ich den heutigen Kursverlauf nicht so toll...

[heikekarina]

VLGC

ist stabil und bleibt stabil

eine wahre Freude

[hevchen]

hallo,

wie sind die erwartungen für die zahlen am 10 feb.?

gruss

hevchen

[Intrader78]

ViroLogic, Inc. Earnings Conference Call (Q4 2003)
Scheduled to start Tue, Feb 10, 2004, 5:00 pm Eastern

Ja da bin ich mal gespannt was da noch geht!!!

[MaxLubin]

so und Heute ist es so Weit ...na mal sehen ...
2/10/2004 02:05 am First-Alert: 5 p.m. Investrend / Bestcalls

[Dolocher]

So,bin pünktlich zu den Zahlen wieder im Lande und hoffe,das diese gut ausfallen,wenn man den Gerüchten glaubt,sollten das der Fall sein.Aber es sind leider nur Gerüchte und 17.00 wissen wir alle mehr.
Das ist wie das warten auf den Weihnachtsmann
MfG

[rockmaster]

Hallo.

weiß schon jemand was über die Zahlen...?

[GoldVogel]

die Zahlen kommen um 23:00 MEZ ( =5:00 pm eastern time) ...

[Bullebio]

SOUTH SAN FRANCISCO, Calif., Feb. 10 /PRNewswire-FirstCall/ -- ViroLogic, Inc. today announced financial results for the fourth quarter and year ended December 31, 2003. Revenue for the fourth quarter of 2003 was $9.3 million, an increase of 34 percent over revenue for the same period of 2002. Revenue for the full year ended December 31, 2003 was $33.4 million compared to $25.3 million for 2002, an increase of 32 percent. Year-over-year revenue from patient testing products increased by 28 percent and pharmaceutical drug development revenue grew by 36 percent compared to 2002.

"We achieved the revenue goals we set for 2003 and significantly improved our operating efficiency and gross margin, which has positioned the Company to generate cash from operations in 2004," said Bill Young, CEO and Chairman of ViroLogic. "ViroLogic remains the partner of choice for resistance testing and continues to lead the way in the field of personalized medicine focused on infectious diseases, such as HIV."

Gross margin for the fourth quarter ended December 31, 2003 was 52 percent compared to 43 percent for the same period of 2002. Gross margin improvement in the fourth quarter was the result of improved efficiencies in laboratory operations as well as an increased contribution from pharmaceutical drug development revenue. Operating expenses for the fourth quarter of 2003 were $9.7 million, compared to $11.5 million for the fourth quarter of 2002.

In the fourth quarter of 2003, the Company completed an automation project that is expected to increase laboratory capacity by approximately 30 percent without additional labor or other costs. The combination of implementing this new automation with an increase in volume delayed the processing of customer samples, resulting in a temporary backlog of approximately $0.5 million at December 31, 2003. These samples were completed and corresponding revenue recorded in the first quarter of 2004.

Net loss for the fourth quarter of 2003 was $0.4 million, or $0.01 per share compared to a net loss of $4.6 million, or $0.17 per share, for the same period in 2002.

In the fourth quarter of 2003, the Company recorded a preferred stock dividend of $0.2 million, resulting in a net loss applicable to common stockholders of $0.01 per share. During the fourth quarter of 2002, the Company recorded a non-cash deemed dividend to preferred stockholders of $7.7 million related to the issuance of Series C Convertible Preferred Stock, and recorded a preferred stock dividend of $0.3 million, resulting in a net loss applicable to common stockholders of $0.48 per share.

In the fourth quarter of 2003, the Company exercised its option to convert the outstanding Series C Convertible Preferred Stock to common stock, which was possible because the Company``s common stock price exceeded $2.42 for 20 consecutive trading days. There were 52.6 million shares of outstanding common stock at December 31, 2003.

The Company had $10.2 million of cash, restricted cash and short-term investments as of December 31, 2003.

Full-Year 2003 Financial Results

Gross margin for the year ended December 31, 2003 was 48 percent, compared to 41 percent for 2002. Operating costs and expenses for 2003 were $39.0 million, compared to $47.3 million for 2002, a decrease of 17 percent. This decrease primarily reflects reductions in compensation and other expenses resulting from the Company``s business restructuring and workforce reduction in November 2002. Net loss for the year was $5.5 million, or $0.16 per share, compared to a net loss of $21.8 million, or $0.90 per share for 2002.

During 2003, the Company recorded a non-cash deemed dividend to preferred stockholders of $2.2 million resulting from a warrant exchange approved by the Company``s stockholders on February 4, 2003 relating to the sale of Series C Convertible Preferred Stock, and recorded a preferred stock dividend of $1.6 million, resulting in a net loss applicable to common stockholders of $0.27 per common share. In 2002, the Company recorded a non-cash deemed dividend to preferred stockholders of $10.6 million from the issuance of the Series B and Series C Convertible Preferred Stock, and recorded a preferred stock dividend of $1.0 million, resulting in a net loss applicable to common stockholders of $1.38 per common share.

Recent Highlights -- The New Jersey Medicaid Program initiated a benefit coverage policy for phenotypic and genotypic HIV drug resistance testing bringing the total number of Medicaid programs now providing reimbursement for the Company``s HIV drug resistance assays to 48 States as well as the District of Columbia; -- ViroLogic scientists and collaborators presented data on development of the Company``s novel Hepatitis C virus (HCV) drug susceptibility assay at the 5th biennial HepDART meeting "Frontiers in Drug Development for Viral Hepatitis" held in Hawaii, in December; and -- Fifteen presentations related to ViroLogic``s drug resistance tests, including those characterizing replication capacity and phenotypic and genotypic resistance to anti-HIV drugs will be made at the 11th Conference on Retroviruses and Opportunistic Infections taking place February 8-11, 2004, at the Moscone West conference center in San Francisco. 2004 Business Outlook

ViroLogic estimates 2004 revenues of between $42 and $47 million based on the anticipated continued acceptance of the Company``s products for patient testing and projected increasing demand from drug development partners. The Company expects the composition of product revenue to be approximately two-thirds from patient testing and one-third from pharmaceutical drug development. The Company anticipates quarterly differences in the revenue growth rate relating to the timing of various clinical studies and seasonal effects observed in patient testing, which in keeping with the historical trend we expect to be most noticeable in the first quarter.

The Company anticipates gross margin to improve to approximately 58 percent by the fourth quarter of 2004. ViroLogic expects to generate cash from operations based on achieving a quarterly revenue run rate of $10 to $11 million in combination with continued cost management measures.

"We will continue to drive our patient testing business through new product and customer service enhancements, increasing our sales force and improving distribution and access to ViroLogic``s broad portfolio of resistance assays," added Mr. Young. "We are also enthusiastic about our opportunities on the drug development side of the business, with numerous clinical trials of novel HIV medicines expected in the coming year. To keep pace with anticipated higher testing volume brought on by increasing demand and use of our products and services, we plan to continue to implement new automation in our laboratory designed to further improve gross margin and throughput in the future."

Conference Call Details

ViroLogic will hold a conference call today, at 5:00 p.m. EST. To participate in the teleconference please call 800-901-5213 fifteen minutes before the conference begins and ask to be connected to the ViroLogic teleconference. International callers please dial 617-786-2962. The call will also be webcast live at http://www.virologic.com/. Please see web site for details.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company``s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company``s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at http://www.virologic.com/.

Certain statements in this press release are forward-looking, including statements relating to cash flow from operating activities in 2004, increased laboratory capacity without additional labor or other costs, overall revenue growth, growth in and expected mix of sales of patient testing and pharmaceutical drug development products, ongoing benefits from cost reduction measures, improvements in gross margin, and other expectations regarding 2004 operating results. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company``s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that gross margins may not increase as expected, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic``s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company``s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic``s actual events to differ from those projected, please refer to the Company``s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

SELECTED FINANCIAL DATA (In thousands, except per share amounts) Three months ended Twelve months ended December 31, December 31, 2003 2002 2003 2002 (Unaudited) (Unaudited) Statement of Operations Data: Product revenue $8,815 $6,935 $31,911 $24,530 Contract revenue (a) 518 34 1,468 731 Total revenue $9,333 $6,969 $33,379 $25,261 Operating costs and expenses: Cost of product revenue 4,223 3,940 16,713 14,589 Research and development 1,208 2,120 4,733 10,406 General and administrative 2,302 2,889 9,256 10,550 Sales and marketing 2,005 2,535 8,306 11,716 Total operating costs and expenses 9,738 11,484 39,008 47,261 Operating loss (405) (4,515) (5,629) (22,000) Interest income 21 55 106 307 Interest expense (21) (177) (141) (423) Other income -- 52 156 347 Net loss (405) (4,585) (5,508) (21,769) Deemed dividend to preferred stockholders -- (7,691) (2,155) (10,551) Preferred stock dividend (224) (262) (1,610) (977) Net loss applicable to common stockholders $(629) $(12,538) $(9,273) $(33,297) Basic and diluted amounts per common share: Net loss $(0.01) $(0.17) $(0.16) $(0.90) Dividends to preferred stockholders -- (0.31) (0.11) (0.48) Net loss applicable to common stockholders $(0.01) $(0.48) $(0.27) $(1.38) Weighted average shares used in computing basic and diluted net loss per common share 45,235 26,259 34,445 24,157 December 31, December 31, 2003 2002 (b) (Unaudited) Balance Sheet Data Cash, cash equivalents and short-term investments $9,430 $11,145 Accounts receivable, net 6,165 4,924 Working capital 13,038 (239) Restricted cash 776 707 Total assets 28,378 30,486 Long term obligations, less current portion 87 419 Redeemable convertible preferred stock 1,994(c) 4,249 Total stockholders`` equity $20,587(d) $7,014 (a) Contract revenue consists of NIH grants, commercial development and other revenue. The costs associated with contract revenue are included in research and development expenses. (b) The balance sheet data is derived from audited financial statements for the year ended December 31, 2002, included in the Company``s Annual Report on Form 10-K filed with the Securities and Exchange Commission. (c) There are 274 shares of Series A Redeemable Convertible Preferred Stock issued and outstanding at December 31, 2003, which are convertible into approximately 2.5 million shares of common stock. (d) There are 52.6 million shares of common stock issued and outstanding at December 31, 2003. During 2003, all outstanding shares of Series C Convertible Preferred Stock were converted into common stock.

ViroLogic, Inc.

© PR Newswire

[Dolocher]

Tja, ales in allem zwar solide Zahlen,aber etwas mehr hatte ich mir schon erhofft,und statt eines Nettoverlusts von 0,01/Share ein Plus von 0,02-0,03 erwartet.Trotzdem ist das Jahr 2003 gut gelaufen,was sich ja auch in den Zuwächsen beim Umsatz zeigt,und ich für dieses Jahr weiterhin optimistisch bin,auch wenn vielleicht in den nächsten Tagen einige nach den diversen Gerüchten enttäuschte Zocker hinschmeissen,wird sich am Kursziel m.E. nichts ändern.

[Dolocher]

Tja, ales in allem zwar solide Zahlen,aber etwas mehr hatte ich mir schon erhofft,und statt eines Nettoverlusts von 0,01/Share ein Plus von 0,02-0,03 erwartet.Trotzdem ist das Jahr 2003 gut gelaufen,was sich ja auch in den Zuwächsen beim Umsatz zeigt,und ich für dieses Jahr weiterhin optimistisch bin,auch wenn vielleicht in den nächsten Tagen einige nach den diversen Gerüchten Enttäuschte ihre Anteile hinschmeissen,ändert sich an meinem Kursziel von 6-8$ nichts,ausserdem glaube ich das bei Virologic im Moment eher langfristig orientierte Anleger investiert sind,so das die Reaktion auch eher gemässigt ausfallen dürfte.Ich bleibe long!

[Dolocher]

Doppelt hält besser

[rockmaster]

@354: .. völlig richtig- bin auch long und bislang gut damit gefahren ...... wird bestimmt weiter aufwärts gehen.

[CutPall]

Ich denke, VLGC hat nun eine ordentliche Bewertung erreicht: 33,4 Mio$ Umsatz bei über 200 Mio$ MK( es sind 52,6 mio Aktien in Umlauf), das läst nun nicht mehr viel Spielraum für Kurssteigerungen übrig. Trotzdem ich sehe das auch wie ihr, das erwartete Umsatzwachstum für 2004 von ca 40% und eine sich kontinuierlich weiterentwickelnde Produktpipeline macht VLGC langfristig interessant. Werde wohl auch noch dabei bleiben, zumindest bis zur Steuerfreiheit . Kurse über 6$ glaube ich allerdings, dass wir frühestens 2005 erreichen, aber ich lasse mich gerne überraschen.

[Dolocher]

Ich glaube das Schlimmste liegt nun hinter uns,nachdem heute Nachmittag wahrscheinlich jede Menge SL`s ausgelöst wurden,zeigt die Erholung gegen Abend,das noch Kaufinteresse an diesem Wert besteht.Ein ähnliches Szenario hatten wir ja im Januar schon,wo wir z.T. bis auf 3$ gefallen waren und ich glaube,genau wie im Jan. werden wir uns auch diesmal wieder an die 4$ Marke zurückkämpfen.Wichtig wäre,das wir heute über 3,70$ schliessen und im Moment siehts gut aus,da wir uns dieser Marke langsam wieder nähern.

[turbos1]

habe meine Aktien von vlgc verkauft. Ich steige bei 2 $
wieder ein.

[MaxLubin]

ok ich bleibe Long ...

[Dolocher]

ViroLogic Studies Supporting Use of Its Novel Technologies for Development Of New Drugs and Vaccines Presented at Major HIV Medical Conference This Week

SOUTH SAN FRANCISCO, Calif., Feb. 13 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that data presented at a major medical conference indicated that the Company`s broad portfolio of proprietary HIV drug resistance assays, in addition to helping improve treatment of HIV, can also be used in the discovery of novel drug targets and the development of new drugs and vaccines. ViroLogic scientists together with collaborators from academia and industry presented 19 studies at this meeting, which took place this week in San Francisco.

"The data presented at this meeting underscores the importance of ViroLogic`s technologies, both to manage HIV infection today and to the continued effort to identify and develop new drugs and new drug targets for the future," said Christos Petropoulos, ViroLogic`s Vice President of Research & Development. "The increased demand for our novel assays by pharmaceutical and research collaborators further demonstrates our leadership position and commitment to HIV research and drug and vaccine development."

Among the highlights was a study that demonstrated the value of ViroLogic`s Replication Capacity(TM) (RC) assay as a tool to predict HIV disease progression in untreated patients. The study, co-authored by the Gladstone Institute of Virology and Immunology and ViroLogic, identified an RC threshold below which HIV-1 has reduced virulence and is less able to deplete the immune system. In the study, the authors found that patients whose viruses had RC values below 43%, as determined by ViroLogic`s RC assay, had CD4+ T-cell counts that were significantly preserved. ViroLogic believes these findings illustrate the important role that the RC assay can play in predicting disease progression and effectively managing HIV infection. ViroLogic currently has the only commercially available test to measure HIV replication capacity, a measure of viral fitness.

In addition:


Three studies used ViroLogic`s recently developed neutralization assay to assess anti-HIV antibody activity in response to infection or immunization. One of those, presented by Dr. Steven Deeks of the University of California, San Francisco, demonstrated that in chronically infected subjects, antibody responses were not directed against the strain of HIV-1 circulating in the patient. Studies such as these exemplify how ViroLogic`s neutralization assay can be used to characterize targeted antibody responses which are relevant for vaccine development;
Five presentations included data generated using ViroLogic`s proprietary entry assay, which measures virus entry into new cells and identifies the preferred cell receptors of HIV for cell entry (i.e., tropism). These studies showed ViroLogic`s expanding capability to support the numerous biopharmaceutical companies now developing entry inhibitor drugs to treat HIV; and
Three presentations highlighted ViroLogic`s comprehensive HIV phenotype-genotype database in the development of more accurate genotypic algorithms for evaluating drug resistance.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.ViroLogic.com.

Certain statements in this press release are forward-looking, including the various statements relating to the data presented at the major medical conference described in this press release. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the Company`s products may not continue to perform in the same manner as indicated in the studies discussed in this press release, whether ViroLogic successfully introduces new products, whether others introduce competitive products, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that gross margins may not increase as expected, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

SOURCE ViroLogic, Inc.

[heikekarina]

ich bleibe long. Nach soviel Monaten des Wartens in 03, sollte ein Abschlag der zwangsläufig kommen musste, keinen mehr aufregen, zumal frühzeitig investierte immer noch mit mehr als 100% imm Plus dastehen.
Ernsthafte Gedanken werde ich mir dann machen, wenn der Kurs unter 3$ rutscht. Hier habe ich für meine komplette Position ein SL gesetzt. Ich gehe allerdings davon aus, das es soweit nicht kommen sollte. Man muss auch positiv denken können.

[wissi71]

# heikekarina

Bin deiner Meinung. Denke auch, dass die 3 $ - Marke ne wichtige Orientierung ist.
Da ich nächste Woche für 14 Tage mal ab in den Süden möchte, habe ich mir auch schon Gedanken über meine Viro-Position gemacht. Bin zu dem Schluss gekommen, alles zu lassen wie es ist.

Schönen Sonntag und LG an alle Investierten!

[Dolocher]

Wir haben in den letzten Tagen eine auffallende Zunahme von Insider Trading.Für alle Interessierten ist hier mal ein Link zu den entsprechenden Mitteilungen:

http://10kwizard.ccbn.com/fil_list.asp?TK=VLGC&CK=1094961&FG…

Das wir die 3$ noch einmal wiedersehen,glaube ich zwar nicht aber auch ich bin in diesem Bereich vorsichtshalber abgesichert.Ich sehe allerdings keine Gründe,warum der Kurs so weit nachgeben sollte,aber die Börse macht ja bekanntlich was sie will und hat oft wenig mit Logik zu tun.

[turbos1]

Es scheint so, dass wir nochmals die 2$ sehen. Zum Glück hatte ich mit 140 % Gewinn rechtzeitig verkaufen können.
Bei 2 $ steige ich wieder ein.

[Dolocher]

Sieht tatsächlich so aus,als würden wir doch wieder in Richtung 3$ marschieren,hätte ich wirklich nicht gedacht.Ich werde trotzdem halten und bei 3$ steht eh ein SL und ich hoffe der fällt nicht,allerdings bin ich mir da im Moment leider nicht so sicher Mir bliebe der Trost von 300% Gewinn und die Chance auf den Neueinstieg,denn ich glaube das wir bis Jahresende bei mind. 6$ stehen

[CutPall]

Vor der 2 kommt die 3
und hier hatten wir schon Anfang Januar einen starken Rebound auf Intraday-Basis, mal gucken ob die hält

[heikekarina]

langsam rückt die 3 näher. Ich habe jetzt zur vorsicht ein sl plaziert. möchte nicht unbedingt kalt erwischt werden.

wissi71

schönen urlaub

[MaxLubin]

Hi, habe gestern zu 2.70€ verkauft ... SL ist genau das auf was die Warten ...dann gehts richtig ab
KZ: 2.90$ die wollen jetzt einfach unter 3$ ...

[turbos1]

Der Abwärtstrend ist nicht aufzuhalten. VLGC ist extrem zu teuer. Ich glaube Ende März liegen wir bei 2 $.

[turbos1]

Heute werden wir bestimmt eine technische Erholung sehen.
Langfristig gesehen, habe ich Vertrauen zu VLGC.

[Intrader78]

Einst eine der stabilsten Papier am Markt und nun diese SCH....

[rockmaster]

genau so isses
was sind die gründe ??

meinungen dazu ????

[Dolocher]

Die Umsätze sind nicht besonders hoch,aber wenn die 3§ heute nicht halten,gehts ganz schnell in den Bereich um 2,50-2,60, wo wieder etwas mehr Unterstützung zu erwarten ist.Bin jetzt bei 3,05 ausgestoppt worden und warte jetzt die Enwicklung ab.Werde ganz sicher wieder einsteigen,da Virologic ein absolut aussichtsreicher Wert ist.
Da es momentan keine Meldungen gibt,kann ich mir den Rückgang nur durch enttäuschte Zocker,welche aufgrund der vielen Gerüchte vor den Zahlen aufgesprungen sind und nun schnell wieder raus wollen oder Shortys,welche nun den Kurs natürlich so weit wie möglich drücken wollen,erklären.Dazu kommt,das in den letzten Monaten auch grössere Investoren institutioneller Art auf VLGC aufmerksam geworden sind und ich könnte mir vorstellen,dass diese diesen kurzen Abwärtstrend recht erfreut beobachten und evtl. noch unterstützen um günstig reinzukommen.Das Interesse ist auf jeden Fall sehr hoch.
Ich denke nächste Woche werden wir sehen, wie der Hase läuft.
MfG

[Bullebio]

RT 3,10$

sieht sehr gut aus. es scheint so, dass die 3$ marke hält. viele sind ausgestiegen, wenn diese immer noch von vlgc überzeugt sind, steigen sie lieber in steigende kurse wieder ein.

der test der 3$ scheint beendet zu sein, zum 2. mal erfolgreich.

kaufpanik wird kommen!!

nächste woche sind locker 3,5$ drinne.

allen investierten ein schönes WE.

tschau

[turbos1]

habe gestern wieder VLGC gekauft. Das Schlimmste haben wir wahrscheinlich überstanden.

[heikekarina]

scheint fast so.

[MaxLubin]

turbos1: Ich meine eben anderes ,zwar da sollte es nochmal nach runter gehen und bei 2.80$ sich aufhalten

[Intrader78]

Is schon komisch was seit einiger Zeit in Amiland abgeht mit dem Kurs. Heute werden wohl wieder die 3 EUR getestet. Ich hoffe mal das die halten sonst

Fundementale News sind auf jeden Fall nicht der Grund für die Momentane schlechte Stimmung.
Denke eher das z.Z ganz einfach die Fanatsie fehlt. Was News angeht sieht es ja seit Monaten eher flau aus.

Da bleibt mir nur zu hoffen.

[Dolocher]

Wenn ich mir den Chart und die Indikatoren so betrachte,könnten wir im laufe der nächsten Woche schon die Wende Richtung Norden schaffen,spätestens Mitte März sollte es wieder sichtbar aufwärts gehen,es fehlt im Moment nur noch ein bischen der Umsatz und 3$ stellt momentan eine recht gute Unterstützung dar.

[Dolocher]

So,hab mir grad noch ein Päckchen ins Depot gelegt zu max. 3$.

[JRB]

Wie lange sollen denn noch die 3 Dollar getestet werden?
Es ist doch Beton angerührt worden!
Auf zu alten Höhen!

Schönes WE
JRB

[wissi71]

@ Dolocher

War wohl eine weise Entscheidung zuzukaufe. Gratulation!
Ein erbitterter Kampf um die 3 $ - Marke, aber es hat sich gelohnt...

[Dolocher]

@wissi71

ich hoffe wir haben nun die Kurve gekriegt.Bei 3$ nochmal nachzukaufen war kein Risiko und die Indikatoren(vor allem RSI und MACD) gaben und geben so langsam wieder positive Signale,nächste Woche werden wir sehen,ob wir uns wieder in Richtung 4$ bewegen,oder noch ein bisschen herumdümpeln.Wahrscheinlich werden die 3,20 nicht auf SK-Basis halten ,da der Umsatz nicht ausreichend hoch war,um hier das Ruder nachhaltig herumzureissen.
Abwarten und Tee trinken...

[JRB]

Rote Nasdaq - Grüne Virologic

Bin gespannt, wie es heute Nachmittag weitergeht.
Die Stückzahlen waren ja nicht der Hit.
Jetzt nur nicht schlapp machen!

[GoldVogel]

12.03.2004
ViroLogic "buy"
Merriman Curhan Ford & Co

Rating-Update:

Die Analysten vom Investmenthaus Merriman Curhan Ford & Co stufen die Aktie von ViroLogic (ISIN US92823R2013/ WKN 936848) unverändert mit "buy" ein. Das Kursziel werde bei 5 USD gesehen.

[MaxLubin]

Man Man hab ich ja ein gutes gefüll ...diese Woche wird was

[JRB]

Auch wenn ich mit dem heutigen Tag nicht zufrieden bin,
weiß ich es doch zu schätzen, dass trotz vieler roter
Ami-Tage das Fundament gehalten hat.
Doch nun sollte endlich was draufgebaut werden!

[wissi71]

Finde auch, dass es langsam wieder Zeit wird, gen Norden zu laufen...

[wissi71]

Sch..., was ist denn jetzt los?? Hat jemand ne Erklärung??

[heikekarina]

es wird schon wieder. Gestern war nicht gerade der grosse Biotag. Und bitte nicht die EWreignisse der vergangenen Tage vergessen

[turbos1]

Lohnt es sich jetzt nachzukaufen ?,
oder sollte man lieber etwas warten in der Hoffnung, es geht noch etwas in Richtung Süden.Fundamental bin ich überzeugt, dass wir spätestens Ende 2004 wieder die 4$ sehen werden.
Man muss Geduld aufbringen.

[Dolocher]

Kommt drauf an,wie lange Du halten willst.Mittel-bis Langfristig kannst beim aktuellen Niveau nix falsch machen(vorausgesetzt Madrid wiederholt sich nicht).Im Moment hängen wir ein bischen zwischen Baum und Borke,d.h. ich sehe durchaus die Möglichkeit,das Du noch für 2,50-2,60 US$ zum Zuge kommst,deshalb würde ich im Moment nicht voll in VLGC einsteigen.Ich persönlich bin bei 3,15 und 2,98 US$ wieder eingestiegen und werde vorerst meine Anteile halten,falls wir noch die 2,50 sehen werde ich noch ne kleine Position eingehen,aber dann ist erst mal Schluss.Ich sehe übrigens fürs Jahresende durchaus immer noch die Möglichkeit auf 6US$,denn die Zahlen waren ja nicht so schlecht,nur eben schlechter als erwartet.VLGC wird ganz sicher in diesem Jahr die Gewinnzone erreichen,da bin ich überzeugt.

[Dolocher]

Seht Euch mal die SEC Filings an,das ist hochinteressant.

http://10kwizard.ccbn.com/fil_list.asp?TK=VLGC&CK=1094961&FG…

[MaxLubin]

#394

was denn?

[MaxLubin]

ViroLogic Launches VLink Online System for HIV Resistance TestReporting

SOUTH SAN FRANCISCO, Calif., Mar 30, 2004 /PRNewswire-FirstCall via COMTEX/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced the launch of VLink online test reporting for its comprehensive portfolio of HIV drug resistance assays, PhenoSense GT(TM), PhenoSense(TM) HIV and GeneSeq(TM) HIV. The VLink system is designed to offer a fast and convenient way for healthcare professionals to access test results via a secure Internet connection.

"Creating secure and convenient online access to up-to-date test results will help improve patient care," said Stephen Becker, MD, Associate Clinical Professor of Medicine at the University of California, San Francisco and an HIV specialist in private practice. "ViroLogic`s online reporting system is a useful tool that places current and historical testing information at my fingertips and provides efficiencies that are not realized by paper-based systems."

Increasingly, healthcare organizations are improving efficiency through the adoption of electronic or web-based procedures. ViroLogic`s secure new online system facilitates data analysis, allowing examination of historical patient resistance data to help identify resistance patterns in patients over time. Importantly, this service is expected to shorten the time period between sample submission and reporting of results. The Company believes the system is fully compliant with the patient confidentiality regulations outlined in the Health Insurance Portability and Accountability Act (HIPAA).

"VLink is intended to facilitate rapid HIPAA-compliant access to test results, enabling more prompt and informed management of patients with HIV," said Tien Bui, ViroLogic`s Vice President of Sales and Marketing. "We are committed to building on our leadership position in HIV resistance testing through continued enhancement of our products and services to healthcare providers."

[Dolocher]

@ MaxLubin
ich meinte das eher allgemein,da hier in den letzten Tagen und Wochen einige sehr interessante Infos aufgelaufen sind z.B. Insider Trading oder auch mal ein paar Info`s zum aktuellen Forschungsstand und den Aussichten.

Ich war leider mal wieder c.a. 2Wochen nicht im Lande und konnte nicht gleich antworten,aber der momentane Ausbruch sieht gut aus,auch wenn ich mir ein wenig mehr Umsatz erhofft hatte,aber es deutet vieles darauf hin,das sich diese Bewegung fortsetzt,vor allem auf RSI und MACD, welche mich bisher sehr selten getäuscht haben, geben eindeutig positive Signale.
Bleibt zu hoffen,das wir noch etwas "Fahrt aufnehmen" und die Richtung nicht aus den Augen verlieren.

MfG

[JRB]

Der Widerstand bei ca. 3,35 Dollar muß ja heftig sein !
Wenn der aber bricht....
-giebt`s fette Beute!

[rockmaster]

wie gehts weiter bei virologic ?
ist da was im busch ?
sieht so aus nimmt die aktie neuen anlauf...
ich sehe es im moment wieder positiver!

[Intrader78]

man is das langweilig. Die sind ja seit Wochen voll ausgebremmst!!! Der heutige Tagesverlauf sagt doch wieder alles. Wird Zeit das hier mal wieder Phantasie auskommt!!

[Dolocher]

Investor Relations - Press Releases



ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ) News Release - 4/22/2004


--------------------------------------------------------------------------------
ViroLogic Announces First Quarter 2004 Earnings Conference Call

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 22, 2004--ViroLogic, Inc. (Nasdaq: VLGC) announced that it will hold a conference call on Monday, May 3, 2004 at 5:00 p.m. ET to discuss first quarter 2004 earnings results. The call will be hosted by Mr. Bill Young, Chairman & CEO of ViroLogic, Inc.

To participate in the teleconference please call [phone] fifteen minutes before the conference begins. International callers please dial [phone].

The call will also be webcast live at www.virologic.com. Please see web site for details.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company`s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic`s technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.virologic.com.

Certain statements in this press release are forward-looking. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.


CONTACT: ViroLogic, Inc.
Karen Wilson, 650-624-4164
[e-mail]

SOURCE: ViroLogic, Inc.



Wir dürfen gespannt sein

[Intrader78]

2,89$
man ist das eine sch...man möchte meinen am Montag geht die Virologic Welt unter!!

[JRB]

Ich bin immer noch positiv gestimmt.
Trotz den negativen Vorgaben der US-Börsen hält die
Unterstützung bei ca. 2,80 Dollar. Bis zum harten
Widerstand bei 3,35 sind immerhin 20% zu erzielen!
Habe deshalb gestern wieder einen Kauf gewagt.
Schönes WE

[Dolocher]

ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ) News Release - 5/3/2004


--------------------------------------------------------------------------------
ViroLogic Announces Nationwide Distribution Agreement With Quest Diagnostics for Portfolio of HIV Phenotypic Tests

ViroLogic Becomes Preferred Provider of HIV Phenotypic Testing
SOUTH SAN FRANCISCO, Calif., May 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- ViroLogic, Inc. (Nasdaq: VLGC) today announced that the Company has signed an expanded referral testing agreement with Quest Diagnostics (NYSE: DGX), the nation`s leading provider of diagnostic testing, information and services. Under the terms of the agreement, Quest Diagnostics will make ViroLogic its preferred provider of HIV phenotypic resistance testing. Quest Diagnostics has the largest national network of laboratories, with more than 30 full-service regional laboratories in major metropolitan areas and nearly 2,000 conveniently located patient service centers, where patients` specimens are collected. No other terms of the agreement were disclosed.

"This agreement will significantly expand ViroLogic`s distribution capabilities for our suite of HIV drug resistance assays, specifically our combination test, PhenoSense GT(TM) and PhenoSense(TM) HIV," said Tien Bui, Vice President of Sales and Marketing at ViroLogic. "Our new relationship provides increased access to ViroLogic`s products to many more patients who are likely to benefit from this personalized approach to managing HIV disease."

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The Company`s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company`s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its web site at www.ViroLogic.com.

Certain statements in this press release are forward-looking, including statements relating to the Company`s distribution agreement with Quest Diagnostics and activities expected to occur in connection with that agreement. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the implementation of the Company`s distribution agreement with Quest Diagnostics, the risks that the Company`s products may not perform in the same manner as indicated in this press release, whether ViroLogic successfully introduces new products, whether others introduce competitive products, the risk that the Company`s products for patient testing may not continue to be accepted or that increased demand from drug development partners may not develop as anticipated, the risk that gross margins may not increase as expected, the risk that ViroLogic may not continue to realize anticipated benefits from its cost-cutting measures, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the FDA or any other agency will decide to regulate ViroLogic`s products or services, whether the Company will encounter problems or delays in automating its processes, whether ViroLogic successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying the Company`s PhenoSense technology is adequate, whether licenses to third party technology will be available, whether ViroLogic is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

SOURCE ViroLogic, Inc.

Karen Wilson, CFO of ViroLogic, Inc., [phone], or
[e-mail]

http://www.virologic.com

[JRB]

Endlich der Kracher!
Habe nachbörslich schon gesehen:
BID: 3,50 Dollar
ASK: 3,61 Dollar


Gute Nacht und morgen einen schönen Handel

[wissi71]

mmh, so schön sieht es gar nicht aus....

[JRB]

Mal sehen , wie die Reaktionen auf die
`Files SEC form 10-Q` von gestern ausfallen werden. Nachzulesen unter:
biz.yahoo.com/e/040505/vlgc10q.html

Erfolgreichen Tag allen Investierten
JRB

[GINOLA]

SÜD San Francisco, Calif., Mai 3 /PRNewswire-FirstCall/ -- ViroLogic,
Inc. berichtete heute über finanzielle Resultate für die drei Monate
beendet März 31, 2004.

Die Firma berichtete über Einkommen von $9.0 Million für das erste
Viertel von 2004, eine Zunahme von 29 Prozent Übereinkommen von $7.0
Million für das erste Viertel von 2003. Das Jahr-über-Jahr Wachstum
war dem des Company`s geduldigen prüfengeschäft, das bis $5.8
Million von $5.3 Million im ersten Viertel von 2003 stieg, und seinem
pharmazeutischen Geschäft zuzuschreibend, das 128 Prozent bis $2.9
Million von $1.3 Million während der gleichen Periode 2003 erhöhte.

Grober Seitenrand war 49 Prozent im ersten Viertel von 2004 verglichen
mit 42 Prozent, die während des gleichen letzten Vierteljahres
berichtet wurden. Verbesserung des groben Seitenrandes wurde durch
verbesserte Leistungsfähigkeiten in den Laborbetrieben sowie einen
erhöhten Beitrag von den pharmazeutischen Einkommen während des
Viertels gefahren. Betriebskosten und Unkosten für das erste Viertel
von 2004 waren $10.3 Million, verglichen bis $9.5 Million während der
gleichen Periode 2003, wegen der höheren Kosten, die mit erhöhter
Probenmenge und einer Aufladung von $0.4 Million für den Endpunkt von
der Miete des Company`s für ursprünglichen Labor- und Büroraum
verbunden sind. Dieser frühe Endpunkt ermöglichte der Firma, die
Betriebskosten zu beseitigen, die auf dieser Miete bezogen wurden, die
vorwärts und seine gesamte restliche Verpflichtung zu verringern
durch ungefähr beinahe geht.

Reinverlust für das erste Viertel von 2004, einschließlich die
Mietendpunktaufladung, war- $1.2 Million, oder $0.02 pro allgemeinen
Anteil, verglichen bis einen Reinverlust von $2.5 Million oder $0.09
pro allgemeinen Anteil, während der gleichen Periode 2003.

Im ersten Viertel von 2004, notierte resultiert die Firma auf
lagerdividenden zu bevorzugten Aktionären von $0.1 Million, und das
im Reinverlust, der auf gemeine Aktionäre von $0.02 pro allgemeinen
Anteil anwendbar ist. Im ersten Viertel von 2003, notierte resultiert
die Firma eine bargeldlose gemeinte Dividende zu bevorzugten
Aktionären von $2.2 Million, resultierend aus einem Ermächtigung
Austausch in bezug auf den Verkauf Reihe C der umwandelbaren
Vorzugsaktie und notierte auf lagerdividenden zu bevorzugten
Aktionären von $0.5 Million, und das im Reinverlust, der auf gemeine
Aktionäre von $0.18 pro allgemeinen Anteil anwendbar ist.

[Intrader78]

Tja zahlen waren ja schon Montag bekannt. Versteh nur wer will das diese Zahlen so einen Kurssturz rechtfertigen sollen????
Manch andere AG wäre über solche Zahlen frog und die notieren in ganz anderen Höhen!!

[wissi71]

Was sagen denn unsere Charttechniker zur weiteren Entwicklung??
Wenn ich heute die Futures sehe, ist ja weiterhin Schlimmes zu befürchten...

[heikekarina]

@wissi71

mit chartechnik hat der kursverfall im moment wirklich nichts zu tun.

a) Bio, pharma und nano schwächeln seit wochen
b) der gesamtmarkt ist am boden
c) der gute alte mai sagt mal wieder "sell in may and go away"
d) die rohölpreise
e) angst vor zinserhöhung in amerika
f) es beginnt langsam die heiße wahlkampfphase in amiland
g) und...
h) und...
i) und...
j) und...
k) und...

usw.

[JapanTrader]

Naja, jetzt mal langsam, so deutlich unter der 200 Tage Linie, wenigstens das ist doch trotzdem ein Indiz, dass man wieder einsteigen koennte, oder nicht? Wie seht Ihr das?

[Intrader78]

ohhhh diese Plätscherei nach unten nervt total. Jeden Tag 1-5% Minus mal nen Tag 3% rauf...so wird das nix. Mag schon gar nicht mehr hin sehen

[wissi71]

Allen ein schönes Pfingstfest!!
Hoffentlich geht es so positiv weiter, wie die letzte Woche endete...

[rockmaster]

Also ich bin momentan dabei mir bei meiner lieblingsaktie wieder eine position aufzubauen
die aktie pendlet seit wochen um die 2 € herum ich denke aber dass es nun langsam aber konsatant wieder nach oben geht ! der langfristchart sieht so schlecht nicht aus...

[wissi71]

Hallochen,

weiß jemand, was bei Virologic los ist. Die Aktie scheint in der letzten Zeit nur noch eine Richtung zu kennen...
Wäre es möglich, dass dies mit der Übernahme zu tun hat??

Allen ein schönes Wochenende!

[buecherwuermer]

Was ist hier los hier wird ja ohne Ende geschmissen...

[rockmaster]

Hallo,

möchte auch mal wissen was zur zeit wieder im busch ist bei Virologic- geht gerade 15% nach unten.
weiß jemand was ???

[rockmaster]

hab nun doch was gefunden :


ViroLogic cuts 2004 sales forecast
By Carla Mozee, CBS MarketWatch
Last Update: 9:01 PM ET July 12, 2004
E-mail it | Print | Alert | Reprint | RSS

SAN FRANCISCO (CBS.MW) - ViroLogic said late Monday that it cut its 2004 revenue forecast primarily because a major pharmaceutical company postponed the start of a significant, late-stage clinical trial.


NEWS FOR VLGC
ViroLogic cuts 2004 sales forecast on customer delay
Select Comfort off, PeopleSoft up after hours
Stocks to watch Wednesday: ALKS, DNA, ALKS, HOV, CMVT
More news for VLGC


ViroLogic (VLGC: news, chart, profile) cut its full-year sales forecast to the $38 million to $41 million range from a prior range of $42 million to $47 million.

Two analysts surveyed by Thomson First Call currently expect the company to post a loss of a penny a share on sales of $45 million.

The biotechnology company based in South San Francisco said its pharmaceutical client would begin its clinical trial in later this year, shifting the anticipated $3 million in revenue from the testing until 2005.

The company also said sales would be hampered due to slower-than-expected growth during first half of 2004.

ViroLogic forecast second-quarter sales of $9.2 million and a net loss range of $1.4 million and $1.7 million, or 3 cents a share, due to lower than anticipated revenue, added expenses from marketing initiatives, and incremental expenses from its planned merger with ACLARA BioSciences.

The company reported a loss of $2.2 million, or 7 cents a share, last year.

Two analysts expect Virologic to post breakeven earnings on sales of $11 million for its second quarter.

Shares of ViroLogic rose 2 cents to close at $2.17.

[heikekarina]

was machen die mit meiner Virologic. Ich fasse es nicht!!!

[steini1DD]

Am Freitag sind wir wieder bei 1,20

so eine Sch...

[Zackes1]

Ich verstehe ehrlich nicht warum der Kurs so einbricht. Hab ebne noch mal geschaut. Habe fast nur Kaufempfehlungen gefunden. Die Ausrichtung von virologic stimmt auch, durch die Fusion entstehen auch neue Synergieeffekte. Eigentlich müsste der Kurs anziehen, nicht fallen. Erschreckend dabei ist auch, dass der Kurs hauptsächlich von Kleinanlegern gemacht wird, die mit Orders von 100 Stück den Kurs bewegen, was geradezu lächerlich ist.
Weiß einer von Euch vielleicht mehr?

[CutPall]

Rockmaster hat es bereits reingestellt:

ViroLogic (VLGC: news, chart, profile) cut its full-year sales forecast to the $38 million to $41 million range from a prior range of $42 million to $47 million. ....

so was nennt man Gewinnwarnung(eigentlich ist es eine Umsatzwarnung ) und das wird üblicherweise bestraft. Der Chart ist leider auch ne Katastrophe:



Das mit den Analystenmeinungen ändert sich auch schon:

13-Jul-04 Merriman Curhan Ford Downgrade from Buy to Neutral
1-Jun-04 Deutsche Securities Downgrade from Buy to Hold

Eigentlich beste Voraussetzungen wieder zu investieren, aber wer greift schon gerne in ein fallendes Messer ?

[steini1DD]

Vielleicht haben sich zwei Fußkranke zusammen getan
und versuchen wieder zu laufen.

[rockmaster]

anscheinend gibts kein halten mehr
wo seht ihr das ende der talfahrt ??

[T.E.]

Die Aktie scheint sich bei knapp 1,80 Dollar stabilisiert zu haben. Ich gehe davon aus, dass es maximal noch eine Woche dauert, bis virologic wieder gegen 2 Dollar laufen wird. Das zeigen auch die relativ geringen Umsätze.

Jetzt noch ein paar Aktien abstauben und in einem Jahr über ein schöes Plus freuen!

[heikekarina]

T.E.

wärst Du vor einem Jahr eingestiegen, dann wärst Du bereits im Plus.

[buecherwuermer]

Geld 1,71

Brief 2,25

Zeit 29.07.04 23:47

Spread 24%

Geld Stk. 900

Brief Stk. 100
Ein verdammt hoher Briefkurs nachbörslich

[T.E.]

heikekarina

Bin ich ja auch bereits. Allerdings nutze ich diese Lowprice-Phase aus, um aufzustocken.

Weiterhin gutes Geschäft!

[buecherwuermer]

langsam geht es wieder hoch 1,88
wieder ein Briefkurs von 2,25 nachbörslich

[heikekarina]

T.E.

wünsche ich Dir auch

[rockmaster]

Virologic steigt seit wochen stetig - scheint aber hier keinen mehr zu interessieren ??

[wissi71]

Doch, habe ich auch registriert. Vom Tief haben sie doch schon wieder einiges getan. Hoffe nur, dass wir auch bald wieder die Höhen, die wir dieses Jahr schon mal gesehen haben, erklimmen...
Sie halten sich derzeit recht stabil.

Allen ein schönes WE!

[wissi71]

Kennt jemand den Grund für den Anstieg der letzten Tage???
Sieht ja erst mal ganz toll aus... Hoffentlich geht es bald zu alten Höhen...

[CutPall]

ts ts ts, bin zwar selber seit ein einiger Zeit nicht mehr drin, dachte aber an einen Neueinstieg. Aber noch 3 Monaten noch eine Umsatzwarnung ist schon ziemlich schwach und dann mal kurz die Fusionbedingungen ändern:

UPDATE 1-ViroLogic, Aclara, revise merger terms
Tue Oct 19, 2004 07:52 AM ET
(Updates with details)
NEW YORK, Oct 19 (Reuters) - ViroLogic Inc. (VLGC.O: Quote, Profile, Research) and Aclara BioSciences Inc. (ACLA.O: Quote, Profile, Research) on Tuesday said they have revised the terms of their merger agreement.

ViroLogic also said it expects its third-quarter revenue to fall to about $8.6 million from $9.2 million a year ago and that revenue for the full year will come in below the low end of its previous estimate of $38 million to $41 million.

The amount of the exchange ratio remains unchanged with each outstanding share of Aclara common stock to be exchanged for 1.7 shares of ViroLogic common stock and 1.7 contingent value rights.

ViroLogic Inc. in June agreed to acquire Aclara for about $200 million, combining products that help identify which drugs will help patients and giving ViroLogic and influx of cash.

Aclara shareholders also were to receive a potential cash payment of up to 50 cents per contingent value right (CVR) depending on ViroLogic`s stock price 12 months following completion of the merger.

The companies said the terms of the CVRs have been revised to increase the maximum potential payment and allow for the increase in the potential payment to be made in stock at ViroLogic`s option. The revised terms also extend the determination date to 18 months after the merger instead of 12 months.

The revised CVR provides for a potential payment in cash and/or stock of up to 88 cents per CVR, equivalent to $1.50 per Aclara share, compared to 50 cents per CVR and 85 cents per Aclara share previously.

The terms also reduce the ViroLogic stock price at which the maximum payment may be made.The changes have been made to give greater flexibility to the two companies` shareholders and to reflect changes in market valuation since the announcement of the transaction, the companies said.

VLGC ist wohl damit endgültig von meiner Watchlist geflogen, aber vielleicht wird es ja noch ...

[heikekarina]

VLGC

ich beobachte dich.

[heikekarina]

[bernie55]

..wenn schon, denn schon

[rockmaster]

kommt jetzt endlich mal wieder bewegung rein in diesen thread ???
der kursverlauf sieht ja nicht schlecht aus

[rockmaster]

virologic erholt sich wieder.

hier ein paar news von der homepage:

Investor Relations - Press Releases



ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ Stock Exchange (.O)) News Release - 5/4/2005


--------------------------------------------------------------------------------
ViroLogic Announces Presentations on Its eTag Technology at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO)

SOUTH SAN FRANCISCO, Calif., May 4 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC) announced today multiple presentations and publications related to its eTag(TM) technology. The presentations and publications are part of the proceedings at the 2005 American Society of Clinical Oncology Annual Meeting (ASCO) being held May 13-17, 2005 at the Orange County Convention Center in Orlando, FL.

ViroLogic scientists will make the following presentations:


Sunday, May 15, 2005
Session: Tumor Biology and Human Genetics
Title: Analysis of ErbB/HER Receptor Pathways in Formalin-fixed and
Paraffin-embedded Cancer Cell Lines using Multiplexed eTag Assays
Abstract #9565: 8:00 a.m. - 12:00 p.m.

Session: Tumor Biology and Human Genetics
Title: Detection of Vascular Endothelial Growth Factor Receptor 2
(VEGFR2) Homodimers, Phosphorylation and Downstream Pathway Activation in
Endothelial Cells using eTag Assay System
Abstract #9595: 8:00 a.m. - 12:00 p.m.

Monday, May 16, 2005
Session: Breast Cancer
Title: ErbB/HER Pathway Profiling in Formalin-fixed Paraffin-embedded
Tissues using Multiplexed Proximity-based Assays
Abstract #645: 2:00 - 6:00 p.m.

Session: Breast Cancer
Title: ErbB/Her Dimerization in Breast and Lung Cancer
Abstract #643: 2:00 - 6:00 p.m.

Tuesday, May 17, 2005
Session: Breast Cancer II
Title: The use of ErbB/HER Activation Status as Prognostic Markers in
Breast Cancer Patients Treated with Trastuzumab (Herceptin(R))
Abstract #553: 8:00 a.m. - 12:00 p.m. Poster Discussion

eTAG Published Abstracts
Abstract #9618
Title: Predictive Value of eTag Dimerization Assay in Patients with
Metastatic
Colorectal Cancer Treated with Erlotinib (Tarceva(R))

Abstract #808
Title: ErbB/Her Dimerization Profiles and Targeted Therapy in Breast and
Lung Cancer

Abstract #3172
Title: Effect of Gefitinib (Iressa(R)) on EGFR Mutated Lung Cancer Cell
Lines

About the eTag System

ViroLogic`s eTag assays enable detailed analysis of protein drug targets and signaling pathways in cancer cells, including samples that are formalin-fixed, paraffin-embedded, which is the standard format in most pathology labs. The assays can provide information on a drug`s mechanism of action, selectivity and potency in a biological setting in pre-clinical research, and enable enrichment or selection of clinical trial populations later in a drug`s development. In addition, ViroLogic believes these assays will be used to help physicians better determine whether certain therapies are more appropriate for individual cancer patients, and whether to combine therapies with different mechanisms or properties.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company`s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company`s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.virologic.com.

NOTE: eTag is a trademark of ViroLogic, Inc. Herceptin(R) and Tarceva(R) are registered trademarks of Genentech. Iressa(R) is a registered trademark of AstraZeneca.

SOURCE ViroLogic, Inc. 05/04/2005
CONTACT: Alfred Merriweather, Vice President and CFO of ViroLogic,
[phone]; or Carolyn Bumgardner Wang of WeissComm Partners,
[phone], or [e-mail], for ViroLogic
Web site: www.virologic.com





© 2005 ViroLogic, Inc.

[rockmaster]

Investor Relations - Press Releases



ViroLogic, Inc. (ticker: VLGC, exchange: NASDAQ Stock Exchange (.O)) News Release - 5/2/2005


--------------------------------------------------------------------------------
ViroLogic Announces First Quarter 2005 Financial Results

Progress with oncology clinical studies and HIV pharmaceutical testing - Conference Call Today at 10:00 a.m. ET
SOUTH SAN FRANCISCO, Calif., May 2, 2005 /PRNewswire-FirstCall via COMTEX/ -- ViroLogic, Inc. (Nasdaq: VLGC) today reported financial results for the first quarter ended March 31, 2005.

Revenue for the first quarter of 2005 of $10.0 million was a record for the Company and compares to revenue of $9.0 million for the first quarter of 2004. Revenue from the Company`s HIV patient testing products was $5.9 million in the first quarter of 2005 compared to $5.8 million in the first quarter of 2004. Revenue from the Company`s HIV pharmaceutical testing products was $2.9 million in the first quarter of 2005 compared to $2.9 million for the same period in 2004. Revenue from oncology and eTag(TM) collaborations was $0.5 million for the first quarter of 2005.

"Individualized medicine is a powerful multi-year trend that is transforming the way serious disease is managed. Our tests are helping make this important change in the treatment of disease a reality," said William D. Young, Chairman and CEO of ViroLogic. "With a new class of HIV drugs emerging, our HIV business has the potential for accelerated growth in the years ahead. In addition, our eTag technology allows us to apply our experience with guiding personalized medicine for HIV patients to the larger opportunity of individualized cancer therapy. With these dual business drivers, we believe that we are well positioned to become a worldwide leader in personalized molecular diagnostics focused on infectious diseases and cancer therapies."

For the first quarter of 2005, the net loss was $7.4 million, or $0.06 per common share, compared to a net loss of $1.2 million, or $0.02 per common share, for the same period in 2004. Included in the net loss for 2005 were substantial non-cash items related to the merger with ACLARA, which are described below. On a proforma basis, adjusted for these non-cash items, the net loss was $4.1 million, or $0.03 per share, in the first quarter of 2005 compared to $1.2 million, or $0.02 per share, in the same period of 2004.

Cash Resources

The Company had $74.9 million of cash, cash equivalents, short-term investments and restricted cash at March 31, 2005. The net change in these balances during the first quarter of 2005 was $4.3 million, including payment of approximately $5 million in transaction costs related to the merger with ACLARA and proceeds from the exercise of warrants amounting to $4.2 million. As previously indicated, we expect to end 2005 with approximately $60 million in cash, cash equivalents and investments.

Recent Corporate Highlights


Initiated a cancer biomarker study of AstraZeneca`s Iressa(R), a selective epidermal growth factor receptor kinase inhibitor. ViroLogic, utilizing its proprietary eTag assays, has received and is in the process of testing approximately 150 tumor samples from lung cancer patients treated with Iressa to evaluate the effectiveness of these assays in targeting patients who would most likely benefit from Iressa.
Began testing in the first of three anticipated pharmaceutical customers` large phase 3 clinical trials of a new class of entry inhibitor drugs. In addition, we continue to provide testing and monitoring of drug treatment responses for almost all of the pharmaceutical and biotechnology companies with HIV drug candidates under clinical development.
Completed the initial phase of consolidation of former ACLARA operations with relocation of approximately half of the technical staff from Mountain View to South San Francisco, with the remainder scheduled to be relocated in May 2005.

Outlook

In the remainder of 2005, ViroLogic expects steady progress in the HIV patient testing and pharmaceutical drug development businesses and expects to leverage its experience and infrastructure in infectious disease to oncology by validating eTag assays as predictive tools for targeted cancer therapies. With increased focus from the medical community and the FDA on the need for better targeting of drugs, especially for diseases such as cancer and HIV, we believe that the current and proposed evaluations of our eTag technology will help pave the way for its commercial introduction.

Specifically, the Company intends to accomplish the following:
HIV:


Growth in HIV pharmaceutical testing revenues in 2005 and 2006 driven by the selection of ViroLogic`s HIV Co-receptor Tropism assay to identify patients for, and to monitor response to, drug treatment during clinical trials for a new class of entry inhibitor drugs, specifically the CCR5 entry inhibitors. If successful in clinical trials, the approval of these drugs could provide a boost to future patient testing revenues;
Continue to grow HIV patient testing revenue for the full year, though seasonal variability may occur from quarter to quarter; and,
Develop clinical data for the Replication Capacity, Entry and Co-receptor Tropism assays to support the commercial launch of these products for the HIV patient testing business.

Oncology:

Complete the consolidation of all personnel and operations into our South San Francisco facilities in the first half of 2005;
Complete the study undertaken jointly with AstraZeneca to analyze approximately 150 Iressa-treated tumor samples and evaluate the capability of eTag assays to predict patient responsiveness;
Continue to perform clinical studies with multiple collaborators. We have, in our labs, approximately 700 patient tumor samples provided by collaborators for evaluation using eTag assays. These samples represent multiple cancer types from patients that have been treated with both approved drugs and drugs that are in development. We anticipate receiving a comparable number of additional patient tumor samples over the remainder of 2005 and are in discussions with over 20 institutions about collaborations on clinical studies. We expect to generate initial revenue from pharmaceutical collaborations in 2005, and we will continue working with several pharmaceutical and biotechnology companies evaluating eTag technology for drug discovery and development; and,
Prepare to launch our first commercial eTag assay in oncology, a test panel measuring activated EGF receptors related to approved targeted cancer therapies during 2006. To achieve this goal, the Company plans to:


Transfer eTag assays from the research setting to our CLIA certified clinical laboratory, a process that is expected to be completed during 2005; and,
Conduct independent validation and clinical studies with pharmaceutical companies and with clinical collaborators to establish the ability of eTag assays to correctly distinguish between responders and non-responders to specific drug therapies.

Merger-Related Costs and Proforma Results

As a result of the merger with ACLARA, there were several items that affected results for the quarter ended March 31, 2005 and were recorded as follows:


A "mark-to-market" adjustment to the liability established on closing of the merger for the potential payment on the Contingent Value Rights (CVRs) issued as part of the purchase consideration for ACLARA. This liability was valued at closing of the merger using a calculation based on a Black-Scholes valuation of the underlying CVR securities of $0.66 per CVR. Because, subsequent to the closing of the merger, an active trading market had been established, this liability was revalued based on the actual closing price of the CVRs on the OTC bulletin board, or $0.23 per CVR at December 31, 2004 and $0.31 at March 31, 2005. This revaluation led to a $5.3 million unfavorable adjustment to the liability in the first quarter of 2005 and this is reflected as non- operating expense in the statement of operations. Further revaluations will be done each quarter while the CVRs remain outstanding.
A favorable non-cash amount of $2.0 million for stock based compensation including the favorable impact in the quarter of variable accounting on all former ACLARA stock options as a result of the CVRs, recognition of expense based on the value of CVRs related to former ACLARA stock options that vested during the period, and amortization of deferred compensation.

We are reporting proforma results excluding these items to provide a clearer view of ongoing expenses without the impact of merger-related costs.

Conference Call Details

ViroLogic will host a conference call today at 10:00 a.m. Eastern Time. To participate in the live teleconference call [phone] fifteen minutes before the conference begins. International callers please dial [phone]. Conference participant passcode is 27623488. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available by following the appropriate links at www.virologic.com and clicking on the Investor Relations link. Following the live broadcast, a replay of the call will also be available at [phone] or [phone] for international callers, until May 12, 2005. The replay passcode is 41395767.

The information provided on the teleconference is only accurate at the time of the conference call, and ViroLogic will take no responsibility for providing updated information except as required by law.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company`s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company`s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.virologic.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, including statements regarding anticipated operating results and activities for 2005, the potential role for entry-inhibitor drugs in the management of HIV-infected patients, the trend toward individualized medicine and the results of yet-to-be completed clinical studies related to the effectiveness of our eTag assays as predictive tools for targeted cancer therapies. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the development of future products; the performance of our products; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; whether the collaboration with AstraZeneca will yield favorable results regarding the predictive capability of eTag assays for responsiveness to Iressa; our ability to establish reliable, high-volume operations at commercially reasonable costs; our ability to successfully integrate the operations of ACLARA into our operations; our ability to realize cost savings from the merger with ACLARA; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements including those with Quest Diagnostics, Pfizer and GSK; competition from larger more established diagnostic providers; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the level of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for our products; whether the FDA or any other agency will seek to regulate ViroLogic`s in house clinical laboratory testing; our ability to comply with FDA regulations in order to establish and maintain diagnostic kit manufacturing operations; whether we will encounter problems or delays in establishing and validating eTag assays within our clinical laboratory; whether we will encounter problems or delays in automating our processes or expanding our capacity; whether the intellectual property underlying the Company`s technology is adequate; whether we may be deemed to infringe on the intellectual property of others and whether licenses to third party technology will be available; whether ViroLogic is able to build brand loyalty and expand revenues; the potential impact of any payments under the CVRs on our common stock and capital resources; and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

PhenoSense and eTag are trademarks of ViroLogic, Inc. Iressa is a registered trademark of AstraZeneca plc.

VIROLOGIC, INC.

SELECTED STATEMENT OF OPERATIONS DATA
(In thousands, except per share amounts)

Three Months Ended March 31,
2005 2004
(Unaudited)
Revenue
Product revenue $8,853 $8,640
Contract revenue 1,141 382

Total revenue 9,994 9,022

Operating costs and expenses:
Cost of product revenue 4,212 4,416
Research and development 4,106 1,393
Sales and marketing 2,563 1,958
General and administrative 1,702 2,080
Lease termination charge - 433

Total operating costs and expenses 12,583 10,280

Operating loss (2,589) (1,258)
Interest and other income, net 535 10
CVR valuation adjustment (5,306) -

Net loss (7,360) (1,248)

Net loss per share, basic and diluted $(0.06) $(0.02)

Weighted average shares used in
computing
basic and diluted net loss per common
share 117,353 53,137

Reconciliation of Proforma Results to
GAAP
Net loss $(7,360) $(1,248)
Adjustments for non cash merger-
related items:
CVR valuation adjustment 5,306 -
Stock based compensation (2,006) -

Proforma net loss $(4,060) $(1,248)

Proforma net loss per common share $(0.03) $(0.02)

Management believes that this proforma financial data supplements our GAAP financial statements by providing investors with additional information which allows them to have a clearer picture of the company`s operations, financial performance and the comparability of the company`s operating results from period to period. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with GAAP. Above, we have provided a reconciliation of the proforma financial information with the comparable financial information reported in accordance with GAAP.

VIROLOGIC, INC.
SELECTED BALANCE SHEET DATA
(In thousands)

March 31, December 31,
2005 2004
(Unaudited) (a)

ASSETS
Current assets:
Cash and cash equivalents $8,106 $6,027
Short-term investments 66,470 72,821
Restricted cash 350 350
Accounts receivable 6,474 7,251
Prepaid expenses 824 838
Inventory 1,186 1,059
Other current assets 1,100 584
Total current assets 84,510 88,930

Property and equipment, net 8,501 8,369
Restricted cash 107 107
Developed product technology 192 198
Goodwill 8,282 8,282
Other assets 1,923 1,749
Total assets $103,515 $107,635

LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $4,018 $3,222
Accrued compensation 1,555 1,697
Accrued liabilities 2,512 6,993
Current portion of restructuring costs 1,841 2,519
Deferred revenue 958 546
Current portion of capital lease obligations 29 51
Current portion of loans payable 258 439
Total current liabilities 11,171 15,467

Long-term portion of capital lease obligations 32 36
Long-term portion of loans payable 292 311
Long-term portion of restructuring costs 1,587 1,710
Contingent value rights 20,666 15,269
Other long-term liabilities 354 359
Redeemable convertible preferred stock 1,810 1,810
Commitments
Stockholders` equity:
Common stock 122 116
Additional paid-in capital 263,206 260,591
Accumulated other comprehensive income (456) (57)
Deferred compensation (207) (275)
Accumulated deficit (195,062) (187,702)
Total stockholders` equity 67,603 72,673

Total liabilities and stockholders`
equity $103,515 $107,635

(a) The balance sheet data is derived from audited financial statements
for the year ended December 31, 2004, included in the Company`s
Annual Report on Form 10-K filed with the Securities and Exchange
Commission.

SOURCE ViroLogic, Inc.

[rockmaster]

06.07.2005 13:50
ViroLogic Announces Multi-Year Service Agreement With Schering-Plough to Support New HIV Drug Discovery and Development Efforts

SOUTH SAN FRANCISCO, Calif., July 6 /PRNewswire-FirstCall/ -- ViroLogic (Nachrichten), announced today that the Company has signed a multi-year, $4.8 million service agreement with Schering-Plough (Nachrichten) Research Institute, the research arm of Schering-Plough Corporation , to use ViroLogic`s novel HIV resistance testing technology to support Schering-Plough`s drug discovery and development programs.

Schering-Plough plans to use ViroLogic`s assays for the clinical development of its CCR5 receptor antagonist, vicriviroc, a potential new drug for HIV infection. CCR5 receptor antagonists are a type of HIV Entry Inhibitor, a class of drugs that is a promising new treatment option for HIV-infected individuals. The Phase III program for vicriviroc is scheduled to commence in 2005 and will use ViroLogic`s PhenoSense(TM) HIV Co-receptor Tropism assay to identify and monitor patients during the trials.

"We have become the preferred partner of industry leaders, like Schering-Plough, to provide them with the technologies they need for the discovery and development of new HIV therapeutics, such as entry inhibitors," stated Bill Young, ViroLogic`s Chairman and Chief Executive Officer. "ViroLogic pioneered the use of testing to help guide better treatment of patients, and we believe our tests have enabled breakthroughs in the way clinical trials are designed. This collaboration with Schering-Plough represents another significant clinical development program in which our co-receptor tropism assay will be used."

As recommended by the U.S. FDA Antiviral Drugs Advisory Committee, biopharmaceutical companies are using HIV resistance testing technology to enhance next-generation HIV drug development. The industry currently has 20 approved HIV drugs and nearly 60 new drugs in the pipeline, which may require resistance testing for their development. ViroLogic`s patented technology can be applied to new HIV drug targets and for use in vaccine research and development. Current ViroLogic tests for pharmaceutical development include PhenoSense(TM) HIV, GeneSeq HIV(TM), PhenoSense GT(TM), PhenoSense and GeneSeq HIV Entry(TM), Replication Capacity HIV(TM), PhenoScreen(TM), Phenosense HIV Antibody Neutralization(TM), and the new PhenoSense(TM) HIV Co-receptor Tropism assay.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company`s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company`s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.virologic.com/.

FORWARD LOOKING STATEMENTS

Certain statements in this press release are forward-looking, including statements regarding activities expected to occur in connection with the service agreement with Schering-Plough Research Institute discussed in this press release and the potential role for entry-inhibitor drugs in the management of HIV-infected patients. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to the performance of our products; our ability to successfully conduct clinical studies and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on a few customers for the majority of our revenues; the annual renewal of certain customer agreements such as the service agreement with Schering-Plough; actual market acceptance of our products and adoption of our technological approach and products by pharmaceutical and biotechnology companies; our estimate of the size of our markets; our estimates of the levels of demand for our products; the timing and ultimate size of pharmaceutical company clinical trials; whether payors will authorize reimbursement for its products; whether the FDA or any other agency will decide to regulate ViroLogic`s products or services; whether the Company will encounter problems or delays in automating its processes; whether intellectual property underlying the Company`s PhenoSense technology is adequate; whether licenses to third party technology will be available; whether ViroLogic is able to build brand loyalty and expand revenues; and whether ViroLogic will be able to raise sufficient capital when required. For a discussion of other factors that may cause ViroLogic`s actual events to differ from those projected, please refer to the Company`s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

[rockmaster]

aufgepaßt:
virologic beobachten !
erholung geht weiter !!!!

[bernie55]

Sept 6 (Reuters)

ViroLogic Inc. (VLGC.O: Quote, Profile, Research) said it will change its name to its name to Monogram Biosciences .
In a statement, the biotechnology company said from Sept. 7 its common stock would trade under the ticker symbol MGRM on the Nasdaq. (Reporting by Preeti Mishra in Bangalore)

[bernie55]

ab heute an der Nasdaq

a new ticker symbol : MGRM

[bernie55]

@alle

Ab wann werden unsere alten Virologic-Aktien als Monogramm Bioscience Aktien in Deutschland gehandelt ???

Grüße bernie55

[bernie55]

MGRM jetzt in D unter WK. Nr. A0F65Y zu handeln ! !

[MarioHe]

Ist keiner mehr in Monogram Bio. (Virologic) investiert ??
Wie sind die Aussichten ?

[m4k3m0n3y]

Ich frage mich, wer für den Verkauf von über 1 Mio Aktien am 11.1 verantwortlich war und was das zu bedeuten hat...

[textra]

Press Release Source: Monogram Biosciences, Inc.


Monogram Biosciences Announces Fourth Quarter 2005 Financial Results Conference Call
Wednesday February 15, 6:30 pm ET


SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM - News) announced that it will hold a conference call on Wednesday, February 22, 2006 at 10:00 a.m. Eastern Time to discuss fourth quarter 2005 financial results. The call will be hosted by Mr. William D. Young, Chairman & CEO of Monogram.
ADVERTISEMENT


To participate in the live teleconference, please call [phone] (or 913-312-1297 for international callers) fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Access to live and archived audio of the conference call will be available by following the appropriate links at http://www.monogrambio.com and clicking on the Investor Relations link. Following the live broadcast, a replay of the call will also be available at [phone] or [phone] for international callers, until March 1, 2006. The replay passcode is 6918864.

The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law.

About Monogram Biosciences, Inc.

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company`s products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company`s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.


Contacts:
Alfred G. Merriweather Jeremiah Hall
Chief Financial Officer Feinstein Kean Healthcare
Tel: [phone] Tel: [phone]
[e-mail] [e-mail]




--------------------------------------------------------------------------------
Source: Monogram Biosciences, Inc.

[textra]

Monogram Announces Year End 2005 Financial Results

— Conference call today at 10:00 a.m. ET —

SOUTH SAN FRANCISCO, Calif., February 22, 2006 – Monogram Biosciences, Inc. (Nasdaq: MGRM) today reported financial results for the fourth quarter and year ended December 31, 2005.

Fourth Quarter Results

The Company had revenue of $12.7 million for the fourth quarter of 2005, which was 28 percent higher than revenue of $9.9 million for the fourth quarter of 2004. Driving this increase was revenue from the Company’s HIV testing products, which was $11.5 million in the fourth quarter of 2005 compared to $9.5 million for the same period in 2004. Revenue from oncology and eTag ™ collaborations was $0.8 million for the fourth quarter of 2005.

For the fourth quarter of 2005, a net loss of $21.3 million, or $0.17 per common share, was recorded, compared to a net loss of $77.2 million, or $1.12 per common share, for the same period in 2004. Included in the results for both 2005 and 2004 were substantial non-cash items, primarily related to the Contingent Value Rights and other charges related to the merger with ACLARA BioSciences, Inc., which are described below under “Proforma Results.” On a proforma basis, adjusted for these non-cash items, the net loss was $3.6 million, or $0.03 per share, in the fourth quarter of 2005 compared to a net loss of $1.7 million, or $0.02 per share, in the same period of 2004.

Annual Results

The Company reported revenue of $48.3 million for the year ended December 31, 2005, an increase of 31 percent over revenue of $36.8 million for the same period of 2004.